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Summary 
 Foxp3+ Regulatory T cells (Tregs) constitute a major immunosuppressive cell 
type within tumours. Here, they impinge on anti-tumour immune responses. Modalities 
aimed at subverting the accumulation and / or suppressive action of Tregs could 
revolutionise cancer immunotherapies in the future. 
 By use of the 3-methylcholanthrene (MCA) model of chemical carcinogenesis, I 
investigated mechanisms of Treg enrichment in tumours. While a large proportion of 
intra-tumoural Tregs expressed the TH1 transcription factor, T-bet, there was no role for 
T-bet-expressing Tregs in tumour control. Additionally, sequestration of Interleukin-2 
(IL-2) in the tumour microenvironment (TME) did not represent a mechanism by which 
Tregs exert dominance at this site. However, the majority of intra-tumoural Tregs 
expressed CD69, a molecule implicated in retaining T cells at the site of antigen. 
Furthermore, CD69-expressing Tregs possessed superior suppressive capacity 
relative to CD69 negative Tregs. Therefore, the consequence of CD69 expression on 
Tregs may be the retention of tumour-infiltrating super-suppressive Tregs, thereby 
ensuring Treg dominance within the TME. 
 By use of the Foxp3DTR mouse model, previous data demonstrated the 
development of ectopic High Endothelial Venules (HEV) within MCA-induced tumours 
following depletion of Treg. HEV demonstrated an absolute concordance with 
increased numbers of T cells inside tumours and reduced tumour growth. I investigated 
the mechanisms supporting development of HEV in tumours in the absence of Tregs.  
 I have eliminated a role for B lymphocytes, instead pinpointing CD8+ T cells as 
key drivers of HEV development in tumours. Ectopic formation of HEV in Treg depleted 
tumours is Tumour Necrosis Factor (TNF) receptor (TNFR) signalling dependent, and 
Lymphotoxin (LT) β receptor (LTβR) signalling independent. Furthermore, the 
proportion of TNFα-producing T cells in the tumour correlated with density of tumour 
HEV. These data suggest that intra-tumoural development of HEV following Treg 
depletion is driven by T cell derived TNFα signalling via TNFR(s). 
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Chapter One 
1 Introduction 
1.1 Cancer Biology and the Process of Tumourigenesis 
Cancer is a leading cause of human morbidity and mortality, responsible for 
approximately 8.2 million deaths worldwide in 2012. Cancer refers to more than 200 
different types of disease, afflicting various parts of the body. Lung, liver, stomach, 
colorectal, breast and oesophageal cancers account for the most cancer-associated 
deaths. One in every two people in the UK will develop cancer in their lifetime (World 
Health Organisation; Cancer Research UK).  
Cancer development encompasses a multistage process of tumourigenesis, 
involving discrete genetic events facilitating transformation of healthy cells. 
Accumulation of spontaneous or inherited genetic mutations results in uncontrolled 
cellular growth, and eventually the formation of a malignant tumour. This process has 
been particularly well documented in colorectal cancer (CRC) (Vogelstein et al. 2013). 
Transformed cells subsequently invade other tissues during metastasis, the major 
cause of mortality from cancer (World Health Organisation). 
Hanahan and Weinberg have defined discrete hallmarks of cancer: traits that 
cells acquire as they progress to a neoplastic state to enable tumour growth and 
metastatic dissemination (Figure 1.1) (Hanahan & Weinberg 2000; Hanahan & 
Weinberg 2011). A fundamental characteristic of cancer cells is the sustenance of 
chronic proliferation, by deregulating signalling activities of growth factors that maintain 
normal cell homeostasis. Cancer cells must evade negative regulation of growth, 
mainly by circumventing growth suppression initiated by tumour suppressor genes. 
Resistance to programmed cell death is a prerequisite if cancer cells are to progress to 
malignancy. Furthermore, cancerous cells must acquire replicative immortality: the 
ability to progress through unlimited cycles of growth and division without being 
diverted down regulatory pathways involving senescence, a non-replicative but viable 
state, or crisis, culminating in cell death (Hanahan & Weinberg 2000).  
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 To guarantee supply of nutrients and oxygen and purge itself of waste products, 
a tumour must develop its own vascular system by initiating angiogenesis: sprouting of 
new vessels from existing vasculature (Hanahan & Weinberg 2000). Due to an 
unbalanced chronic pro-angiogenic signature, tumours are characterized by aberrant 
heterogeneous vasculature including precocious sprouting, excessive branching and 
distorted vessels, causing erratic blood flow, leakiness, hypoxia, increased interstitial 
pressure and micro-haemorrhaging (Hagen et al. 2008). Another key trait is invasion of 
local tissues and formation of distant metastases (Hanahan & Weinberg 2000).  
In 2011, Hanahan and Weinberg updated their review, to include two new 
emerging hallmarks of neoplastic disease. Firstly, to fuel limitless growth and division, 
cancerous cells must deregulate cellular energetics. The final emerging hallmark 
involves evasion of immune system recognition and attack, which is absolutely 
necessary for progression of a developing tumour (Hanahan & Weinberg 2011).  
Figure 1.1 | The Eight Hallmarks of Cancer. 
The hallmarks of cancer are traits cells acquire as they progress to malignancy. Cancer cells 
must sustain chronic proliferative signalling, evade negative regulation of growth, resist 
apoptotic programmed cell death, acquire replicative immortality, initiate angiogenesis, and 
activate a program of invasion of local tissues and formation of distant metastases. More 
recently recognised hallmarks are deregulation of cellular energetics, and escape from 
recognition and attack by a competent immune system. Brown circles represent tumour. 
Adapted from (Hanahan & Weinberg 2000; Hanahan & Weinberg 2011). 	
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1.2 Cancer Immunology   
1.2.1 A history of Cancer Immunosurveillance 
The concept that the immune system can recognize, target and destroy nascent 
transformed cancer cells was conceived in the early 1900’s. Paul Ehrlich proposed that 
the immune system suppresses formation of what would otherwise be an 
“overwhelming frequency” of carcinomas. Thereby followed a century of robust debate 
surrounding immune system involvement in control of tumour formation (Dunn et al. 
2002).  
Medawar and colleagues clarified a role for cellular components of the immune 
system in allograft transplant rejection in the mid 1900’s (Medawar 1944). However, 
transplanted tumours from non-inbred mice were destroyed on the basis of allogeneic, 
rather than tumour-specific, rejection. Successful immunization against carcinogen or 
virally induced syngeneic tumours in inbred mice established that tumour cells were 
immunologically distinct from healthy cells, proving the existence of tumour specific 
antigens (Old & Boyse 1964; Klein et al. 1960). These landmark discoveries supported 
the formal ‘Cancer Immunosurveillance’ hypothesis, originally proposed by Burnet and 
Thomas: that thymus-dependent cells of the immune system act as sentinels in 
continual surveillance of host tissues for nascent, transformed cells, which they 
recognize and eliminate (Burnet 1957).  
Several studies subsequently tested predictions of the hypothesis; that 
immunocompromised animals are more susceptible to spontaneous or chemically 
induced tumours, relative to immunocompetent counterparts (Dunn et al. 2002). 3-
methylcholanthrene (MCA) is a polycyclic aromatic hydrocarbon, and a chemical 
carcinogen found in environmental pollutants. MCA induces tumour formation, usually 
fibrosarcomas, at the site of injection, and induces cellular transformation via 
accumulation of multiple random mutations. The MCA carcinogenesis model has been 
used extensively in tumour immunology studies: this system, in contrast to 
transplantable tumour models and tumour cell line models, accurately models 
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reciprocal interactions between the immune system and the tumour during very early 
stage carcinogenesis (Blankenstein & Qin 2003).  
Osias Stutman found no difference in incidence of tumours induced by MCA 
between athymic nude mice, which carry a genetic immunologic defect, and wild-type 
(WT) animals (Stutman 1974; Outzen et al. 1975). There was also no difference in 
incidence of spontaneous non-viral tumour development between WT and nude mice 
(Rygaard & Povlsen 1974a; Rygaard & Povlsen 1974b). These studies argued against 
the Cancer Immunosurveillance hypothesis, which was largely abandoned at the time. 
With technological advances and availability of inbred mouse strains genetically 
deficient for immune system components in the 1990’s, came resurgence in the 
Cancer Immunosurveillance hypothesis. Interferon (IFN)-γ deficient mice or mice 
lacking perforin (a component of cytolytic granules that mediate CD8+ Cytotoxic T 
Lymphocyte (CTL) or Natural Killer (NK) cell killing) demonstrated increased incidence 
of transplanted, chemically induced or spontaneous tumours relative to 
immunocompetent animals (Dunn et al. 2002). In support of lymphocyte involvement in 
Immunosurveillance, gene-targeted recombination activating gene (RAG)-2 deficient 
animals, which lack T, B and Natural Killer T (NKT) cells, developed MCA-induced 
sarcomas quicker and at greater frequency than WT controls (Shankaran et al. 2001). 
 Indeed, mice lacking various immune constituents, such as NK, NKT, γδ T, and 
αβ T cells, and IFN-γ and Interleukin (IL)-12, all displayed increased susceptibility to 
tumour development (Dunn et al. 2002). These studies lent considerable weight to the 
idea of immune involvement in cancer, and demonstrated involvement of both innate 
and adaptive arms. Additionally, significant caveats to Stutman’s experiments were 
identified; most notably that nude mice are incompletely immunocompromised. Finally, 
a landmark study in 2007 provided definitive evidence for the involvement of adaptive 
immunity in control of tumour development (Koebel et al. 2007). Collectively, this 
enormous body of work by multiple independent investigators solidified the concept of 
Cancer Immunosurveillance: that the immune system can recognize and destroy 
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developing primary tumours, during which lymphocytes and lymphocyte-derived 
cytokines are key (Dunn et al. 2002; Burnet 1957).  
Accumulation of direct evidence for Cancer Immunosurveillance in humans is 
problematic: anti-tumour immune responses that effectively clear tumour are not 
recorded by researchers or physicians, as the patient does not present clinically. 
Conversely, patients that do present clinically are arguably people in which immune-
mediated mechanisms of tumour control have failed (Gallimore & Godkin 2008).  
Long-term epidemiological data show that immunocompromised patients 
demonstrate an increased risk for development of non-viral primary tumours relative to 
the general population (Penn 1999). However, the strongest evidence for Cancer 
Immunosurveillance in humans is provided by the significant correlation between 
number of tumour infiltrating lymphocytes (TILs) and prognostic markers, such as 
patient survival, for many types of cancer, including breast, colon and melanoma (Dunn 
et al. 2002; Gallimore & Godkin 2008). Specifically, presence of IFN-γ producing CD4+ 
T-helper (TH)1 type cells and CD8+ CTLs is associated with better clinical outcome 
(Naito et al. 1998; Sato et al. 2005; Pagès et al. 2005; Galon et al. 2006). These 
studies illustrate the existence and physiological relevance of Cancer 
Immunosurveillance in humans as well as animal models (Gallimore & Godkin 2008). 
1.2.2 Cancer Immunoediting  
Surveillance of tumour development is now known to represent just one 
dimension of the complex interaction between the immune system and cancer. It has 
long been recognized that the immune system can initiate and even promote tumour 
progression during chronic inflammation (Grivennikov et al. 2010). The Cancer 
Immunosurveillance hypothesis has undergone extensive resculpturing in recent 
decades, owing to the recognition that the immune system can also modify the 
immunogenicity of a developing tumour: tumours originated in immunodeficient hosts 
are more immunogenic than those developed in immunocompetent environments 
(Shankaran et al. 2001). Evidence now indicates that the immune system can even 
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select for and promote emergence of low immunogenicity tumour variants, thereby 
aiding tumour escape from immune destruction.  
The paradoxical ways in which the immune system influences tumour 
development are recognized in the revolutionized ‘Cancer Immunoediting’ hypothesis, 
which encompasses both host-protective and tumour-sculpting functions of the immune 
system. Cancer Immunoediting consists of three phases that occur independently or 
sequentially: Elimination, Equilibrium and Escape (Figure 1.2). ‘Elimination’ refers to 
classical immunosurveillance, during which transformed cells are eliminated by a 
collaborative effort between innate and adaptive immune arms. Specific immune 
components required likely depends on characteristics such as origin, and anatomical 
location of the tumour (Schreiber et al. 2011; Mittal et al. 2014). 
Cancer cell variants that avoid immune destruction may subsequently undergo 
editing and sculpting by the adaptive immune system during ‘Equilibrium’. Tumour 
outgrowth is controlled during this phase, leading to tumour dormancy (Schreiber et al. 
2011). Koebel’s study in 2007 unequivocally demonstrated a role for adaptive immunity 
in maintaining MCA-induced fibrosarcomas in a state of immune-mediated dormancy 
(Koebel et al. 2007). These data were corroborated by studies in other models (Loeser 
et al. 2007; Eyles et al. 2010). Immunological restraint of transformed cells is also 
inferred from reports of tumour development in immunosuppressed patients following 
transplantation of an organ harbouring occult cancer cells (MacKie et al. 2003).  
Immune-meditated dormancy can be a prolonged stage, maintained by the 
balance between elimination-promoting IL-12 and tumour-promoting IL-23 (Teng et al. 
2012). Additionally, the relative balance of immunosuppressive cells, such as Foxp3+ 
Regulatory T cells (Tregs; described in detail in section 1.5 below) and Myeloid Derived 
Suppressor Cells (MSDCs), to those underpinning anti-tumour immune responses, 
such as CD8+ CTLs and NK cells, influences whether tumours are maintained in a 
state of dormancy (Wu et al. 2013). Transition through Equilibrium also depends on cell 
intrinsic mechanisms of T cell regulation via co-stimulatory and co-inhibitory receptors 
and ligands (Mittal et al. 2014). Equilibrium is the target of many cancer 
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immunotherapies, which largely aim to tip the balance in favour of elimination at the 
expense of escape (Quezada et al. 2011).   
In the final stage of Escape, immunologically edited tumours that have 
circumvented immune recognition progress to become clinically apparent. Escape 
mechanisms are highly complex and varied, and involve loss of tumour antigen 
expression, resistance to cytotoxicity, and establishment of an immunosuppressive 
microenvironment capable of suppressing further immune attacks (Schreiber et al. 
2011). Novel immunotherapies target checkpoint molecules that contribute to 
immunosuppression (see Section 1.3.3) (Mittal et al. 2014). 
The concept of Cancer Immunoediting relies upon the premise that T cells 
recognize Tumour-Associated Antigens (TAAs), which dictates whether a developing 
tumour is efficiently eliminated or immunologically sculpted (Mittal et al. 2014). These 
so-called ‘cancer rejection epitopes’ presented in Major Histocompatibility Complex 
(MHC) complexes on tumour cells or Antigen Presenting Cells (APCs) could be non-
mutated self non-tolerogenic proteins recognized by T cells, or new proteins, 
completely absent from the normal human genome, formed by mutational events 
during tumour formation. The latter are referred to as neo-antigens (Schumacher & 
Schreiber 2015).  
Until recently, the existence of tumour neo-antigens, and those that are 
recognized by T cells and capable of inducing immune responses, has remained 
elusive. Matsushita and colleagues used exome sequencing and MHC Class I 
prediction algorithms to study the mutational landscape of a highly immunogenic, 
unedited MCA-derived tumour raised in RAG2 deficient mice. A mutation in the gene 
encoding Spectrin-β2 was discovered as a source of a tumour-associated neo-antigen 
epitope, which functioned as an immunodominant rejection antigen. Tumour cell clones 
lacking expression of this antigen displayed decreased immunogenicity and outgrew 
clones expressing the antigen by a process of T cell-dependent immunoselection 
(Matsushita et al. 2012). Such data support the notion that Cancer Immunoediting 
involves T cell mediated elimination and/or immunological sculpting of tumours based 
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on recognition of tumour-associated neo-antigens. Clinical studies have demonstrated 
the existence of Cancer Immunoediting reliant upon neo-antigens in humans. 
Immunoselection and outgrowth of tumours lacking expression of tumour-associated 
neo-antigens has been found following immunotherapy (Boehmer et al. 2013; 
Nicholaou et al. 2011). Such studies highlight the requirement to target several TAAs in 
immunotherapy if outgrowth of low immunogenic tumour variants is to be prevented 
(Mittal et al. 2014). 
 
Figure 1.2 | The Concept of Cancer Immunoediting. 
Cancer Immunoediting consists of Elimination, Equilibrium and Escape. Immunoediting acts as 
an extrinsic tumour suppressor, functioning once healthy cells have undergone transformation. 
The immune system is alerted to the presence of a tumour in ways potentially encompassing 
release of “danger signals” such a Type 1 IFN; presentation of tumour antigens in MHC 
complexes; expression of stress ligands, such as ligands for NK receptors (NKR) like NKG2D; 
and exposure of calreticulin which signals hyperploidy and thereby increases immunogenicity of 
transformed cells. Elimination involves a collaborative effort between components of innate and 
adaptive immune systems, as listed/ depicted here. If rare tumour variants escape immune 
destruction during elimination, they can undergo immunogenicity editing and sculpting during 
Equilibrium. During this stage, cells of the adaptive immune system, primarily T cells, halt 
tumour progression to prevent outgrowth by inducing a state of functional dormancy, for which 
the cytokines IL-12 and IFN-γ are absolutely required. An alternative, however, is the 
emergence of tumour variants that have lost MHC and/or tumour antigen presentation and are 
invisible to the immune system. These variants can hence enter the escape phase, where 
tumour outgrowth to clinical appearance occurs. Other mechanisms leading to tumour escape 
include increased insensitivity to immune-mediated tumour cell killing, and/or the establishment 
of an immunosuppressive microenvironment by recruitment of Tregs and MDSCs, which 
suppress activity of immune cells via the molecules listed, and up-regulation of 
immunomodulatory molecules on tumour cells, such as PD-L1. Adapted from (Schreiber et al. 
2011; Mittal et al. 2014). 	
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1.3 Cancer Immunotherapy 
 Advances in our understanding of the interplay between developing tumours 
and the immune system is enabling immunological manipulation to treat human 
malignancies. Successful immunotherapy proves challenging, due to the plethora of 
mechanisms underpinning immune-mediated tolerance to self-antigens. A growing 
appreciation of immune tolerance has accelerated development of new approaches to 
combat cancer using the immune system, as discussed below (Makkouk & Weiner 
2015).  
1.3.1 Adoptive Cell Therapy  
 Adoptive Cell Therapy (ACT) is a highly personalized therapy, involving the 
infusion of immune cells into a patient. The immune cells administered tend to be 
naturally occurring autologous lymphocytes isolated from tumour, which exhibit anti-
tumour reactivity and are expanded ex vivo prior to infusion. Alternatively, host 
lymphocytes are genetically engineered to express TCRs or Chimeric Antigen 
Receptors (CARs) specific for tumour antigens (Rosenberg & Restifo 2015).  
 Clinical trials of ACT therapy for melanoma have consistently yielded 
impressive objective response rates in approximately 50% of patients, with complete 
responses observed in up to 22% of patients (Hinrichs & Rosenberg 2014). However, 
melanomas seem to be one of the only tumour types amenable to ACT therapy 
(Rosenberg & Restifo 2015). Transfer of lymphocytes engineered to express a TCR 
specific for the melanoma-melanocyte antigen Melan-A (MART-1) led to tumour 
regression in patients (Morgan et al. 2006), setting the stage for engineering T cells to 
express receptors specific for antigens expressed on different tumour types. Transfer 
of T lymphocytes engineered to express a CAR targeting CD19 led to successful 
regression of advanced B cell lymphoma (Kochenderfer et al. 2010), and, more 
recently, sustained remission in up to 67% of leukaemia patients (Maude et al. 2014). 
However, targeting of antigens over expressed on tumours but expressed at low levels 
on healthy tissue, such as Melan-A, leads to considerable on-target off-tumour toxicity 
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in patients (Johnson et al. 2009). Considering the durable and complete tumour 
regression in metastatic melanoma patients, identification of the antigens recognized 
by melanoma TILs could enable discovery of suitable tumour-specific targets to 
translate the clinical benefit of ACT to other cancer types (Rosenberg & Restifo 2015).  
1.3.2 Cancer Vaccines 
 Rationale for cancer vaccines was proven by demonstration of T cell 
recognition of a melanoma antigen, MAGE-A1 (van der Bruggen et al. 1991). A 
plethora of TAAs have since been identified (Vigneron et al. 2013). The majority of 
targets belong to the cancer testis antigen family, a class of proteins with endogenous 
expression restricted to male germ cells, which are over expressed in tumours. Peptide 
vaccines targeting one of two cancer testis antigens, MAGE-A3 and NY-ESO-1, have 
been explored extensively for clinical benefit in trials (Dougan & Dranoff 2009). These 
approaches have limited efficacy, possibly due to the inability to break immunological 
tolerance to self. Addition of immune adjuvants, such as IL-2, to boost peptide-specific 
T cell activation has proven effective in some cases (Makkouk & Weiner 2015). 
 Whole tumour cell and antigen-pulsed Dendritic Cell (DC) vaccination 
approaches have also been explored. Tumour cells act as potent multivalent vaccines, 
generating an immune response against multiple antigens. GVAX is composed of two 
irradiated prostate cancer cell lines, engineered to express Granulocyte-Macrophage 
Colony Stimulating Factor (GM-CSF). However, despite evidence of an immune 
response, clinical trials of GVAX showed no survival benefit (Makkouk & Weiner 2015).  
Antigen-pulsed DC vaccines have arguably shown the most promise, 
evidenced by US Food and Drug Administration (FDA) approval of Sipuleucel-T 
(Provenge), for metastatic hormone-refractory prostate cancer in 2010, following 
demonstrable increased overall survival in three independent phase III clinical trails 
(Higano et al. 2009; Small et al. 2006; Kantoff et al. 2010; Kissick & Sanda 2015). 
Sipuleucel-T consists of autologous DCs loaded with a fusion protein of Prostatic Acid 
Phosphatase (PAP) and GM-CSF (Makkouk & Weiner 2015). The failure of cancer 
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vaccines has been attributed to endogenous T cell exhaustion caused by chronic 
antigen exposure in the tumour microenvironment, prohibiting the required rapid 
division of CD8+ T cells in response to antigen presentation. By combining existing 
cancer vaccines with new modalities aimed at circumventing T cell exhaustion (see 
Section 1.3.3), efficacy of vaccination could be significantly improved (Kissick & Sanda 
2015).  
1.3.3 Checkpoint Inhibitors  
Checkpoint inhibitor therapy represents a radical shift in cancer immunotherapy. 
The goal is not to enhance activity of the immune system against tumour cells, but 
remove inhibition of endogenous T cell activity, circumventing T cell exhaustion. 
Checkpoint inhibitor therapy works on the premise that activation of naïve T cells by 
TCR recognition of tumour-antigen-MHC complexes requires co-stimulatory signals in 
the form of T cell expressed CD28 engagement by B7 ligands CD80 (B7.1) and CD86 
(B7.2) expressed on APCs (Sharma & Allison 2015; Salomon & Bluestone 2001). 
 T cell activation results in proliferation and differentiation but also activation of 
inhibitory pathways that eventually terminate T cell responses. These inhibitory 
feedback loops function to mitigate uncontrolled, harmful immune responses (Sharma 
& Allison 2015; Quezada & Peggs 2013). One major inhibitory pathway is mediated by 
Cytotoxic T Lymphocyte associated Antigen 4 (CTLA-4). CTLA-4 binds CD80 and 
CD86 with higher affinities than CD28 and therefore opposes CD28-mediated T cell 
stimulation, promoting down-regulation of T cell responses (Sharma & Allison 2015). 
 Early studies in mouse models demonstrated that CTLA-4-mediated inhibitory 
signals limit anti-tumour immune responses, and blockade of CTLA-4 enabled 
sufficient persistence of anti-tumour T cell responses to facilitate tumour rejection, 
without prior knowledge of TAAs (Leach et al. 1996; Krummel & Allison 1996). Two 
seminal phase III clinical trials demonstrated considerable improved overall survival in 
metastatic melanoma patients treated with Ipilimumab, a fully human anti-CTLA-4 
monoclonal antibody (Hodi et al. 2010; Robert et al. 2011), resulting in FDA approval in 
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2011 (Sharma & Allison 2015). Crucially, a durable response of survival up to 4 years 
was observed in approximately 20% of treated patients, with a subset of patients 
surviving to 10 years or more (Schadendorf et al. 2015). However, anti-tumour affects 
of Ipilimumab are accompanied by considerable immune-related Adverse Events (irAE) 
in approximately 60% of patients (Hodi et al. 2010).  
 It was initially suggested that Ipilimumab functions via direct blockade of CTLA-
4 on effector T cells (Walunas et al. 1994; Krummel & Allison 1995; Krummel & Allison 
1996; Sutmuller et al. 2001). However, as CTLA-4 is constitutively expressed at high 
levels on both murine and human Tregs (see Section 1.5.4.2) (Read et al. 2000; 
Takahashi et al. 2000; Wing et al. 2008; Dieckmann et al. 2001), anti-CTLA-4 could 
directly deplete Tregs or inhibit their suppressive capacity (Read et al. 2006). Quezada 
and colleagues demonstrated a requirement for anti-CTLA-4 to bind both effector T 
cells and Tregs for full anti-tumour activity (Peggs et al. 2009). Many groups have 
shown that anti-CTLA-4 in fact expands the Treg compartment in both mice and 
humans (Quezada et al. 2006; Schmidt et al. 2009; Kavanagh et al. 2008). However, 
successful rejection of tumour following anti-CTLA-4 treatment is commonly associated 
with an increased effector T cell : Treg ratio, specifically in the tumour (Shrikant et al. 
1999; Quezada et al. 2006; Kavanagh et al. 2008; Liakou et al. 2008; Chen et al. 2009; 
Curran & Allison 2009; Waitz et al. 2012). Quezada and colleagues have elegantly 
demonstrated through T cell tracking experiments that anti-CTLA-4 therapy results in 
an increase in absolute numbers of effector T cells and Tregs in lymph nodes, but a 
reciprocal decrease in absolute numbers of Tregs with an increase in absolute 
numbers of effector T cells in the tumour. Depletion of Tregs in the tumour was shown 
to be dependent on the presence of Fcγ-receptor expressing macrophages, explaining 
the paradoxical effects of this antibody therapy on T cell ratios in lymphoid organs and 
tumour (Simpson et al. 2013).  
 In 2000, another immune checkpoint molecule, Programmed cell Death (PD) 1 
(PD-1), was found to circumvent the responses of activated T cells (Freeman et al. 
2000). In contrast to CTLA-4, PD-1 interferes with TCR signalling, when activated by 
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one of two ligands, PD-Ligand (PD-L)1 or PD-L2 (Sharma & Allison 2015). PD-1 is also 
up-regulated on T cells following activation, but unlike CTLA-4 is more broadly 
expressed on B cells, monocytes and NKT cells in addition to T cells (Greenwald et al. 
2005). PD-L1 is broadly expressed on T and B cells, DCs, and macrophages, and is 
significantly up-regulated on several human tumours, possibly in response to T cell-
derived IFNγ, where it is thought to attenuate anti-tumour immune responses. PD-L2 is 
expressed mostly on macrophages and DCs following activation (Madorsky Rowdo et 
al. 2015; Quezada & Peggs 2013).  
 PD-1 is highly expressed on Tregs, and promotes their function when bound to 
a cognate ligand, leading to the hypothesis that PD-1 blockade could attenuate the 
number or function of intra-tumoural Tregs (Madorsky Rowdo et al. 2015). Blockade of 
the PD-1 pathway in mouse models increased anti-tumour T cell activity (Dong et al. 
2002; Iwai et al. 2002; Fife et al. 2009). The humanized anti-PD-1 monoclonal 
antibody, pembroluzimab, received FDA approval in 2014, following good clinical 
response rates in advanced melanoma patients (Hamid et al. 2013; Robert et al. 2014; 
Topalian et al. 2012; Topalian et al. 2014). However, as for anti-CTLA-4, 
Pembroluzimab results in toxic effects in 79% of patients (Hamid et al. 2013), and can 
induce autoimmune diabetes (Martin-Liberal et al. 2015). A second anti-PD-1 
monoclonal antibody, Nivolumab, has been approved for metastatic melanoma and 
metastatic or advanced NSCLC (Robert et al. 2015; Sharma & Allison 2015).  
The distinct mechanisms of action of anti-CTLA-4 and anti-PD-1 antibodies 
suggest that combinatorial therapy may result in more efficacious T cell responses 
(Parry et al. 2005; Sharma & Allison 2015). Pre-clinical studies have shown better 
outcome following combined therapy relative to either therapy alone (Curran et al. 
2010). A phase I clinical trial recently demonstrated tumour regression (most with 
regression of ≥80%) in approximately half of advanced melanoma patients treated with 
combination therapy (Wolchok et al. 2013).  
Checkpoint blockade therapies have achieved unprecedented overall response 
rates in the clinic. However, complete response rates remain at the few per cent for 
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both therapies, indicating room for improvement. Furthermore, the observed irAE, 
consistent with a mechanism of action based on general activation of the immune 
system, could represent a significant limitation. Improving lymphocytic infiltration into 
the tumour mass could improve efficacy and selectivity of these treatments in the future 
(Madorsky Rowdo et al. 2015). 
1.3.4 Neo-antigens in Cancer Immunotherapy 
 The clinical studies mentioned above demonstrate the inherent tumouricidal 
potential of endogenous T lymphocytes and the ability of therapies to potentiate robust 
anti-tumour immune responses without prior knowledge of tumour antigens. However, 
therapies designed by exploitation of information regarding tumour specific neo-
antigens are now becoming feasible. The neo-antigens expressed by a tumour from 
one patient are unlikely to be shared at any considerable frequency with those from 
another patient’s tumour, and hence are largely patient specific. Attempts to interrogate 
T cell reactivity towards any particular neo-antigen therefore need to be centred 
entirely on the genome of an individual patient’s tumour. With the advent of deep 
sequencing, it is now feasible to sequence an individual patient’s tumour exome (the 
protein-encoding part of the genome) to find mutated proteins, from which putative 
neo-antigens for T cell recognition can be predicted using computational algorithms. 
The feasibility of this approach has been demonstrated by several recent seminal 
studies in mouse and human (Castle et al. 2012; Matsushita et al. 2012; Robbins et al. 
2013; van Rooij et al. 2013; Schumacher & Schreiber 2015).  
1.4 The Tumour Microenvironment as a Hostile Site of Immune Privilege  
A prerequisite of successful cancer immunotherapy is physical contact between 
anti-tumour T cells and target cancer cells. Stromal and immune cells resident of the 
Tumour Microenvironment (TME) can restrict access of tumour-specific T cells (Joyce 
& Fearon 2015). A study in 1960 demonstrated the inability of an immune response 
initiated by a primary MCA-induced tumour to control tumour growth, despite the ability 
of this response to inhibit establishment of a secondary tumour derived from primary 
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tumour cells. Hence tumours establish an immune-privileged microenvironment, 
shielding themselves from immune recognition and attack (Klein et al. 1960).  
Immune suppression by the TME was demonstrated in humans by the co-
existence of progressing melanoma in patients with T cells capable of recognizing 
MAGE-A1 (van der Bruggen et al. 1991). Such studies illustrate that induction of 
tumour antigen-specific T cells via vaccination or ACT may be insufficient for robust 
control of tumour growth. Indeed, infiltration of highly activated anti-tumour effector T 
cells via tumour vasculature is a frequently overlooked prerequisite for successful 
immunotherapy (Chen et al. 2003). This hurdle could explain that, despite the induction 
of vast quantities of circulating T cells by vaccination and no evidence for cancer cell 
antigen shedding, melanoma patients frequently demonstrate disease recurrence 
(Rosenberg et al. 2005). The difference in composition and penetrability of the 
microenvironment of leukaemias relative to solid tumours could explain the limited 
efficacy of ACT in the latter (Joyce & Fearon 2015). 
 Clinical success of checkpoint blockade therapies could be attributed to their 
ability to overcome some of the immunosuppressive functions of the TME (Joyce & 
Fearon 2015). As previously mentioned, anti-CTLA-4 therapy in mice results in a 
reduction in the number of immunosuppressive Foxp3+ Tregs in tumours (Simpson et 
al. 2013). PD-1 pathway blockade is thought to function by preventing the negative 
regulatory signals derived from tumour cell-expressed PD-L1. The inability to achieve 
objective clinical responses in a large fraction of patients following checkpoint inhibitor 
therapy, however, could reflect the plethora of immunosuppressive mechanisms 
employed by tumours (Joyce & Fearon 2015). 
1.4.1 The Tumour Vasculature: a Prominent Component of the 
Immunosuppressive Tumour Microenvironment 
Due to the aberrant exposure to pro-angiogenic factors such as Vascular 
Endothelial Growth Factor (VEGF)-A, tumours develop a highly disorganized, distorted 
vasculature (Hagen et al. 2008). Tumour vasculature represents a major component of 
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the immunosuppressive TME, employing multiple mechanisms to selectively recruit or 
exclude cells (Figure 1.3) (Joyce & Fearon 2015; Motz & Coukos 2011). VEGF 
additionally acts as an immunosuppressive factor, and elevated VEGF levels on 
endothelium of human ovarian tumours is associated with decreased infiltration of 
effector anti-tumour T cells and a worse prognosis (Zhang et al. 2003). The anti-VEGF-
A monoclonal antibody, Bevacizumab, became the first anti-angiogenesis agent 
approved for treatment of metastatic CRC by the FDA in 2004 (Ellis & Hicklin 2008). 
Low doses of anti-VEGF-A therapy results in so-called “normalization” of tumour 
vasculature, involving reversal of the highly chaotic structure to a mature, healthy 
vascular bed (Jain 2005; Tong et al. 2004; Willett et al. 2004). Vascular normalization 
by antiangiogenic therapy significantly improves infiltration of effector T cells, boosting 
ACT or vaccine efficacy in mouse models (Shrimali et al. 2010; Huang et al. 2012). 
Molecules expressed by tumour endothelial cells enforce a barrier to anti-
tumour T cells (Joyce & Fearon 2015). One study revealed establishment of a “tumour 
endothelial death barrier” via endothelial expression of the apoptosis inducer Fas 
ligand (FasL) within human ovarian, breast, bladder, prostate, colon and renal cancers. 
High endothelial FasL expression was associated with a paucity of CD8+ CTLs and an 
abundance of Tregs in tumours; the latter are thought to protect themselves against 
FasL-mediated killing by high expression of c-FLIP, an apoptosis inhibitor. In mouse 
models, FasL inhibition significantly increased infiltration of anti-tumour T cells, which 
mediated tumour control, and substantially improved efficacy of ACT. FasL expression 
was induced by immunosuppressive factors in the TME, including VEGF, prostaglandin 
E2 (PGE2), and IL-10 (Motz et al. 2014). The vasculature of human ovarian tumours 
also expresses endothelin B receptor (ETBR), which correlates with lower frequencies 
of infiltrating T cells and poor outcome. ETBR inhibition increased effector T cell 
infiltration into tumours and significantly improved efficacy of vaccination (Buckanovich 
et al. 2008). Expression of B7-H3, another ligand for CTLA-4, on tumour endothelium 
has also been associated with reduced T cell infiltration and worse clinical outcome in 
ovarian carcinoma patients (Figure 1.3) (Zang et al. 2010).  
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 Tumour vessels are characterized by sub-threshold expression of lymphocyte 
trafficking molecules (Fisher et al. 2011). Tumour vasculature is also incredibly 
refractory to endothelial activation induced by pro-inflammatory cytokines. Tumour 
Necrosis Factor (TNF)α potently induces expression of vascular adhesion molecules 
on peritumoural vessels during inflammation, aiding lymphocytic recruitment. Local 
administration of TNFα in mouse models results in only marginal improvements in 
leukocyte adhesion to tumour vessels, whilst nearby normal vasculature is fully 
responsive (Chen et al. 2003). Induction of biophysical stress responses by fever-
range thermal therapy can increase tumour vascular perfusion and selective adhesion 
of CD8+ CTLs at the expense of Tregs (Repasky et al. 2013). Collectively, the 
aforementioned studies illustrate an important requirement to modulate the tumour 
vasculature to drive anti-tumour T cell infiltration into the TME for efficient tumour 
clearance (Joyce & Fearon 2015). 
Figure 1.3 | The Immunosuppressive Tumour Vasculature. 
Tumours display highly aberrant vasculature, including incomplete pericyte coverage. Tumour 
endothelium expresses FasL, which is induced by VEGF, PGE2 and IL-10. FasL induces 
apoptosis of anti-tumour effector T cells, while Tregs are refractory to FasL-induced killing due 
to their high surface expression of c-FLIP. Other immunosuppressive molecules expressed on 
tumour endothelium include B7-H3, a ligand for CTLA-4, and ETBR. FasL, Fas Ligand; VEGF, 
Vascular Endothelial Growth Factor; PGE2, Prostaglandin E2; IL-10, Interleukin-10; c-FLIP, 
cellular FLICE (FADD-like IL-1 β-converting enzyme)-Like Inhibitory Protein; ETBR, Endothelin B 
Receptor. Adapted from (Joyce & Fearon 2015). 
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1.5 Foxp3+ Regulatory T cells 
1.5.1 Introducing Foxp3+ Regulatory T cells 
 CD4+ CD25+ Forkhead box protein 3 (Foxp3)+ Regulatory T cells (Treg) 
represent a major immunosuppressive cell type within tumours, where they impinge on 
many of the anti-tumour immune responses discussed in detail above (Nishikawa & 
Sakaguchi 2010; Gallimore & Godkin 2008). Anti-tumour T cells are reactive to self-
antigens aberrantly expressed by tumour cells, such as cancer testis antigens as 
described earlier (see Section 1.3.2). It was therefore reasoned that mechanisms 
responsible for maintaining immunological tolerance to self could also inhibit anti-
tumour immune responses (Scanlan et al. 2004; Nishikawa & Sakaguchi 2010). 
Two major processes underpin tolerance to self, which is essential for 
continued preservation of immune homeostasis. Central tolerance encompasses a 
process whereby T cells harbouring a high affinity self-antigen specific TCR undergo 
negative selection (clonal deletion) in the thymus, and are directed to programmed cell 
death by apoptosis. Peripheral tolerance is established by differentiation of Tregs 
(clonal deviation) in the thymus, which exert immunosuppression to maintain tolerance 
to self at peripheral sites throughout the lifetime of an animal (Klein et al. 2014).  
 According to the model of thymocyte selection, the developmental fate of T 
cells in the thymus is specified by the nature (i.e. strength) of the interaction between 
their TCR and cognate self-peptide-MHC complexes expressed by thymic APCs (Klein 
et al. 2014). Treg differentiation appears to occur within an intermediate window of 
TCR affinity for self-antigen that lies between the upper limit imposed by TCR 
interactions that drive negative selection and the lower limit demarked by TCR 
interactions driving positive selection (Jordan et al. 2001). Positive selection is the 
process by which CD4+ CD8+ double positive thymocytes that express low affinity 
TCRs specific for self-peptide-MHC complex differentiate into either mature CD4+ or 
CD8+ single positive thymocytes (Hsieh et al. 2012). 
 Tregs are indispensible for maintenance of immune homeostasis and promotion 
of peripheral immunological tolerance to self-antigens. Tregs prevent autoimmunity by 
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keeping in check the activation and expansion of over-reactive immune cells, therefore 
limiting excessive and harmful immune responses. Tregs largely control the responses 
of self-reactive T cells, which have escaped thymic deletion and entered the peripheral 
T cell pool. Developmental or functional defects in Tregs result in profound 
autoimmune and inflammatory disease pathology in both humans and animals, 
illustrating their physiological significance as a dominant, cell-extrinsic mechanism of 
self-tolerance (see Section 1.5.2) (Sakaguchi et al. 2008; Attridge & Walker 2014).   
 The vast majority of endogenous Tregs develop in the thymus as a functionally 
distinct, mature population of T cells, termed Thymus-derived Tregs or ‘tTregs’ 
(Sakaguchi 2005; Huehn & Beyer 2015). Tregs can also be generated de novo in the 
periphery by conversion of conventional naïve Foxp3- CD4+ T cells into Foxp3+ Tregs 
following antigen exposure, termed peripherally derived Tregs or ‘pTregs’. pTregs are 
thought to make an essential contribution to the peripheral Treg TCR repertoire by 
supplying TCR specificities directed towards non-pathogenic foreign antigens, 
including those derived from food, commensal gut microbiota, and foetal proteins. 
Lastly, induced Tregs or ‘iTregs’ encompasses Tregs induced in vitro from naïve 
conventional CD4+ T cells by TCR stimulation and IL-2 and Transforming Growth 
Factor (TGF)-β cytokine exposure (Huehn & Beyer 2015; Abbas et al. 2013).  
 Two early studies in which autoimmune disease developed following either 
neonatal thymectomy or adult thymectomy with sublethal X-irradiation made a 
significant contribution to the early appreciation of a Treg-mediated mechanism of self-
tolerance (Nishizuka & Sakakura 1969; Penhale et al. 1973). In both cases, the 
autoimmunities were suspected to be a result of a loss of a suppressor T cell subset 
(Sakaguchi et al. 1982; Penhale et al. 1976). Evidence for the existence of an 
immunosuppressive CD4+ T cell population also came from studies of spontaneous 
rodent models of autoimmunity: transfer of WT CD4+ T cells to non-obese diabetic 
(NOD) mice or Bio-Breeding (BB) rats, which normally develop spontaneous Type 1 
Diabetes mellitus (T1D), prevented disease onset. Transfer of diabetogenic T cells to 
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T-cell deficient hosts can also induce disease, but co-transfer of pathogenic T cells with 
normal CD4+ T cells prevents disease (Greiner et al. 1987; Boitard et al. 1989).  
Attempts were then made to define this immunosuppressive subset of cells by 
expression of a cell surface molecule. Co-transfer of CD5high T cells inhibited 
autoimmunity induced by the transfer of CD5-depleted CD4+ T cells alone 
(Sakaguchisaka 1985; Sugihara et al. 1988). Subsequent studies used CD45RB to 
differentiate between immunosuppressive CD4+ T cells (CD45RBlow) and inflammatory 
CD4+ T cells (CD45RBhigh) (Powrie et al. 1993; Morrissey et al. 1993). The cell surface 
CD25 (IL-2 receptor α chain (IL-2Rα)) molecule was then identified as the first putative 
marker of suppressive T cells and the term ‘regulatory T cell’ was coined: CD25+ T 
cells were contained in the CD5high CD45RBlow CD4+ population and constituted 5-10% 
of the peripheral CD4+ T cell pool and <1% of peripheral CD8+ T cells in both mice and 
humans. Critically, co-transfer of a small number of CD25+CD4+ T cells alongside CD4+ 
T cells was sufficient to inhibit the development of autoimmunity that occurs in 
syngeneic athymic nude mice transferred with CD25-depleted CD4+ T cell 
suspensions. Furthermore, depletion of CD25+CD4+ Tregs not only provoked 
autoimmunity but also augmented responses to non-self-antigens, including microbial 
and tumour antigens (Sakaguchi et al. 1995).  
1.5.2 The discovery of Foxp3 
 Immune deregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) 
syndrome was first described in 1982 as a fatal X-linked immunodeficiency syndrome 
in humans. X-linked Scurfy mutant mice, initially identified in the 1950s, but more 
extensively characterized in the 1990s, exhibit hyperactivation of CD4+ T cells, 
extensive multi-organ immune infiltration and elevated proinflammatory cytokine 
secretion (Sakaguchi 2004). The defective gene in Scurfy mice was later identified and 
coined Foxp3, a member of the forkhead/winged-helix family of transcriptional 
regulators (Brunkow et al. 2001). Several independent studies confirmed that 
mutations in the human ortholog of the murine Foxp3 gene were responsible for IPEX 
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syndrome (Chatila et al. 2000; Wildin et al. 2001; Bennett et al. 2001). Foxp3 
expression was predominantly restricted to CD4+ CD25+ Treg in the thymus and 
periphery, and was essential and sufficient for development of functional, suppressive 
Tregs (Hori et al. 2003; Fontenot et al. 2003; Khattri et al. 2003). Collectively these 
studies implicated Foxp3 as a master regulatory gene in Treg cell-lineage commitment, 
differentiation and function (Sakaguchi 2004). Subsequent studies confirmed that 
Foxp3 was also the Treg-lineage specific transcriptional master regulator in humans 
(Yagi et al. 2004; Roncador et al. 2005). In addition to its crucial role in Treg 
differentiation, sustained Foxp3 expression is also critical for maintenance of the Treg 
differentiation and functional program in mature T cells in adults (Lahl et al. 2007; Kim 
et al. 2007; Williams & Rudensky 2007; Zheng & Rudensky 2007).  
Foxp3 is a multi domain transcription factor encoded by an X-chromosome 
encoded gene (Huehn & Beyer 2015). In Foxp3-deficient humans and mice, 
hemizygous males carrying the mutant Foxp3 allele on their X chromosome are 
afflicted whereas heterozygous females harbouring the mutant Foxp3 allele on one of 
their X chromosomes are healthy. The Foxp3 mutation does not affect random X 
chromosome inactivation in T cells, and hence this process results in genetic 
mosaicism of defective and normal Treg cells. Therefore, Treg cells expressing WT 
Foxp3 allele are competent in terms of keeping in check hyperactive T cells and 
mediating peripheral tolerance in a dominant manner (Zheng & Rudensky 2007).  
1.5.3 Foxp3+ Treg Characteristics 
 The central defining feature of Tregs is their immunosuppressive activity, 
mediated through a variety of mechanisms (see Section 1.5.4) (Shevach 2009; 
Josefowicz et al. 2012). The induction of immunosuppressive function by Tregs is 
antigen specific, and relies on TCR stimulation. However, the suppressive capacity of 
Tregs seems to be antigen non-specific in vitro (Thornton & Shevach 2000), while it is 
still unclear whether antigen-specific suppression is important in vivo (Corthay 2009).  
Of note, Foxp3 expression can be temporarily induced in activated T cells in mouse or 
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human where it is not associated with suppressor activity, demonstrating potential 
plasticity of Foxp3 expression in T cells (Miyao et al. 2012; Gavin et al. 2006; Miyara et 
al. 2009). Additional important characteristics of Tregs include absolute dependence on 
the cytokine interleukin 2 (IL-2; see Section 1.5.5), immunosuppressive cytokine 
production, and unique intracellular metabolic regulation (Xudong Li & Zheng 2015).  
One of the cardinal features of Foxp3+ Tregs is exhibition of anergy (a 
reversible antiproliferative state) in vitro: in contrast to other CD4+ T cells, Tregs are 
unresponsive to agonistic TCR ligation in culture (Takahashi et al. 1998; Thornton & 
Shevach 1998; Read et al. 1998; Itoh et al. 1999; Kuniyasu et al. 2000). The 
development of transgenic Tregs with a known TCR specificity has greatly benefitted 
our understanding of physiological homeostasis and function of Tregs in vivo (Attridge 
& Walker 2014). Despite some contradictory results reporting an anergic state of Tregs 
following peptide-MHC complex presentation and costimulation in vivo (Gavin et al. 
2002), tracking of TCR-transgenic Tregs in multiple independent studies demonstrated 
the rapid hyperproliferation displayed by Tregs during a response to cognate antigen in 
vivo (Walker et al. 2003; Klein et al. 2003). Human Tregs also demonstrated in vitro 
proliferative anergy, but Tregs from blood displayed significantly higher proliferation 
than conventional CD4+ T cells, and the proliferative response of Tregs in secondary 
lymphoid organs was even higher than those in blood (Ng et al. 2001; Taams et al. 
2001; Vukmanovic-Stejic et al. 2008; Peters et al. 2013). These studies highlighted that 
local antigenic environments shape population dynamics of Tregs in vivo. As for other 
T cells, Tregs are capable of homeostasis-driven proliferation, as demonstrated by 
rapid proliferation in response to lymphopenia when transferred to RAG-1-/- hosts 
(Gavin et al. 2002; Annacker et al. 2001). In vitro anergy in CD25+ Tregs is closely 
linked to the inherent suppressive capacity of this cellular population: Treg suppression 
is simultaneously abrogated upon breaking of their anergic state by addition of high 
doses of IL-2 or an anti-CD28 monoclonal antibody (Takahashi et al. 1998).  
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1.5.4 Mechanisms of Treg-Mediated Suppression  
 A key challenge is understanding modes of Treg-mediated suppression, and 
their relevance for distinct disease states (Sakaguchi et al. 2008). Antigen stimulated 
murine and human Tregs suppress proliferation, cytokine production, and 
differentiation of naïve T cells in vitro in the presence of APC (Thornton & Shevach 
1998; Takahashi et al. 1998; Read et al. 1998). Additionally, Tregs directly inhibit T cell 
proliferation in the absence of APCs (Ermann et al. 2001; Dieckmann et al. 2001). 
Tregs are also capable of functional suppression of differentiated CD4+ and CD8+ T, 
NK, NKT, and B cells, and DCs, macrophages and osteoclasts (Sakaguchi et al. 2008). 
Four mechanisms of Treg-mediated suppression of Foxp3- CD4+ conventional T 
cells have been described based on results of in vitro Treg suppression assays (Figure 
1.4). These mechanisms act either directly on responder T cells, indirectly on 
responder T cells via direct action on APCs, or both (Schmidt et al. 2012; Vignali 
2012). Other molecules expressed on the surface of Tregs, such as Galectin-1 and 
Neuropilin-1 (Nrp-1), might also contribute to immunosuppression (Shevach 2009).  
 
Figure 1.4 | Mechanisms of Treg-Mediated Suppression. 
Mechanisms include 1) secretion of immunosuppressive cytokines IL-35, TGF β and IL-10, 2) 
expression of inhibitory receptors such as CTLA-4, which down-regulates CD80 and CD86, and 
up-regulates IDO on DCs, 3) direct killing via Granzyme B and perforin, and 4) metabolic 
disruption, including CD39/ CD73 mediated conversion of ATP or ADP to Adenosine, or 
‘scavenging’ of IL-2.  
Adapted from (Sakaguchi et al. 2009; Schmidt et al. 2012; Vignali 2012; Shevach 2009). 
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1.5.4.1 Synthesis of Inhibitory Cytokines 
 One recently discovered cytokine implicated in Treg-mediated suppression is 
IL-35. IL-35 is formed of the proteins encoded by the Epstein-Barr Virus-induced gene 
3 (Ebi3) and Il12a, both of which are significantly up-regulated in actively suppressing 
murine Tregs. Tregs from Ebi3-/- or Il12a-/- mice are severely functionally compromised 
in vitro, and Ebi3-/- and Il12a-/- animals are unable to regulate excessive immune 
responses in an in vivo Inflammatory Bowel Disease (IBD) model (Collison et al. 2007). 
 TGF-β is required for conversion of non-Tregs into pTregs, generation of iTregs 
and Treg homeostasis (Chen et al. 2003; Liu et al. 2008; Marie et al. 2005). However, 
whether TGF-β mediates Treg suppression remains controversial: use of anti-TGF-β 
antibodies in vitro has produced contrasting results (Nakamura et al. 2001; Piccirillo et 
al. 2002; Shevach 2009). Some studies have shown that while TGF-β deficient Tregs 
are capable of conventional T cell suppression in vitro, Treg-expressed TGF-β is 
necessary for control of colitis in vivo (Read et al. 2000; Izcue et al. 2009). In contrast, 
other studies have shown that TGF-β deficient Tregs are competent at controlling 
diseases such as IBD in vivo (Mamura et al. 2004; Fahlén et al. 2005).  
The anti-inflammatory cytokine IL-10 seems to play a crucial role in Treg-
mediated suppression (Belkaid 2007; McGeachy et al. 2005). Despite the failure of in 
vitro suppression assays to identify a suppressive function of Treg-generated IL-10, IL-
10 secretion by Tregs in vivo seems to be important for control of gut inflammation, 
infection and Experimental Autoimmune Encephalomyelitis (EAE) but dispensable for 
regulation of other autoimmunities and control of allergic responses (Schmidt et al. 
2012). A recent study has revealed that Treg-derived IL-10, but not IL-35 or TGF-β, is 
required to regulate effector T cell derived IFN-γ in the skin (Sojka & Fowell 2011; 
Schmidt et al. 2012).  
1.5.4.2 Expression of Inhibitory Receptors 
 One mechanism of direct APC inhibition involves expression of the coinhibitory 
molecule CTLA-4, which is constitutively expressed by both murine and human Tregs 
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(Read et al. 2000; Takahashi et al. 2000; Dieckmann et al. 2001). Addition of Tregs 
can ameliorate the spontaneous autoimmunity induced by genetic deficiency of CTLA-
4 or CTLA-4 blockade (Bachmann et al. 1999; Takahashi et al. 2000). Furthermore, 
anti-CTLA-4 abrogates the immunosuppressive effects of Tregs in vivo, thereby 
exacerbating murine colitis (Read et al. 2000). Selective CTLA-4 deficiency in Tregs is 
sufficient to induce fatal systemic autoimmunity, underpinning the significance of Treg-
specific CTLA-4 expression in maintenance of immune tolerance (Wing et al. 2008). 
However, some studies have shown that murine CTLA-4-deficient Tregs are still 
capable of suppression in vivo and in vitro, reportedly via mechanisms involving TGF-β 
and / or IL-10 (Tang et al. 2004; Read et al. 2006). Similar contradictory results have 
been obtained for human Tregs (Schmidt et al. 2012).  
Treg-expressed CTLA-4 down-regulates co-stimulatory molecules CD80 and 
CD86 on the surface of DCs or other APCs (Wing et al. 2008; Cederbom et al. 2000; 
Misra et al. 2004; Serra et al. 2003). Furthermore, CTLA-4 ligation with CD80 or CD86 
can result in up-regulation of indoleamine 2,3-dioxygenase (IDO), a potent regulatory 
enzyme that generates proapoptotic metabolites, ultimately leading to starvation and 
induction of cell cycle arrest in effector T cells (Fallarino et al. 2003; Onodera et al. 
2009; Grohmann et al. 2002). Lastly, CTLA-4 is capable of removing CD80 and CD86 
ligands from the surface of APCs by trans-endocytosis, thereby impairing future 
costimulation to the APC (Qureshi et al. 2011). Binding of another Treg-expressed 
inhibitory receptor LAG3 (CD223) to DC-expressed MHC-Class II molecules 
suppresses maturation and co-stimulatory ability of DCs (Liang et al. 2008). Together, 
these downstream affects of inhibitory receptor expression by Tregs result in a 
heightened threshold for T cell activation by DCs, ultimately prohibiting autoreactive T 
cell activation (Schmidt et al. 2012).  
1.5.4.3 Direct Killing of Immune Cells (Cytotoxicity) 
 Tregs are capable of direct cytolysis of target responder cells (Shevach 2009). 
Perforin is a pore-forming toxin and Granzymes are proapoptotic serine proteases; 
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together, these two molecules form the perforin/granzyme cell death pathway, which is 
the principal cytotoxic mechanism executed by NK lymphocytes and CTLs against 
intracellular pathogens and transformed cells (Hoves et al. 2010). Human Foxp3+ 
Tregs express Granzyme B upon activation and directly kill activated CD4+ and CD8+ T 
cells, as well as other immune cells including APCs, in a manner dependent on 
Perforin but independent of Fas-FasL interactions (Grossman et al. 2004). Murine 
Foxp3+ Tregs also up-regulate Granzyme B once activated (Shevach 2009), and have 
been shown to exhibit granzyme B-dependent killing of responder cells in a perforin-
independent manner (Gondek et al. 2005). Another report described an inability of 
Granzyme B-expressing Tregs to kill responder cells, despite killing of antigen-
presenting B cells (Zhao et al. 2006).  
Up to 30% of Tregs in tumour microenvironments produce Granzyme B and can 
induce lysis of NK and CTLs in a manner dependent on both Granzyme B and perforin 
(Cao et al. 2007). Furthermore, using two-photon live microscopy, Boissonnas and 
colleagues have observed direct perforin-dependent killing of DCs by Tregs in tumour-
draining lymph nodes in vivo (Boissonnas et al. 2010). Additionally, Granzyme B-
mediated Treg suppression seems to be required for maintenance of tolerance 
following transplant (Gondek et al. 2008).  
1.5.4.4 Metabolic Disruption of Immune Cells 
Extracellular Adenosine Triphosphate (ATP) is an indicator of cell damage and 
trauma in the immune system, and is sensed by DCs (Shevach 2009). CD39 is an 
ectoenzyme constitutively expressed on the surface of murine Tregs and 
approximately 50% of human Tregs that converts ATP or Adenosine diphosphate 
(ADP) to Adenosine monophosphate (AMP) (Borsellino et al. 2007; Shevach 2009). A 
proportion of Tregs co-express another ectoenzyme CD73 which further degrades 
AMP to Adenosine, a nucleoside with direct immunosuppressive effects on T cells and 
DCs (Schmidt et al. 2012). Deaglio and colleagues demonstrated that pericellular 
adenosine could inhibit the function of effector T cells (Deaglio et al. 2007). Therefore, 
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inactivation of ATP danger signals and generation of adenosine could represent 
important immunosuppressive mechanisms of Tregs. Deprivation of the cytokine IL-2 
represents another potential Treg-mediated mechanism of suppression, as discussed 
in detail in the following section (Schmidt et al. 2012; Shevach 2009). 
1.5.5 The Role of IL-2 in Treg Homeostasis and Suppression 
Interleukin-2 (IL-2) is required for expansion of TH1 and CD8+ CTLs. However, 
IL-2 is also necessary for survival and expansion of Tregs, and therefore plays a 
crucial role in both promotion of immunity and maintenance of immune tolerance 
(Boyman & Sprent 2012; Sakaguchi et al. 2008). The critical reliance upon IL-2 for 
Treg differentiation, survival and suppressor function is illustrated by animals deficient 
in IL-2 or components of the IL-2 receptor, which are devoid of peripheral Tregs and 
demonstrate severe autoimmunity. Furthermore, transfer of CD25+ CD4+ Tregs to mice 
harbouring these genetic deficiencies prevents the onset of disease (Sakaguchi 2004; 
Malek 2008; Gasteiger & Kastenmuller 2012). Neutralization of IL-2 by administration 
of monoclonal antibodies also reduces Treg numbers and concurrently induces 
autoimmune disease reminiscent of that elicited by Treg depletion (Setoguchi et al. 
2005; Murakami et al. 2002). Furthermore, IL-2 is necessary for maintained Foxp3 and 
CD25 expression and suppression activity by Tregs in vitro (Fontenot et al. 2005; 
Shevach et al. 2006; Thornton et al. 2004).  
IL-2 stimulates signalling via either the high affinity trimeric IL-2 receptor (IL-2R) 
or the weak affinity dimeric IL-2R. The dimeric IL-2R consists of CD122 (IL-2Rβ) and 
the common cytokine receptor γ chain (γc; CD132), and must be expressed at high 
levels for IL-2 responsiveness. The trimeric IL-2R has in addition CD25 (IL-2Rα), which 
increases the affinity for IL-2 by 10-100 fold (Boyman & Sprent 2012). 
Dimeric receptor expression is low on naïve CD8+ and memory CD4+ T cells, 
and high on memory CD8+ T and NK cells. Following TCR stimulation, CD4+ and CD8+ 
T cells transiently up-regulate the trimeric IL-2R. Tregs constitutively express CD25 at 
high levels, presumably endowing them with a superior ability to exploit the IL-2 
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resource provided by other T cells. In addition to TCR stimulation, exposure to IL-2 
also results in up-regulation of CD25 expression on T cells (Boyman & Sprent 2012; 
Malek 2008). 
Under steady state conditions, IL-2 is secreted primarily by Foxp3- CD4+ TH 
cells within secondary lymphoid organs and other activated Foxp3- CD4+ T cells. IL-2 
can also be synthesized by CD8+ T cells, NK cells, NKT cells and, under certain 
conditions, activated DCs and mast cells (Malek 2008; Boyman & Sprent 2012). Tregs 
cannot synthesize significant amounts of IL-2, due to Foxp3-dependent repression of 
il2 transcription (Boyman & Sprent 2012; Wu et al. 2006; Ono et al. 2007).  
Under homeostatic conditions equilibrium is reached between Tregs and 
Tconvs where Foxp3+ Tregs make up 10-15% of the peripheral CD4+ T cell pool in 
normal animals (Sakaguchi et al. 2008). The frequency of peripheral Tregs is regulated 
by the number of IL-2 producing T cells (Almeida et al. 2006). Conversely, limitation of 
IL-2 production by other cells and/or sequestration of IL-2 are potential Treg-mediated 
immunosuppressive mechanisms (Figure 1.4) (Shevach 2009; Schmidt et al. 2012). 
In vitro, Tregs are capable of inducing transcriptional repression of il2 in Foxp3- 
CD4+ T cells (Takahashi et al. 1998; Thornton & Shevach 1998; Oberle et al. 2007; 
Barthlott et al. 2005). Instead, Pandiyan and colleagues proposed a model whereby 
Tregs compete with conventional CD4+ T cells for IL-2 protein in the microenvironment 
and scavenge it, causing IL-2 deprivation-mediated apoptosis of responder T cells 
(Pandiyan et al. 2007). However, human Tregs can actively suppress proliferation of 
mouse responder T cells when IL-2 is prohibited from binding to Treg-expressed CD25 
(Tran et al. 2009). Furthermore, extensive in vitro and in vivo studies conducted by 
Szymczak-Workman and colleagues demonstrated the ability of Tregs to suppress 
transgenic conventional T cells that were resistant to cytokine-withdrawal mediated 
apoptosis, in complete contrast to the results of Pandiyan and colleagues (Szymczak-
Workman et al. 2011). Such contradictory results have meant that the importance of 
competitive consumption of IL-2 by Tregs as a mechanism of suppression has 
remained controversial (Schmidt et al. 2012; Shevach 2009).  
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1.5.6 Specialization of Regulatory T cells 
Naïve CD4+ T lymphocytes differentiate into functionally distinct effector TH cell, 
T follicular helper (Tfh) cell, or Treg subsets depending on the nature of the antigen 
signal they receive and cytokines secreted by APCs (Figure 1.5). A unique cytokine 
profile and effector, or immunosuppressive function, defines each lineage. Lineage 
specification depends on intrinsic and extrinsic factors, which determine the genetic 
program. Lineage-specific transcription factors are crucial (Tripathi & Lahesmaa 2014).  
Typically, intracellular pathogens induce TH1 immune responses. TH1 cells 
produce signature cytokines IFNγ, IL-2, TNFα and Lymphotoxin (LT). The cytokine IL-
12 initiates TH1 differentiation and T-bet is the master transcription factor that regulates 
the TH1 distinct program of gene expression (Szabo et al. 2000; Szabo et al. 2003).  
TH2 cells are typically involved in responses against parasitic helminths and 
nematodes, and produce cytokines IL-4, IL-5, IL-6 and IL-13 (Zhu & Paul 2010). GATA-
3 is the transcriptional regulator necessary and sufficient for TH2 differentiation (Zheng 
& Flavell 1997). IL-4 is the initiator for TH2 differentiation (Ansel et al. 2006).  
Yeasts, fungi and extracellular bacteria induce TH17 responses, involving 
production of IL-17, IL-22 and IL-23 (Zhu & Paul 2010). RORγt is the master 
transcription factor in TH17 differentiation, but others are also involved (Ivanov et al. 
2006). IL-6, IL-23 and TGFβ can initiate TH17 differentiation (Chen et al. 2007).  
More recently identified sub-types of CD4+ T cell include TH9 and TH22 cells 
and Tfh cells. TH9 differentiation in vitro is initiated by TCR activation with IL-4 and 
TGFβ, which stimulate expression of IRF4 and Purine-rich box 1 (PU.1) transcription 
factors, respectively (Tripathi & Lahesmaa 2014). A recent study clarified a role for the 
IRF1 transcription factor, induced in TH9 cells by IL-1β, in enhancement of TH9 function 
(Végran et al. 2014). Transcriptional control of the TH22 lineage requires IL-6 and TNF, 
and the Aryl hydrocarbon receptor (AhR). Tfh differentiation is stimulated by IL-6 and 
IL-21, which induce expression of the transcription factor Bcl6 which is necessary and 
sufficient for Tfh lineage commitment (Tripathi & Lahesmaa 2014). Tfh cells are 
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essential for generation of T-cell dependent B cell responses in germinal centres 
(Crotty 2014).  
Recently, studies have highlighted expression of canonical TH-cell lineage 
transcription factors by Tregs, and thus ‘mirroring’ of the TH polarized immune 
response by the Treg population (Campbell & Koch 2011; Linterman et al. 2011). T-bet 
is expressed by a subset of Treg cells in response to IFNγ, and T-bet+ Tregs 
accumulate at sites of TH1-type immune responses. Furthermore, T-bet expression 
Figure 1.5 | Differentiation of Naïve CD4+ T cells. 
Upon TCR-peptide-MHC-complex ligation with a DC, naïve CD4+ T cells differentiate into one of 
a number of different T helper cell (TH) subtypes. Alternatively, naïve CD4+ cells can 
differentiate into T follicular helper (Tfh) cells, or Foxp3+ regulatory T cells (Tregs). Different 
cytokines are influential in this process of lineage commitment, and each TH cell subset is 
defined by the expression of a lineage specific transcription factor (shown in the cell nucleus). 
Each distinct cell lineage is defined by the production of a set repertoire of effector or 
immunosuppressive cytokines, shown on the far right. Adapted from (Tripathi & Lahesmaa 
2014). 
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was found to be required for Treg-mediated control of TH1-orientated inflammatory 
responses (Koch et al. 2009). In a different study, a proportion of Tregs were shown to 
express IRF4, a transcription factor important for TH2 differentiation. IRF4+ Tregs were 
required for suppression of TH2-directed inflammatory responses, as ablation of IRF4 
specifically in Foxp3+ T cells resulted in deregulated TH2 responses (Zheng et al. 
2009). Treg-expression of the TH17 associated transcription factor STAT3 has also 
been reported, and control of TH17-driven intestinal inflammation was dependent on 
STAT3 expression by Tregs (Chaudhry et al. 2009). Lastly, Linterman and colleagues 
demonstrated differentiation of Tfh cell repressor Tregs, via expression of the Tfh-
specific Bcl6 transcription factor. These follicular Tregs were required for control of Tfh 
cell number and germinal centre responses in vivo (Linterman et al. 2011). Hence, 
Tregs may co-opt components of the canonical TH-associated transcriptional 
machinery to effectively hamper a corresponding type of immune response (Campbell 
& Koch 2011).  
1.6 Regulatory T cells in Cancer  
1.6.1 The Role of Regulatory T cells in Anti-Tumour Immunity 
 Seminal studies in the 1970s and 1980s began establishing a critical role for 
‘suppressor’ T cells in the anti-tumour immune response, although the identity of the 
cellular subset was yet to be determined (Zou 2006). In a series of pioneering studies, 
Robert North and colleagues demonstrated that despite induction of an effective anti-
tumour T cell response to Meth A tumours (a tumour cell line model in which the cells 
are derived from MCA-induced fibrosarcomas), the immune response was unable to 
completely prohibit tumour growth due to suppressor T cell activity induced by the 
tumour. Indeed, concomitant immunity, defined as rejection of a second inoculum of an 
identical tumour cell line in a host already bearing tumour, decreased over time, 
simultaneous with the establishment of suppressor T cell function (North & Bursuker 
1984; Gallimore & Godkin 2008). The suppressor T cell subset in question was later 
revealed as CD4+ CD8- T cells, and specific depletion of CD4+ T cells using 
monoclonal antibodies resulted in efficient tumour rejection (Awwad & North 1988). 
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 These early studies illustrated the ability of naturally occurring Tregs to dampen 
effective anti-tumour immune responses (Gallimore & Godkin 2008). With the 
identification of CD25 as a specific Treg marker in 1995 (see Section 1.5.1) (Sakaguchi 
et al. 1995), use of depleting anti-CD25 monoclonal antibodies was shown to induce 
effective anti-tumour CD8+ T cell responses, and confer control of tumour growth in a 
number of different tumour cell line models (Onizuka et al. 1999; Shimizu et al. 1999). 
Other groups corroborated these findings and demonstrated that tumour rejection and 
long-term CD4+ and/or CD8+ T cell mediated immunity against tumour cells could be 
established in mice depleted of CD25+ Tregs (Sutmuller et al. 2001; Jones et al. 2002). 
Similar studies reported that depletion of CD25+ Tregs also resulted in effective 
concomitant immunity (Turk et al. 2004). Furthermore, adoptive transfer of CD25+ 
Tregs into tumour bearing hosts provided a direct functional link between Treg 
presence and abrogation of anti-tumour immunity (Turk et al. 2004; Antony et al. 2005). 
 However, most early studies only demonstrated efficacy of CD25+ T cell 
depletion if conducted in a prophylactic setting prior to tumour cell inoculation: efficacy 
was lost when antibodies were administered simultaneously with tumour cell 
inoculation or after inoculation, likely as a result of depletion of CD25hi anti-tumour 
effector T cells as well as Tregs (Onizuka et al. 1999; Shimizu et al. 1999; Sutmuller et 
al. 2001; Jones et al. 2002; Li et al. 2003; Teng et al. 2010; Ko et al. 2005; Quezada et 
al. 2008; Tanaka et al. 2002).  However, efficient rejection of established tumours could 
sometimes be initiated, for instance by intra-tumoural injection of anti-CD25 antibodies 
(Yu et al. 2005). 
These early studies were almost entirely conducted using tumour cell line 
models. These models preclude study of the effect of CD25+ Tregs on rejection of 
tumours that have developed in vivo in the context of mechanisms of Cancer 
Immunoediting (Gallimore & Godkin 2008). Analyses of tumours induced by injection of 
MCA revealed a reduction in the rate and frequency of tumour development in animals 
devoid of CD25+ T cells relative to WT counterparts, even if CD25+ T cell depletion is 
only transient in nature (Tawara et al. 2002; Betts et al. 2007).  
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Following the identification of Foxp3 as a Treg-specific marker, several 
independent studies demonstrated the prevention of tumour development or regression 
of established tumour, following efficient and selective depletion of Foxp3+ Tregs 
(Klages et al. 2010; Li et al. 2010; Teng et al. 2010; Hindley et al. 2012). These studies 
made use of transgenic mouse lines in which Foxp3-expressing cells express the 
primate diphtheria toxin receptor (DTR): selective depletion of Foxp3+ Tregs is 
achieved in these models by diphtheria toxin (DT) administration (Lahl et al. 2007; Kim 
et al. 2007). Such studies underpin the idea that Tregs play a central role in the 
generation of immunity against developing tumours in vivo. 
The tightly controlled homeostatic ratio of Tconv to Treg under normal 
conditions is significantly perturbed in patients with cancer and mouse models 
(Quezada et al. 2011). Many murine tumour models exhibit a preferential accumulation 
of Tregs within the tumour mass (Betts et al. 2007; Hindley et al. 2011). Furthermore, a 
plethora of studies have demonstrated selective enrichment of Tregs in peripheral 
blood or TME of patients with a range of malignancies, including liver, lung, pancreatic, 
breast, gastrointestinal tumours and melanomas, relative to peripheral blood or healthy 
tissue in healthy controls (Nishikawa & Sakaguchi 2010; Whiteside 2012; Wilke et al. 
2010; Quezada et al. 2011; Scurr et al. 2012). Importantly, some of these studies 
illustrated the correlation between high numbers of tumour-infiltrating Tregs and a poor 
clinical outcome (Curiel et al. 2004; Sato et al. 2005; Bates et al. 2006; Perrone et al. 
2008). Strikingly, several of these studies demonstrated that an elevated CD8+ CTL to 
Foxp3+ Treg ratio was significantly associated with an improved clinical prognosis (Gao 
et al. 2007; Sinicrope et al. 2009; Sato et al. 2005). This correlation between effector T 
cell to Treg ratio and outcome is also observed in mouse models: CTLA-4 blockade 
together with GVAX vaccine therapy in the B16 melanoma model resulted in a 
significantly altered ratio of effector T cells to Tregs, in favour of effectors, which 
correlated with tumour rejection (Quezada et al. 2006). Collectively, such studies 
establish the importance of the balance between effector anti-tumour T cells and 
immunosuppressive Tregs in dictating disease outcome. Hence, therapies aimed at 
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altering this balance, to steer the response in the direction of an effector response at 
the expense of regulation, could be beneficial in the future (Quezada et al. 2011). 
Crucially, it is becoming evident that the type of cancer dictates whether a high 
infiltration of Foxp3+ Tregs determines a good or bad clinical outcome (Whiteside 
2012). For certain types of cancer, inflammation is considered a major driving force in 
progression to malignancy (Ruffell et al. 2010). This raises the possibility that Tregs 
could exert some anti-tumourigenic effect via their demonstrable ability to suppress 
cancer-promoting inflammation (Erdman et al. 2005; Grivennikov et al. 2010). 
Paradoxically, presence of Tregs in Hodgkin’s lymphoma correlates with 
improved prognosis (Alvaro et al. 2005). Many studies reported that density of tumour 
infiltrating Tregs correlates with improved prognosis and survival for CRC patients 
(Scurr et al. 2012). However, tumour antigen-specific Tregs are capable of suppressing 
beneficial anti-tumour T cell responses in CRC (Bonertz et al. 2009). Furthermore, 
suppression of tumour antigen specific T cells by Tregs prior to tumour resection 
positively correlates with recurrence 1 year later (Betts et al. 2012). Confirmation of the 
prognostic value of Tregs in different types of cancer is crucial for development of 
strategies targeting them (Scurr et al. 2012; Whiteside 2012).  
1.6.2 Mechanisms of Treg Enrichment in Tumours 
Several mechanisms of intra-tumoural Treg enrichment have been suggested 
(Figure 1.6) (Ondondo et al. 2013). Both tTregs and pTregs can suppress anti-tumour 
immune responses in mice (Zhou & Levitsky 2007). However, the relative contribution 
of pTregs and tTregs to anti-tumour immunity remains a contentious issue (Tanchot et 
al. 2013). Adoptively transferred CD4+ CD25- T cells convert into Foxp3+ CD25+ CD4+ 
Tregs in vivo (Valzasina et al. 2006; Schreiber et al. 2012; Weiss et al. 2012). Some 
studies have shown that the high levels of TGF-β made by tumour cells and/or DCs 
within tumours enable conversion of conventional CD4+ T cells into Tregs in situ 
(Ghiringhelli et al. 2005; Liu et al. 2007). However, many of these studies utilized 
adoptive transfer systems, which do not robustly reflect mechanisms underpinning 
Treg enrichment in tumours in vivo.  
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The debate has been fuelled by the lack of a specific marker for pTregs or 
tTregs (Ondondo et al. 2013). Helios, an Ikaros transcription factor, has been identified 
as a specific marker of tTregs in both mouse and human (Thornton et al. 2010). Nrp-1, 
a type 1 transmembrane protein, is also a purported tTreg specific marker (Bruder et 
al. 2004). A large number of studies support the hypothesis that the majority of Tregs 
enriched in mouse or human tumours are Helios and / or Nrp-1 expressing tTregs 
(Curiel et al. 2004; Ghiringhelli et al. 2005; Wainwright et al. 2011; Bui et al. 2006; 
Hansen et al. 2012; Teng et al. 2010; Weiss et al. 2012; Elkord et al. 2011). Work from 
our own lab has demonstrated that Tregs enriched in MCA-induced fibrosarcomas are 
tTregs: intra-tumoural Tregs demonstrated an entirely distinct TCR repertoire relative to 
tumour-derived naïve conventional T cells (Hindley et al. 2011). Our more recently 
published work corroborated these data in demonstrating expression of Helios by the 
vast majority of intra-tumoural Tregs in MCA tumours (Colbeck et al. 2015). 
Figure 1.6 | Mechanisms of Foxp3+ Treg Enrichment in Tumours. 
Mechanisms include preferential recruitment or trafficking over other populations of T cells, and/ 
or superior proliferation once within the tumour microenvironment, possibly by exploitation of a 
limited resource. De novo generation of Tregs, by conversion from naïve CD4+ conventional T 
cells has also been suggested. Lastly, preferential retention of Tregs by unknown mechanisms 
could contribute to dominance of Tregs in the tumour. 
Adapted from (Ondondo et al. 2013). 
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Collectively, definitive evidence supporting a role for conversion of non-Treg cells into 
suppressive Tregs in tumours is lacking. 
Preferential recruitment by a selective chemokine axis is another possible 
mechanism of Treg enrichment in tumours. Chemokine axes responsible for 
recruitment of Tregs include inflammatory chemokine ligand receptor pairs C-C motif 
chemokine receptor (CCR)5- C-C motif chemokine ligand (CCL)5, CCR4-
CCL17/CCL22, and C-X-C motif chemokine receptor (CXCR)3- C-X-C motif chemokine 
ligand (CXCL)9/10/11. However, data support a critical role for CCR5 and CXCR3 axes 
in recruitment of effector anti-tumour T cells, as well as Tregs, to tumours. 
Furthermore, expression of IFN-γ-induced chemokine ligands for CCR5 and CXCR3 by 
tumour cells is associated with a favourable prognosis in multiple human cancers 
(Ondondo et al. 2013). In support of these data, our recently published study 
demonstrated that Foxp3+ Tregs and Foxp3- T cells utilize multiple and overlapping 
chemokine axes to access MCA-induced tumours, and selective recruitment of Tregs 
cannot be accounted for by a distinct chemokine axis (Ondondo et al. 2014a).  
CCR4 signalling seems to be influential in mediating Treg accumulation in 
multiple human cancers (Ondondo et al. 2013). Anti-CCR4 monoclonal antibody 
treatment selectively depletes Tregs, unleashing an anti-tumour immune response in 
melanoma patient derived peripheral blood mononuclear cells (PBMC) ex vivo 
(Sugiyama et al. 2013). The hypoxic conditions within tumours can also induce up-
regulation of hypoxic chemokines CCL28 and CXCL12, which bind CCR10 and 
CXCR4, respectively. These chemokines have been shown to contribute to 
accumulation of Tregs expressing cognate receptors in human and mouse tumours 
(Ondondo et al. 2013). In particular, the CXCR4-CXCL12 axis seems to direct 
preferential migration of Tregs (Wald et al. 2006; Jaafar et al. 2009).  
The CCR7-CCL21 axis, classically associated with lymphocyte migration in 
secondary lymphoid organs, is implicated in Treg enrichment in B16 tumours (Shields 
et al. 2010; Förster et al. 2008). However, a body of evidence supports a crucial role 
for this chemokine axis in facilitating entry of effector anti-tumour immune cells and 
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subsequent tumour control in mouse and human tumours. Hence, while targeting 
CCR5 / CXCR3 / CCR7 axes will unlikely result in the desired outcome, targeting 
CCR4 / CXCR4 axes could selectively deplete Tregs from tumours without hindering 
infiltration of beneficial anti-tumour T cells (Ondondo et al. 2013). 
Studies have highlighted a superior proliferative ability of Foxp3+ Tregs relative 
to other T cells (Attridge & Walker 2014). Bui and colleagues noted preferential 
proliferation of Tregs within carcinogen-induced tumours, relative to Tregs in tumour 
draining lymph nodes and CD25- CD4+ T cells within the tumour (Bui et al. 2006). 
Moreover, Helios+ Foxp3+ tTregs within tumours of a mouse model of glioblastoma 
were significantly more proliferative than Helios- and / or Foxp3- counterparts 
(Wainwright et al. 2011). Tumour derived TGF-β and / or VEGF-A could be responsible 
for driving superior Treg proliferation (Ghiringhelli et al. 2005; Terme et al. 2013). 
These studies highlight superior proliferation as a major mechanism contributing to 
expansion of Tregs within tumours (Ondondo et al. 2013; Attridge & Walker 2014).  
1.6.3 Methods for Manipulating Tregs in Cancer Immunotherapy 
The significant enrichment of Tregs in tumours represents a major obstacle 
tempering successful immunotherapy. All in vitro and in vivo data to date support a 
model whereby Tregs exert their suppressive effects in a dose-dependent manner 
(Quezada et al. 2011). Hence, depletion of Tregs has been investigated as a potential 
method to encourage tumour regression either alone or in combination with vaccination 
programs. Preclinical studies have underpinned the efficacy of such an approach to 
augment powerful anti-tumour immune responses (see Section 1.6.1).  
Cyclophosphamide (CTX; N,N-bis (2-chloroethyl)-1,3,2-oxazaphosphinan-2 
amine 2-oxide) is a nitrogen mustard alkylating agent. High doses of CTX are used as 
a chemotherapy for human tumours as this compound displays direct selective 
cytotoxicity for tumour cells (Sistigu et al. 2011). However, the activity of CTX is dose 
dependent: low doses induce effective anti-tumour immune responses in mouse and 
human. This affect is at least partly due to modulation of the Treg compartment by low-
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dose CTX, including a reduction in suppressive capacity of Tregs, and apoptosis 
induction (Le & Jaffee 2012). In a phase II clinical trial, low dose CTX reduced Treg 
numbers and boosted anti-tumour immune responses induced by vaccination, 
increasing overall survival in renal cell carcinoma patients (Walter et al. 2012).  
As the balance between effector T cells and Tregs is crucial in dictating an 
effective anti-tumour immune response, attempts are now being made to tip the 
balance away from suppressive Tregs, in favour of effector T cells (Quezada et al. 
2006; Quezada et al. 2011). To this end, costimulatory therapies, including anti-CTLA-
4 and anti-PD-1 therapies, are proving successful in simultaneously increasing intra-
tumoural numbers of CD8+ CTL and reducing intra-tumoural accumulation of Tregs, in 
both mice (Quezada et al. 2006; Curran et al. 2010; Curran & Allison 2009) and human 
cancer patients (Chen et al. 2009; Liakou et al. 2008). A better understanding of 
mechanisms leading to Treg enrichment in tumours and how immunotherapies lead to 
increased effector T cell to Treg ratios will aid modification of future immunotherapy 
regimes to maximize beneficial clinical outcome (Quezada et al. 2011). 
1.6.4 The link between Regulatory T cells and Tumour Angiogenesis 
Despite the induction of powerful anti-tumour immune responses following 
depletion of Tregs, infiltration of activated T cells into tumours represents a significant 
bottleneck to effective tumour control (Hindley et al. 2012; Quezada et al. 2008). There 
is an emerging link between tumour angiogenesis and establishment of peripheral 
immune tolerance in the TME (Joyce & Fearon 2015; Motz & Coukos 2011). Tumour 
vasculature impairs infiltration of effector T cells, while enabling entry of 
immunosuppressive Tregs and MDSCs (Huang et al. 2013; Ganss et al. 2002; 
Ryschich et al. 2002; Buckanovich et al. 2008; Facciabene et al. 2011; Gabrilovich et 
al. 2012; Carretero et al. 2015). Furthermore, anti-VEGF-A prevents infiltration of 
Tregs, enhancing immune responses initiated by vaccination (Li et al. 2006).  
Interestingly, in what appears to be a reciprocal relationship, 
immunosuppressive cells in tumours promote angiogenesis (Motz & Coukos 2011). 
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Tregs, recruited to the tumour by hypoxic chemokine CCL28 expression, contribute to 
the VEGF-A rich microenvironment, and depletion of Tregs decreases available VEGF-
A and inhibits tumour angiogenesis (Facciabene et al. 2011). Hence, Tregs promote 
disease progression via pro-angiogenic reprogramming of the TME, in addition to 
canonical anti-tumour immunity subversion (Facciabene et al. 2012). In line with these 
data, depletion of Tregs results in normalization of tumour vasculature, which promotes 
effector T cell infiltration (Li et al. 2010; Hamzah et al. 2008). Hence, tumour immune 
tolerance and angiogenesis work in concert to promote tumour outgrowth. 
Tumour angiogenesis is generally associated with disease progression 
(Martinet & Girard 2013; Joyce & Fearon 2015). However, development of specialised 
tumour-associated blood vessels, termed High Endothelial Venules (HEV), has 
recently been associated with a good prognosis for multiple cancers in several reports 
(Ager & May 2015; Goc et al. 2013). Furthermore, our lab have discovered tumour-
associated HEV in MCA-induced tumours in the absence of Tregs, underpinning the 
link between tumour angiogenesis and immunosuppression (Hindley et al. 2012). 
1.7 High Endothelial Venules 
1.7.1 Introducing Secondary Lymphoid Organs 
Secondary Lymphoid Organs (SLOs) in mice and humans function primarily in 
initiation of adaptive immune responses to pathogens. SLOs provide a location for 
interactions between rare, antigen-specific naïve lymphocytes and APCs. SLOs are 
also sites where rapid recall responses to a returning antigen are mounted via central 
memory T cells (van de Pavert & Mebius 2010; Andrian & Mempel 2003).  
SLOs comprise Lymph Nodes (LN), splenic white pulp, appendix (in humans) 
and Mucosal Associated Lymphoid Tissues (MALTs), the latter including intestinal 
Peyer's patches (PP) and isolated lymphoid follicles (ILF). SLOs are strategically 
placed at predetermined sites throughout the body, forming a sophisticated network 
that continually surveys interstitial areas, mucosal surfaces and the blood. SLOs have 
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highly organised architecture, specifically adapted to promote cellular interactions 
necessary for immune response initiation (Randall et al. 2008; Drayton et al. 2006). 
Development of SLOs is a genetically pre-programmed process initiated during 
embryogenesis. Whilst some SLOs (LNs, PP) develop prenatally, the organogenesis of 
some SLOs occurs in early postnatal development. Prenatal and postnatal 
development follows a similar underlying program, despite some differences reflecting 
distinct anatomical sites in which SLOs develop (van de Pavert & Mebius 2010).  
1.7.2 High Endothelial Venules in the Lymph Node    
The basic architecture of all SLOs is similar. The structure of the LN, as the 
prototypical SLO, is described in Figure 1.7. In brief, LNs comprise a capsule and 
subcapsular sinus (SCS), within which cells are topologically segregated into the 
cortex, paracortex and medulla. The cortex consists of B cells and Follicular Dendritic 
Cells (FDCs), tightly packed into primary follicles. The paracortex harbours loosely 
arranged T cells, DCs and Fibroblastic Reticular Cells (FRCs). Lymphatic tissues 
constitute the medulla (Ruddle & Akirav 2009; Girard et al. 2012; Drayton et al. 2006).  
LNs contain two distinct vasculature systems: lymphatic vasculature, and High 
Endothelial Venules (HEVs; Figure 1.7). Afferent lymphatic vessels deliver lymph 
carrying soluble antigen and immune cells, primarily DCs. Lymph percolates through 
cortical and medullary sinuses, and leaves the LN via the efferent lymphatic vessel, 
which delivers lymph to the venous blood (Girard et al. 2012; Drayton et al. 2006).  
HEV are specialised post-capillary venules found in the blood vascular bed 
within the paracortical region of the LN and other SLOs, except the Spleen (Ager & 
May 2015). The primary function of HEV is homeostatic delivery of naïve B and T 
lymphocytes from the adjacent bloodstream. Central memory T cells, Tregs, 
plasmacytoid DCs (pDCs) and NK cells also extravasate via HEV under homeostatic 
conditions (Girard et al. 2012). Endothelial cells lining HEV have a distinct plump, 
cuboidal morphology, engendering the name ‘High’ endothelial venules (Rosen 2004). 
The HEV network is spatially organised to control the anatomical site of cellular entry 
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and contribute to overall structural organisation of the tissue (Ager & May 2015). T and 
B lymphocytes continually circulate through LNs, entering the tissue via HEV and 
exiting through efferent lymphatic vessels (Drayton et al. 2006). 
Sir James Gowans was the first to definitely demonstrate extensive but 
selective infiltration of HEV by lymphocytes, suggesting a special affinity of 
lymphocytes for HEV endothelial cells (Gowans & Knight 1964). Lymphocytes 
extravasate through HEV according to a multistep adhesion cascade, involving 
tethering, rolling and arrest, dictated by the expression of adhesion molecules and 
chemokines on the HEV endothelial cell surface (Figure 1.8) (Girard et al. 2012). 
Mechanisms of lymphocyte homing to SLOs differ, with the process of naïve 
Figure 1.7 | The Structure of the Lymph Node. 
Lymph nodes comprise a collagen-rich fibrous capsule and an underlying SCS. Cells are 
segregated into 1) the cortex, consisting of B cells and FDCs arranged in primary follicles, in 
which B cells survey antigens presented on the FDC stromal network, and 2) the paracortex, 
which accommodates T cells and DCs, and FRCs that form stromal cell networks and reticular 
fibres, along which T cells and DCs migrate. The inner medulla is composed of lymphatic 
tissues (medullary cords) separated by medullary sinuses consisting of lymph. FRCs express 
CCL19 and CCL21, whereas CXCL13 is expressed by FDCs. MRCs form a third stromal cell 
network, situated just under the SCS. Lymph nodes contain lymphatic vasculature and HEV. 
Afferent lymphatic vessels deliver lymph containing antigen and immune cells, and HEV are 
specialised post-capillary venules that primarily deliver naïve and central memory lymphocytes. 
SCS, subcapsular sinus; FDC, Follicular Dendritic Cell; DC, Dendritic Cell; FRC, Fibroblastic 
Reticular Cell; MRC, Marginal Reticular Cell; HEV, High Endothelial Venule. Adapted from 
(Girard et al. 2012; Drayton et al. 2006). 
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lymphocyte homing to peripheral (subcutaneous) lymph nodes (PLN) in the mouse 
remaining the best understood (Figure 1.8) (Rosen 2004).  
Homing is initiated by tethering of the lymphocyte to the surface of an 
endothelial cell via the lymphocyte-expressed homing receptor, L-selectin (CD62L). L-
selectin recognises the carbohydrate epitope 6-sulpho sialyl Lewis X, present on N-
glycans and extended core 1 and 2 O-glycans that decorate heavily sulphated, 
fucosylated and sialylated sialomucins. 6-sulpho sialyl Lewis X decorated sialomucins 
are collectively referred to as peripheral node addressins (PNAd), and are highly 
specific to HEV. HEV sialomucins include the CD34 family, nepmucin, endomucin,  
murine Glycosylation-dependent Cell Adhesion Molecule-1 (GlyCAM-1) and Mucosal 
Addressin Cell Adhesion Molecule-1 (MAdCAM-1) (Girard et al. 2012).  
 
 
 
Figure 1.8 | The Multistep Adhesion Cascade of Naïve Lymphocyte Homing to Peripheral 
Lymph Nodes. 
Tethering involves interactions between lymphocyte expressed L-Selectin and 6-sulpho sialyl 
Lewis X carbohydrate epiptopes expressed on N- or O-Glycans decorating sialomucins 
expressed on endothelial cells (PNAd). This facilitates reversible adhesion, manifested as rolling 
(1). CCL19 / CCL21 signalling via CCR7 allows LFA-1 to interact with ICAM-1 and/ or 2, 
resulting in integrin-mediated arrest (2). Lymphocytes then ‘crawl’ on the endothelium (3) before 
rapidly transmigrating via ‘exit ramps’ (4). Some lymphocytes transiently accumulate in ‘HEV 
pockets’. HEV, High Endothelial Venule; PNAd, peripheral node addressin; LFA-1, Lymphocyte 
function-associated antigen 1; ICAM-1, InterCellular Adhesion Molecule-1; FRC, Follicular 
Reticular Cell. 
Adapted from (Girard et al. 2012). 	
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Initial tethering via the L-selectin-PNAd interaction leads to reversible adhesion, 
which manifests as lymphocyte ‘rolling’ along the endothelium under the force of blood 
flow. Rolling lymphocytes encounter CCL19 and CCL21 immobilized on the surface of 
endothelial cells. Signalling of CCL19 / CCL21 via the cognate lymphocyte-expressed 
CCR7 receptor activates lymphocyte-expressed integrin Lymphocyte function-
associated antigen 1 (LFA-1; αLβ2). LFA-1 engages adhesion molecules InterCellular 
Adhesion Molecule (ICAM)-1 and/or ICAM-2 expressed on endothelial cells, resulting 
in integrin-mediated arrest. The lymphocyte will then ‘crawl’ along the surface of the 
endothelium for several minutes before rapidly transmigrating the endothelial layer via 
‘exit ramps’ formed by FRCs. Alternatively, lymphocytes temporarily reside in HEV 
endothelial cell ‘pockets’ before transmigrating (Girard et al. 2012). 
HEV are detected in mouse and human using the anti-PNAd antibody (clone 
MECA-79), which recognizes the 6-sulpho sialyl Lewis X epitope expressed on core 1 
O-glycans, highly specific to HEV. Other HEV-specific markers include enzymes 
involved in synthesis of the HEV sialomucins, GlcNAc6ST-2 and fucosyltransferase 7 
(FucTVII). MAdCAM-1 is expressed on the surface of HEV in mucosal lymphoid organs 
such as mesenteric LNs, where it facilitates lymphocyte arrest via lymphocyte-
expressed α4β7 integrin (Girard et al. 2012). However, MAdCAM-1 is not HEV-specific, 
due to broad expression on blood vessels of the lamina propia, marginal sinus-lining 
cells of the spleen and stromal cells within embryonic LNs (Ager & May 2015). 
Following recruitment of lymphocytes and DCs, positioning of these cells within 
the LN is dictated by compartmentalised expression of lymphoid chemokines by 
stromal cell populations (Drayton et al. 2006). Constitutive expression of CCL19 and 
CCL21 by stromal FRCs and FRC networks allows directed migration of CCR7+ T cells 
and DCs along FRC networks to T cell zones. CXCL13 is constitutively expressed by 
FDCs in the centre of B cell follicles, and is responsible for directing B cells that 
express the CXCL13 receptor, CXCR5, to these areas (Girard et al. 2012). On their 
way to B cell follicles, B cells crawl along FRC networks in the T cell zones (Bajénoff et 
al. 2006). 
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1.7.3 Lymph Node Development during Embryogenesis 
Many of the molecular mechanisms involved in LN development have been 
defined (Figure 1.9). A body of work has demonstrated that successful development of 
LNs critically depends upon coordinated interactions between stromal lymphoid tissue 
organizer cells (LTo) and haematopoietic lymphoid tissue inducer cells (LTi). These 
interactions occur via signalling between the LTα1β2 ligand, expressed on the surface 
of LTi cells, and the LTβ Receptor (LTβR), expressed on LTo cells (van de Pavert & 
Mebius 2014; van de Pavert & Mebius 2010; Mebius 2003).  
The first haematopoietic precursor LTi (pre-LTi) cells are attracted to sites of 
future LNs (LN anlagen) between embryonic day post-coitus (E)12.5 and E13.5, by the 
chemokine CXCL13, expressed by local stromal cells (van de Pavert & Mebius 2014; 
van de Pavert & Mebius 2010). To migrate to such locations, pre-LTi cells must 
express CXCR5 (van de Pavert & Mebius 2014). Mice genetically deficient in CXCL13 
or CXCR5 lack several PLNs, have a reduced number of PP, and a full complement of 
mesenteric LNs (van de Pavert et al. 2009; Luther et al. 2003; Ansel et al. 2000; 
Förster et al. 1996; Ohl et al. 2003). Animals deficient in both CXCR5 and CCR7 
develop no PLNs, implying cooperation between these two receptors (Ohl et al. 2003; 
Luther et al. 2003). However, all LNs form in mice deficient in CCR7/CCL21 but 
competent in CXCR5/CXCL13 signalling (Förster et al. 1999). Hence CXCL13 
expression is a crucial event in early LN development, by initiating LTi clustering. 
Retinoic acid (RA), potentially derived from proximal nerve fibres, induces CXCL13 
expression by stromal cells (van de Pavert et al. 2009).  
Following recruitment, LTα1β2 expression is induced on pre-LTi cells (see 
Section 1.7.3.1). LTα1β2 expressing pre-LTi cells differentiate into mature LTi cells, 
which form stable interactions with LTβR-expressing stromal cells, causing them to 
differentiate into stromal LTo cells (van de Pavert & Mebius 2010). Signalling via LTβR 
results in expression of CCL19, CCL21 and CXCL13, and adhesion molecules 
Vascular Cell Adhesion Molecule-1 (VCAM-1), ICAM-1 and MAdCAM-1, by stromal 
LTo cells, which are absolutely required for attraction and retention of further 
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haematopoietic cells leading to LN growth (van de Pavert & Mebius 2010; Cupedo et 
al. 2004; Roozendaal & Mebius 2011). 
 
LTβR signalling also results in up-regulation of IL-7 and tumour necrosis factor 
(TNF)-related activation induced cytokine (TRANCE) expression by LTo cells, which 
induces LTα1β2 expression on newly arriving pre-LTi cells, thereby constituting a 
positive feedback loop (Mebius 2003; Yoshida et al. 2002; Vondenhoff et al. 2009; 
Honda et al. 2001). Furthermore, LTβR signalling induces expression of the 
lymphangiogenic factor, VEGF-C, by stromal LTo cells, which aids connection of the 
developing LN to surrounding lymphatic vasculature (Vondenhoff et al. 2009). The 
developing LN is colonized by infiltrating lymphocytes around day E15.5, eventually 
giving rise to a highly organized LN (van de Pavert & Mebius 2010). 
Figure 1.9 | Molecular Mechanisms of Lymph Node Development. 
Retinoic Acid (RA) induces expression of CXCL13 by local mesenchymal stromal cells at the 
site of the future Lymph Node. This attracts CXCR5-expressing precursor LTi cells (pre-LTi 
cells) from the blood, and these form the first haematopoietic cell clusters. Clustering of these 
cells facilitates signalling via either TRANCE-TRANCER or IL-7-IL-7R between stromal cells 
and pre-LTi cells, which induces LTα1β2 expression on the pre-LTi cell. These pre-LTi cells then 
differentiate into mature LTi cells. Signalling of LTi-expressed LTα1β2 via LTβR expressed on 
stromal cells causes the latter to differentiate into LTo cells. This crucial interaction between LTi 
and LTo causes the up-regulation of adhesion molecules VCAM-1, ICAM-1 and MAdCAM-1 and 
chemokines CXCL13, CCL21 and CCL19 by stromal LTo cells, leading to further recruitment of 
haematopoietic cells, fostering lymph node growth. LTα1β2-LTβR signalling also causes 
expression of TRANCE and IL-7, constituting a positive feedback loop to facilitating LTα1β2-
LTβR signalling between stromal cells and newly arriving pre-LTi cells. TRANCE, tumour 
necrosis factor (TNF)-related activation induced cytokine; LTi, lymphoid tissue inducer cell; LTo, 
lymphoid tissue organizer cell; VCAM-1, Vascular Cell Adhesion Molecule-1; ICAM-1, 
InterCellular Adhesion Molecule-1; MAdCAM-1, Mucosal Addressin Cell Adhesion Molecule-1. 
Adapted from (van de Pavert & Mebius 2010). 
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1.7.3.1 Lymphoid Tissue Inducer cells in Lymph Node Development 
LTi cells were originally described in the mouse by the Mebius and Nishikawa 
groups (Mebius et al. 1996; Mebius et al. 1997; Adachi et al. 1997; Yoshida et al. 
1999). LTis are haematopoietic cells that derive from a lymphoid progenitor found in 
mouse foetal livers (Mebius et al. 2001; Yoshida et al. 2001), and express a defined 
repertoire of markers (Table 1.1) (Lane et al. 2012a; Lane et al. 2012b). An absolute 
requirement for LTi cells in LN development is evident by the complete lack of LNs in 
animals genetically deficient in either one of two genes required for LTi development 
and maturation: the Rorc gene, which encodes the transcription factor RORγt, and the 
Id2 gene (Sun et al. 2000; Eberl et al. 2004; Yokota et al. 1999).  
Table 1.1 | Marker Expression of Murine Lymphoid Tissue inducer (LTi) cells 
Marker Expression 
Th17-associated 
gene 
IL-22 + 
IL-17A + 
IL-23 receptor + 
Transcription 
factor 
retinoic acid receptor-related orphan receptor-γt 
(RORγt) 
+ 
helix-loop-helix protein inhibitor of DNA binding 2 
(ID2) 
+ 
Surface marker CD3 - 
CD4 +/- 
CD117 + 
IL-7Rα (CD127) + 
IL-2Rα (CD25) + 
TNFSF members TRANCE + 
TNF, LTα, LTβ ++ 
Chemokine 
receptors 
CXCR5 + 
CCR7 + 
CCR6 + 
Adapted from (Lane et al. 2012a; Lane et al. 2012b). 
Both IL-7 and TRANCE induce LTα1β2 expression by LTi cells, and are 
differentially required in different SLOs (Yoshida et al. 2002). The function of LTi cells 
is absolutely dependent on expression of LTα1β2 (Yoshida et al. 2001; Yoshida et al. 
2002). However, initial LTi clustering proceeds uninterrupted when LTα1β2 expression 
by LTi cells, or LTβR expression by LTo cells is prevented (van de Pavert & Mebius 
2010). Moreover, over expression of TNFα can compensate for the loss of classical 
	 56 
RORγt+ LTis to a certain degree, enabling organogenesis of some functional LNs, in a 
LTβR signalling dependent manner (Furtado et al. 2014).   
1.7.3.2 Cellular Signalling in Lymph Node Development 
1.7.3.2.1 Introducing the Tumour Necrosis Factor Superfamily  
 The extended Tumour Necrosis Factor (TNF) superfamily consists of 19 ligands 
and 29 receptors. TNF superfamily signalling results in diverse immunological 
outcomes, from pro-inflammatory functions to cell survival signals to promotion of 
cellular apoptosis (Aggarwal et al. 2012). TNF superfamily cytokines exert such effects 
by initiating rapid transcription of genes, primarily via activation of the Nuclear Factor 
κB (NFκB) family of inducible transcription factors (Hayden & Ghosh 2014).  
 The immediate TNF/LT family comprises four cytokines, TNFα, LTα, LTβ, and 
LT-related inducible ligand that competes for glycoprotein D binding to herpesvirus 
entry mediator on T cells (LIGHT), and five communal receptors. This signalling 
circuitry is complex, consisting of both unique and overlapping ligand-receptor 
interactions (Figure 1.10). LTα can exist as part of an exclusively secreted LTα3 
homotrimer, which signals via one of the two structurally similar but functionally distinct 
TNF receptors, TNFR1 (p55) and TNFR2 (p75). LTα can alternatively form part of one 
of two membrane-anchored heterotrimers together with LTβ. The predominant LTα1β2 
binds to the high affinity LTβ receptor (LTβR), whereas LTα2β1 is expressed by fewer 
than 2% of T cells, has no defined role, and is capable of engaging TNFR1, TNFR2 
and LTβR but only with low avidity (Ware 2005; Aggarwal et al. 2012).  
TNFα is expressed as a homotrimeric transmembrane protein (mTNFα), or a 
cleaved extracellular soluble ligand (sTNFα). It has been reported that while sTNFα 
results in robust activation of TNFR1 but limited or no activation of TNFR2, mTNFα 
primarily signals via TNFR2 (Grell et al. 1995; Grell et al. 1998; Aggarwal 2003). LIGHT 
signals via either herpes virus entry mediator (HVEM) receptor or LTβR. Decoy 
receptor 3 (DcR3) is a secreted receptor for LIGHT, which limits engagement of LIGHT 
in active signalling (Ware 2005; Aggarwal et al. 2012).  
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Stromal cells including fibroblasts, and epithelial and myeloid cells constitutively 
express LTβR. LTα1β2 is expressed by activated T, B and NK cells. TNFα is expressed 
in diverse cell types in response to inflammatory stimuli, but is produced in substantial 
quantities by myeloid cells. TNFR1 is ubiquitously expressed, whereas TNFR2 
expression is mostly restricted to immune cells: TNFR2 is constitutively expressed on 
monocytes and inducible on T and B cells. TNFR1 facilitates most of the 
proinflammatory, apoptotic and cytotoxic functions traditionally associated with TNFα. 
LIGHT demonstrates constitutive expression on myeloid cells and inducible expression 
on T cells. HVEM is widely distributed in lymphoid and non-lymphoid compartments 
(Chen & Oppenheim 2011; Ware 2005). 
Figure 1.10 | The Immediate TNF/ LT Family and their Signalling Circuitry.  
Two distinct signalling pathways can be defined: the TNF signalling pathway is activated by 
TNFα or LTα3, which bind TNFR1 (p55) or TNFR2 (p75).  TNFα exists as a membrane bound 
ligand (mTNFα) or soluble ligand (sTNFα). Both ligands are capable of binding either receptor, 
but mTNFα initiates most of its signalling via TNFR2 and sTNFα signals primarily via TNFR1. 
Signalling via either TNFR activates the p50/p65 cytoplasmic complex for target gene 
transcription. The p50/p65 complex belongs to the canonical (classical) NFκB pathway, leading 
to transcription of genes encoding adhesion molecules and cytokines as shown. The LT/ LIGHT 
signalling pathway consists primarily of two dominant ligands, LTα1β2 and LIGHT, both of which 
signal via LTβR. LIGHT also interacts with HVEM and DcR3. Signalling via the LTβR initiates 
the non-canonical (alternative) NFκB pathway. This activates the p52/ RelB complex for 
transcription of genes including those encoding the chemokines shown. Signalling via the LTβR 
can also initiate the canonical NFκB pathway. TNF, Tumour Necrosis Factor; LT, Lymphotoxin; 
TNFR, TNF receptor; LIGHT, LT-related inducible ligand that competes for glycoprotein D 
binding to herpesvirus entry mediator on T cells; HVEM, Herpes Virus Entry Mediator; DcR3, 
Decoy receptor 3.  
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 TNFα was discovered over a century ago: following reports of regression of 
established tumours in human patients after bacterial infection by a German physician, 
William Cooley, an American oncologist, successfully treated some human cancers 
with bacterial extracts, later named ‘Coley’s toxins’ (Coley 1891; Coley 1910; Aggarwal 
2003). Lipopolysaccharide (LPS) within the bacterial extracts was the agent 
responsible for regression of tumours, as it induced haemorrhagic tumour necrosis. 
The anti-tumour effects of LPS were indirect and were facilitated by the production of a 
factor within the serum in response to LPS, at the time referred to as tumour-
necrotizing factor (Aggarwal 2003). Lloyd Old’s group coined the name tumour 
necrosis factor (TNF) in 1975, and demonstrated that TNF was produced in serum in 
response to endotoxin and caused necrosis when injected directly into tumours 
(Carswell et al. 1975). LT was initially described in the 1960s, as a factor produced by 
lymphocytes, capable of killing tumour cells (Williams & Granger 1968).  
The NFκB family consists of five transcription factors: p50 (NFκB1), p52 
(NFκB2), p65 (RelA), RelB and cRel (Rel). These proteins exist as homodimers or 
heterodimers, and bind directly to DNA to either induce or repress target gene 
transcription. Cytosolic NFκB dimers are prevented from binding to DNA targets during 
the resting state by an association with inhibitor of κB (IκB) proteins. Two IκB proteins, 
IκBα and p100, represent the primary regulators of the ‘canonical’ or ‘classical’ and 
‘non-canonical’ or ‘alternative’ NFκB signalling pathways, respectively (Hayden & 
Ghosh 2014). Signalling via TNFRs triggers transduction via the canonical NFκB 
pathway, whereas signalling via the LTβR can initiate signal transduction via both 
canonical and non-canonical pathways (Figure 1.10) (Mebius 2003). 
1.7.3.2.2 Lymphotoxin/ Tumour Necrosis Factor Signalling in Lymph Node 
Development 
The absolute requirement for LTβR signalling for LN development is illustrated 
by failure of lymphoid organogenesis in mouse models genetically deficient in 
components of the LTβR signalling pathway (Mebius 2003). De Togni and colleagues 
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were the first to report complete absence of all PLNs and PP in LTα-deficient mice (De 
Togni et al. 1994). Banks and colleagues largely confirmed these findings, but noted 
rudimentary LN-like structures in the mesentery of some LTα-/- mice; an early indication 
of the differential requirement for LT signalling in the organogenesis of SLOs in distinct 
anatomical sites (Banks et al. 1995). Expression of the LTα transgene under the 
control of the rat insulin promoter (RIP) in the pancreas, kidney and skin of LTα-/- mice 
(RIPLT.LTα-/- mice) restored LNs, supporting a critical role for LTα (Sacca et al. 1997). 
Despite significant similarities between LTα and TNFα, mice genetically 
deficient in TNFα, TNFR1 or TNFR2, displayed relatively normal LN organogenesis. 
However, mice harbouring disruptions at the TNFα or TNFR genetic loci display 
defective PP development, which were either completely absent or reduced in number 
and structurally disrupted. These data implicated TNFα-TNFR signalling in PP 
organogenesis (Körner et al. 1997; Pasparakis et al. 1996; Pasparakis et al. 1997; 
Erickson et al. 1994; Kuprash et al. 2005; Neumann et al. 1996; Pfeffer et al. 1993; 
Rothe et al. 1993). 
The discrepancy between LTα and TNFα/TNFR genetically deficient mouse 
models indicated that LTα may be controlling lymphoid organogenesis independent of 
TNFRs (De Togni et al. 1994). These data were resolved by the observation that LTα 
forms heterotrimers with LTβ (Androlewicz et al. 1992; Browning et al. 1993), and the 
resulting membrane bound ligand signals through the then newly discovered LTβR 
(Rennert et al. 1996; Crowe et al. 1994). A role for LTαβ-LTβR signalling in 
orchestration of SLO development was soon confirmed by a series of studies of LTβ- 
or LTβR-deficient animals, showing either a complete lack of all LNs and PP (Fütterer 
et al. 1998) or formation of only cervical, mesenteric and sacral LNs (Koni et al. 1997; 
Alimzhanov et al. 1997; Kuprash et al. 1999; Soderberg et al. 2004). 
Injection of soluble LTβR-immunoglobulin antagonist fusion protein during 
embryogenesis inhibited formation of some LNs and PP (Yamamoto et al. 2000; 
Rennert et al. 1996; Rennert et al. 1997; Rennert et al. 1998). Importantly, the first of 
these studies also elegantly demonstrated sequential development of LNs during 
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embryogenesis: injection of the protein on various gestational days affected 
development of distinct LNs (Rennert et al. 1996). Abolished development of LNs in 
LTα-/- mice is rescued by in utero injection of agonist anti-LTβR monoclonal antibodies 
(Rennert et al. 1998). These studies unequivocally demonstrate the absolute 
requirement for LTα1β2-LTβR signalling for LN and PP development.  
The fact that LTα-/- mice lack all LNs (De Togni et al. 1994; Banks et al. 1995) 
while LTβ-/- mice retain cervical, sacral and mesenteric LNs (Koni et al. 1997; 
Alimzhanov et al. 1997; Kuprash et al. 1999) suggests a degree of cooperation 
between surface and membrane bound ligands. Additionally, as the aforementioned 
LNs can develop in LTβ-/- but not LTβR-/- mice (Fütterer et al. 1998), the alternative 
LTβR ligand, LIGHT, is implicated specifically in development of cervical, sacral and 
mesenteric lymphoid organs. Indeed, LIGHT-/- LTβ-/- mice harbour a lower frequency of 
mesenteric LNs compared to that of LTβ-/- mice. However, intact development of all 
LNs, including those in the mesentery, in LIGHT-/- animals suggests LTα1β2-LTβR 
signalling holds a dominant role (Scheu et al. 2002).  
A number of LNs, including mesenteric, cervical, lumbar and sacral, were still 
able to form when LTβR-immunoglobulin fusion protein was administered during utero 
(Rennert et al. 1996; Rennert et al. 1997). In contrast, development of all LNs was 
completely blocked by in utero treatment with LTβR.Ig and either a TNFR1 
immunoglobulin fusion protein (TNFRp55.Ig) or an anti-TNF antibody. This study 
illustrates that TNF-TNFRp55 signalling also contributes to SLO development, perhaps 
in a redundant fashion to LTβR signalling (Rennert et al. 1998).  
Simultaneous triggering of canonical and non-canonical NFκB pathways is 
required for expression of the adhesion molecules and chemokines necessary for 
successful SLO development (Randall et al. 2008). Mice harbouring a spontaneous 
mutation in the aly gene, which encodes for NFκB-inducing kinase (NIK), an essential 
component of the non-canonical NFκB pathway (Miyawaki et al. 1994; Shinkura et al. 
1999), or NIK-/- mice (Yin et al. 2001), lack all PP and LNs. Conversely, Rela x tnfr1-/- 
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mice, which cannot initiate canonical NFκB signalling, also lack all PP and LNs 
(Alcamo et al. 2002).  
1.7.4 High Endothelial Venule Development and Maintenance in Lymph Nodes 
The final steps of LN development require recruitment and positioning of 
lymphocytes. This is delayed until approximately 3 days after birth, due to sequential 
expression of addressins on HEV, the portals for lymphocytic infiltration. Before day 3, 
LN HEV exclusively express MAdCAM-1 (Mebius et al. 1996). Hence only cells 
expressing the cognate selectin α4β7, such as LTi cells and γδ T cells, can access the 
LN via HEV (Yoshida et al. 2001; Mebius et al. 1997; Mebius et al. 1998). Around day 
3, MAdCAM-1 expression is down-regulated concurrently with the up-regulation of 
PNAd, enabling L-selectin-expressing naïve T and B cells to gain entry (Mebius et al. 
1996; Randall et al. 2008). 
Generation of PNAd on the surface of HEV endothelial cells is critically reliant 
upon two enzymes, GlcNAc6ST-1 and GlcNAc6ST-2, which sulfate core glycoproteins 
(Rosen 2004). GlcNAc6ST-2 demonstrates a highly restricted pattern of expression in 
LN HEV, where it is responsible for the expression of PNAd on the inner, apical surface 
of HEV endothelial cells: luminal PNAd (Hemmerich et al. 2001). In contrast, 
GlcNAc6ST-1 is broadly expressed and is thought to facilitate generation of both 
luminal and abluminal PNAd (Uchimura et al. 2005; Uchimura et al. 2004; Kawashima 
et al. 2005). Loss of both GlcNAc6ST-1 and -2 enzymes completely abolishes PNAd 
expression on HEV, rolling of lymphocytes on HEV endothelial cells and lymphocyte 
homing to all PLN (Uchimura et al. 2005; Kawashima et al. 2005). 
 Abluminal PNAd expression on ectopic HEV is initiated by overexpression of 
the LTα transgene in pancreas and kidney (Kratz et al. 1996; Drayton et al. 2003). 
Residual abluminal PNAd expression also remains on LN HEV in LTβ-/- animals, or 
mice in which LTβR signalling has been blocked by antagonist LTβR.Ig (Browning et al. 
2005; Drayton et al. 2003; Liao & Ruddle 2006). In line with these data, LTα3-TNFR1 
signalling has been implicated in regulation of abluminal PNAd expression on HEV, but 
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a direct role has not yet been demonstrated (Drayton et al. 2003). In contrast, 
GlcNAc6ST-2 and GlyCAM-1 expression, required for luminal PNAd expression, 
requires co-expression of LTβ with LTα, and thus LTα1β2-LTβR signalling directly 
controls luminal PNAd expression on HEV (Drayton et al. 2003; Drayton et al. 2004; 
Hemmerich et al. 2001).  
The stromal compartment of LNs actively maintains the differentiated status of 
HEV: PNAd expression and cuboidal morphology of HEV endothelial cells, as well as 
lymphocyte transmigration across endothelial cells, are rapidly down-regulated 
following isolation from adult mice (Ager & May 2015). Early studies during which 
afferent lymphatic flow to LNs was ligated illustrated an essential requirement for 
components of lymph in active maintenance of LN architecture and function (Mebius et 
al. 1991; Mebius et al. 1993; Swarte et al. 1998; Liao & Ruddle 2006). Within 1 week of 
afferent lymphatic occlusion, lymphocytic influx into the LN is significantly decreased, 
accompanied by a loss in the characteristic ‘high’ morphology of HEV endothelial cells 
and changes in adhesion molecule expression. Specifically, HEV revert from a mature 
(MECA-79hi GlyCAM1hi FucTVIIhi GlcNAc6ST-2hi MAdCAM-1lo) to an immature (MECA-
79lo GylCAM1lo FucTVIIlo GlcNAc6ST-2lo MAdCAM-1hi) phenotype (Mebius et al. 1991; 
Mebius et al. 1993; Swarte et al. 1998). Hence, lymphatic flow and presumably factors 
within lymph are required for homeostatic maintenance of HEV, although the identity of 
such factors remains elusive (van de Pavert & Mebius 2014). Additionally, LTβR 
signalling is required for normal homeostatic maintenance of HEV structure and 
function (Lu & Browning 2014). Administration of a LTβR.Ig decoy receptor to adult 
mice phenocopies afferent lymphatic occlusion in that adhesion molecule expression 
by HEV endothelial cells is altered and HEV function is impaired (Browning et al. 2005; 
Liao & Ruddle 2006).  
DCs, well known for their role in antigen presentation, are implicated in the 
modulation and maintenance of the HEV phenotype in the adult, via expression of the 
LTβ ligand. Following depletion of CD11c+ DCs in adult mice, cellularity and size of 
PLNs was significantly reduced, expression of HEV markers was down-regulated and 
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homing of lymphocytes to LNs impaired. The authors noted a similar reversion of HEV 
to an immature phenotype as induced by afferent lymphatic occlusion. This effect was 
the result of a direct interaction between DCs and endothelial cells, presumably via LT 
ligands expressed by DCs and endothelial cell-expressed LTβR (Moussion & Girard 
2011).  
Due to arrested development of lymphoid organs in LT deficient mice, the role 
of LT signalling in development of LN HEV has been more difficult to elucidate. 
However, HEV addressin expression is reduced in mesenteric LNs of LTβ-/- mice and 
rudimentary LNs of mice treated with LTβ blocking reagents during gestation (Rennert 
et al. 1997; Alimzhanov et al. 1997). Indeed, HEV express LTβR and are capable of 
responding to LTαβ ligands (Liao & Ruddle 2006; Browning et al. 2005; Drayton et al. 
2003). A recent study illustrated that LTβR signalling is directly required for 
development of functional HEV in PLNs. When LTβR was ablated in vascular 
endothelial cells beginning at day E8 (before initial stages of LN development), mice 
failed to develop up to 45% of PLNs. Importantly, in LNs that did develop, the HEV 
network was severely impaired, as noted by a significant reduction in addressin 
molecule and chemokine expression, and a loss of cuboidal morphology. These 
structural and phenotypic defects translated to a significant reduction in lymphocyte 
homing via HEV. However, the phenotype of animals in which vascular LTβR 
expression was ablated was not absolute: HEV were not completely absent in PLNs 
that did develop (Onder et al. 2013). These data suggest the existence of complex 
levels of redundancy in signalling circuitries underpinning HEV development in LNs, 
and illustrate the on-going gap in our knowledge surrounding normal HEV genesis.  
1.8 High Endothelial Venule Neogenesis in Chronic Inflammation and Cancer 
1.8.1 Tertiary Lymphoid Organs 
Soon after birth, developmental programs driving lymphoid organogenesis are 
turned off (Drayton et al. 2006). However, tissues can support development of 
lymphoid organs into adulthood. This recapitulation of SLO organogenesis is 
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manifested in the formation of Tertiary Lymphoid Organs (TLOs). TLOs, also termed 
Ectopic Lymphoid-like Structures (ELSs), form at sites of microbial infection or chronic 
inflammation and have been reported in autoimmune disease, and more recently 
cancer (Pitzalis et al. 2014). De novo development of TLOs is referred to as ectopic 
lymphoid neogenesis (Pitzalis et al. 2014; Kratz et al. 1996). TLO development has 
been documented in practically all organ settings during chronic inflammation. ‘TLO’ 
refers to structures of varying organization, from simple clusters of lymphocytes, to 
sophisticated, histologically organized organs highly reminiscent of SLOs (Neyt et al. 
2012; Lu & Browning 2014; Pitzalis et al. 2014; Stranford & Ruddle 2012; Aloisi & 
Pujol-Borrell 2006; Carragher et al. 2008).  
1.8.1.1 Tertiary Lymphoid Organs in Cancer 
 TLOs of varying degrees of organization have been reported in multiple types of 
primary and metastatic cancer (Table 1.2) (Goc et al. 2013). PNAd+ HEV can be found 
within tumours in the presence or absence of TLOs (Ager & May 2015). Tumour TLOs 
and / or isolated PNAd+ HEV are largely associated with a favourable clinical prognosis 
(Goc et al. 2013). In a retrospective study of 74 NSCLC patients, Dieu-Nosjean and 
colleagues reported the presence of tumour-induced bronchus-associated lymphoid 
tissue (Ti-BALT), consisting of organized DC and T cell clusters, and B cell follicles. 
The density of mature DC-LAMP+ DCs, a marker of Ti-BALT, correlated with increased 
overall, disease-specific and disease-free survival (Dieu-Nosjean et al. 2008). Martinet 
and colleagues found a significant correlation between presence of intra-tumoural 
PNAd+ HEV, located within lymphocyte-rich clusters, and increased disease-free, 
metastasis-free and overall survival in 146 breast cancer patients (Martinet et al. 2011). 
Furthermore, regression of primary cutaneous melanoma correlated with presence of 
PNAd+ HEV within the tumour mass (Avram et al. 2013). An interpretation of these data 
is that TLO and / or isolated HEV serve to facilitate trafficking of naïve T cells, which 
become primed and sensitized to tumour antigens locally at the tumour site (Ruddle 
2014). 
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However, some studies have demonstrated a protumoural role for TLOs and / 
or HEV. Development of HEV-containing TLO in B16 melanomas engineered to 
express CCL21 led to rapid recruitment of immunosuppressive Tregs and MDSCs, 
which promoted tumour growth (Shields et al. 2010). Furthermore, high numbers of 
Tregs within lymphoid aggregates of primary breast tumours was indicative of an 
increased risk of disease relapse or death (Gobert et al. 2009; Bates et al. 2006; 
Bohling & Allison 2008). A detailed study in our own lab using resected tumour 
samples from 62 CRC patients found that despite identification of PNAd+ HEV in the 
extra-tumoural area of most patients, intra-tumoural HEV were rare. Extra-tumoural 
HEV were associated with lymphoid aggregates which correlated with advanced 
disease (Bento et al. 2015). It will therefore be important to establish characteristics of 
tumour-associated TLO / HEV that correlate with good prognostic features in the 
future.  
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Table 1.2 | Tertiary Lymphoid Organs in Human Cancer 
Cancer type TLO features References 
Lung T cells, mature DCs, 
HEVs 
(de Chaisemartin et al. 
2011) 
 
Lung (non-small-cell) 
 
T cells, Mature DCs (Goc et al. 2014) 
T cells, B cells, mature 
DCs, FDCs 
(Dieu-Nosjean et al. 2008) 
 
 
 
Colorectal carcinoma 
 
T cells, B cells, mature 
DCs 
(Suzuki et al. 2002) 
T cells, B cells, HEVs (Bento et al. 2015) 
T cells, mature DCs (McMullen et al. 2010) 
T cells, B cells, FDCs (Coppola et al. 2011) 
T cells, B cells, FDCs (Bergomas et al. 2011) 
T cells, B cell, HEVs (Martinet et al. 2011) 
T cells, B cells, mature 
DCs 
(Remark et al. 2013) 
Colorectal carcinoma (with lung 
metastases) 
T cells, B cells, mature 
DCs 
(Remark et al. 2013) 
Colorectal carcinoma (with liver 
metastases) 
Mature DCs (Miyagawa et al. 2004) 
 
 
 
Breast carcinoma 
 
T cells, mature DCs (Bell et al. 1999) 
T cells, B cells, FDCs (Coronella et al. 2002) 
T cells, B cells, FDCs  (Gu-Trantien et al. 2013) 
T cells, B cells, PCs, 
FDCs 
(Nzula et al. 2003) 
T cells, B cell, HEVs (Martinet et al. 2011) 
T cells, B cells, mature 
DCs, HEVs 
(Martinet et al. 2013) 
Lymphocytes (Gobert et al. 2009) 
 
 
Melanoma 
 
 
T cells, B cells, HEVs (Martinet et al. 2012) 
Memory T cells, mature 
DCs 
(Ladányi et al. 2007) 
T cells, B cells, mature 
DCs 
(Messina et al. 2012) 
T cells, B cells, mature 
DCs, FDCs, HEVs 
(Cipponi et al. 2012) 
Lymphocytes, HEVs (Avram et al. 2013) 
 
Ovarian 
T cells, B cells, HEVs (Martinet et al. 2011) 
T cells, B cells (Nielsen et al. 2012) 
Seminoma T cells, HEVs (Sakai et al. 2014) 
Renal cell carcinoma T cells, B cells, mature 
DCs 
(Remark et al. 2013) 
Renal cell carcinoma (with lung 
metastases) 
T cells, B cells, mature 
DCs 
(Remark et al. 2013) 
 
Mucosal-associated lymphoid 
tissue lymphoma 
T cells, B cells, FDCs (Bombardieri et al. 2007) 
T cells, B cells, FDCs (Barone et al. 2008) 
T cells, HEVs (Kobayashi et al. 2011) 
Adapted from (Pitzalis et al. 2014; Neyt et al. 2012; Ager & May 2015; Goc et al. 2013). 
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1.8.2 Development of Tertiary Lymphoid Organs 
Ontogenic development of SLOs provides a paradigm for understanding TLO 
formation. Despite structural differences, data from studies utilizing knockout and 
transgenic mouse models have indicated cooperation between TNF superfamily 
members and lymphoid chemokines in TLO neogenesis, much as in SLO 
development. However, a detailed understanding of exact mechanisms by which TLOs 
form in various pathogenic settings is still lacking (Drayton et al. 2006; van de Pavert & 
Mebius 2014; van de Pavert & Mebius 2010; Pitzalis et al. 2014).  
1.8.2.1 Lymphotoxin/ Tumour Necrosis Factor Signalling in Tertiary Lymphoid 
Organ Neogenesis 
Overexpression of Ltα in kidney and pancreas results in chronic inflammation 
and induction of functional, highly organized TLO, displaying T and B cell 
compartmentalization, and HEV expressing HEV-specific adhesion molecules (Kratz et 
al. 1996). Although TLO can form in Ltα deficient mice, the observed structures are 
much less organized than those in WT animals, and lack many TLO features including 
FDC networks and HEV (Moyron-Quiroz et al. 2004; Moyron-Quiroz et al. 2006). 
Interestingly, TNFR1 expression, but not LTβ expression, is required for LTα-induced 
chemokine expression and TLO neogenesis in the Ltα over-expression model 
(Hjelmström et al. 2000; Sacca et al. 1998). Meanwhile, TLOs in RIPLTαβ transgenic 
animals displayed more distinct T and B cell zone separation, higher expression of 
CXCL13, CCL19 and CCL21, luminal expression of PNAd on HEV, and increased 
infiltration of naïve lymphocytes, relative to RIPLTα mice (Drayton et al. 2003). Hence, 
LTα plays a crucial role in TLO development in at least some settings, and when 
present in combination with LTβ, TLO formation can be enhanced (Pitzalis et al. 2014).  
In models of TLO induction in pancreatic islets, loss of LTα1β2-LTβR signalling 
resulted in reversion of many aspects of TLO formation, including HEV dedifferentiation 
(Luther et al. 2000). Additionally, administration of the LTβR.Ig fusion protein to NOD 
mice resulted in reversion of key features of TLO, including PNAd+ HEV, that form in 
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association with Sjögren syndrome (SS)-like salivary gland disease (Gatumu et al. 
2009; Fava et al. 2011). Development of TLOs in the aortas of atherosclerosis mouse 
models is also a LTβR signalling dependent process, as demonstrated by significant 
interruption of TLO neogenesis following LTβR.Ig administration (Gräbner et al. 2009). 
Lastly, overexpression of LTαβ specifically in the acinar cells of the pancreas resulted 
in robust TLO induction in a mouse model of autoimmune pancreatitis (Seleznik et al. 
2012). Such studies implicate LTα1β2-LTβR signalling in TLO neogenesis at sites of 
chronic inflammation, and in particular in the development and maintenance of 
particular TLO associated lymphoid structures, namely FDC networks and HEV (Lu & 
Browning 2014).  
Signalling via the LTβR has also been implicated in neogenesis of TLOs and / 
or HEV in cancer. Targeting of an antibody-LTα fusion protein directly to mouse 
melanomas resulted in neogenesis of TLO-like lymphoid aggregates including PNAd+ 
HEV (Schrama et al. 2001). These LTα-induced TLO aggregates could foster an active 
anti-tumour immune response in the absence of canonical SLOs in LTα-/- animals 
(Schrama et al. 2008). Expression of LIGHT in a fibrosarcoma cell line resulted in up-
regulation of CCL21 and MAdCAM-1, facilitating recruitment of vast numbers of naïve 
CD8+ T lymphocytes, which were then sufficiently activated in situ to facilitate rejection 
of established tumours (Yu et al. 2004). Martinet and colleagues demonstrated that 
DC-LAMP+ DCs were the major producers of LTβ ligand in human breast tumours, a 
cytokine overexpressed in tumour displaying a high density of HEV. Furthermore, the 
authors showed that DC-LAMP+ DCs positively correlated with HEV density and were 
significantly associated with a favourable clinical prognosis (Martinet et al. 2013). 
Presence of DC-LAMP+ DCs was also shown to correlate with HEV density in primary 
melanoma (Martinet et al. 2012). However, despite clustering of DCs around HEVs in 
breast cancer, the vast majority of DCs are located outside basal laminal layers 
encapsulating HEV, as in LNs, and are therefore unlikely to be capable of direct 
contact with endothelial cells; a likely prerequisite for functional LTβR signalling to drive 
HEV neogenesis (Martinet et al. 2013; Ager & May 2015). Therefore, the precise role 
	 69 
of LT and / or TNF signalling in TLO and / or HEV development within tumours remains 
to be established.   
1.8.2.2 Chemokine Involvement in Tertiary Lymphoid Organ Neogenesis 
Chronically inflamed tissues containing TLOs display heightened expression of 
homeostatic chemokines involved in SLO development, including CXCL12, CXCL13, 
CCL19 and CCL21 (Pitzalis et al. 2014). In the pancreas, all four lymphoid chemokines 
are individually capable of inducing TLO formation when overexpressed (Luther et al. 
2000; Luther et al. 2002; Chen et al. 2002; Fan et al. 2000; Marinkovic et al. 2006). 
Conversely, loss of CXCL13, CXCR5, or CCR7 prohibits formation of TLO in disease 
settings (Rangel-Moreno et al. 2007; Wengner et al. 2007; Winter et al. 2010). These 
chemokines seem to function upstream of LTα1β2 signalling, as LTα1β2 expression on T 
or B cells is induced by CCL19, CCL21 or CXCL13 (Luther et al. 2000; Luther et al. 
2002).  
  Human studies have implicated chemokines CCL19, CCL21 and CXCL13 in the 
formation of intra-tumoural TLOs (Goc et al. 2013). Up-regulated expression of these 
lymphoid chemokines was found in tumour TLOs of both lung carcinoma and breast 
carcinoma patients (Gu-Trantien et al. 2013; de Chaisemartin et al. 2011). In lung 
carcinoma associated TLOs, CCL19 expressing cells belonged predominantly to the 
mature DC-LAMP+ DC population, CXCL13 expression was detected on FDCs within 
GC-like areas, and CCL21 expression was restricted to lymphatic vessels (de 
Chaisemartin et al. 2011). Alternatively, CXCL13-expressing CD4+ Tfh were found in 
breast carcinoma TLOs, and a strong Tfh signature robustly predicted an increased 
patient survival rate (Gu-Trantien et al. 2013).  
1.8.2.3 Requirement for LTi cells in Tertiary Lymphoid Organ Neogenesis 
The recent discovery of adult RORγt+ LTi cells, members of the innate lymphoid 
cell (ILC) family, prompted speculation that such a population could direct TLO 
neogenesis (Schmutz et al. 2009; Sawa et al. 2010; Pitzalis et al. 2014). Meier and 
colleagues demonstrated that induction of ectopic lymphoid tissue by over expression 
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of IL-7 was entirely dependent on adult LTi cells, as TLOs failed to develop in the 
absence of RORγt (Meier et al. 2007). Another study demonstrated the ability of adult 
WT LTi cells, adoptively transferred into neonatal CXCR5-/- mice, to induce TLOs in the 
intestine (Schmutz et al. 2009).  
However, TLOs can develop in the absence of canonical RORγt+ LTi cells. In a 
mouse model of TLO formation induced by CCL21 overexpression, absence of LTi 
cells results in a complete lack of LNs and PP, but normal development of TLOs. 
Instead, mature CD3+ CD4+ T cells are absolutely required for TLO development 
(Marinkovic et al. 2006). TLOs also develop in the colon of Rorc(γt)-/- animals following 
inflammatory insult (Lochner et al. 2011). Furthermore, inducible-BALT (iBALT) form in 
the lungs of Rorc(γt)-/- animals subjected to pulmonary inflammation (Rangel-Moreno et 
al. 2011). Interestingly, TNF/Rorc(γt)-/- mice demonstrate development not only of some 
SLOs but also TLOs in the absence of LTi cells, provided TNFα signalling is increased. 
However, although TNFα compensates for LTi cell loss to a certain degree, Id2 
expression and LTβR signalling are required for complete SLO organogenesis and de 
novo TLO neogenesis (Furtado et al. 2014). 
 In the study by Rangel-Moreno and colleagues, the investigators concluded that 
CD4+ T cell-derived IL-17 was responsible for iBALT development by inducing LTα-
independent CXCL13 expression (Rangel-Moreno et al. 2011). Other studies have 
linked IL-17 and/ or TH17 cells to TLO neogenesis (Deteix et al. 2010; Peters et al. 
2011). A recently published study demonstrated the involvement of TH17 and Tfh cells 
in synovial ectopic lymphoid structure development in both experimental and clinical 
rheumatoid arthritis (RA). This process was under the control of IL-27, a cytokine that 
is often elevated in RA patient synovial and serum samples (Jones et al. 2015). 
Interestingly, the IL-17 producing capability of LTi cells indicates an ancestral 
relationship between LTis and TH17 cells (Pitzalis et al. 2014). However, the identity of 
a distinct TLO-inducing cell type remains elusive, with B cells and TNF-producing 
myeloid cells also representing candidates (Lochner et al. 2011; Furtado et al. 2014; 
Pitzalis et al. 2014). 
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1.9 High Endothelial Venules in Treg Depleted Carcinogen-Induced Tumours 
 The Gallimore group has extensively investigated the feasibility of Treg 
depletion as a mechanism of facilitating a robust effective anti-tumour immune 
response in the Foxp3DTR mouse model of carcinogenesis. In this model, we induce the 
formation of fibrosarcomas by injection of MCA into the hind leg. As previously 
mentioned, near complete ablation of Foxp3+ Treg can be achieved by administration 
of DT to Foxp3DTR mice (Kim et al. 2007). This strategy has proven effective at 
unleashing a powerful CD8+ T cell centred anti-tumour immune response that is 
capable of stunting tumour growth in both B16 melanoma models and MCA models of 
carcinogenesis (Klages et al. 2010; Teng et al. 2010). However, this strategy is limited, 
as only a proportion of established tumours in Treg depleted animals demonstrate 
significant regression. As previously mentioned, it has been suggested that inefficient 
infiltration of effector T cells into the tumour mass represents a significant impediment 
to realizing the potential of Treg depletion (Quezada et al. 2008). 
 To definitively assess the factors underlying an effective anti-tumour immune 
response following Treg depletion, Hindley and colleagues set out to determine the 
features distinguishing regressing from progressing tumours (Hindley et al. 2012). 
Despite profound activation of Foxp3- CD4+ and CD8+ T cells, and an overall highly 
significant reduction in tumour growth rate following Treg ablation in this model, a large 
proportion of Treg depleted animals displayed no significant alteration in tumour control 
(Kim et al. 2007; Hindley et al. 2012). Tumour growth rate was inversely correlated with 
the extent of CD4+ and CD8+ T cell infiltration into the tumour mass, rather than T cell 
activation status, suggesting T cell infiltration following Treg depletion dictates 
successful tumour control. Critically, successful tumour control was determined by the 
development of ectopic, isolated HEV within the tumour mass of a proportion of 
animals. HEV were only ever observed in tumours following Treg depletion, and there 
was an absolute concordance between HEV presence, high numbers of TIL and 
tumour growth control (Hindley et al. 2012).  
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1.10 Hypothesis and Aims 
My hypothesis states that Foxp3+ Tregs, having been recruited to the tumour by 
incompletely understood mechanisms, exert local suppression of immune cell/s. 
Following Treg depletion and the lifting of immunosuppression, extensive and robust 
activation of immune cells enables the production of ‘HEV-inducing’ cytokine(s) or 
signalling molecule(s) that directs HEV neogenesis in MCA tumours. Considering the 
profound activation of T and B lymphocytes following Treg depletion, I hypothesise that 
T and / or B cells are the immune cells responsible for initiating a program of HEV 
neogenesis in tumours.  
Furthermore, in light of data described above, I hypothesise that the ‘HEV-
inducing’ cytokine(s) are LT and / or TNF. My hypothesis then follows that development 
of PNAd+ HEV in tumours facilitates infiltration of vast numbers of CD4+ and CD8+ T 
lymphocytes, and possibly other immune cells. These infiltrating immune cells underpin 
an effective anti-tumour immune response to promote tumour regression (Figure 1.11).  
  
The aims of this PhD thesis were: 
1) To investigate mechanisms underlying enrichment of Foxp3+ Tregs in 
MCA fibrosarcomas (see Chapter Three) 
2) To investigate the involvement of;  
2a) T and B lymphocytes (see Chapter Four), and 
2b) LT and TNF (see Chapter Five) 
in HEV neogenesis in MCA fibrosarcomas following Foxp3+ Treg 
depletion in Foxp3DTR animals 
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Figure 1.11 | Hypothesis of HEV Neogenesis in Carcinogen-Induced Tumours 
after Treg Depletion. 
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Chapter Two 
2 Materials and Methods 
2.1 In vivo mouse work 
2.1.1 Mice 
Genetically engineered Foxp3DTR mice, gratefully received from Professor 
Alexander Rudensky, have been described previously (Kim et al. 2007). Foxp3DTR mice 
were backcrossed with C57BL/6 mice (bred in house) for ≥5 generations by the host 
lab. T-betfl/flFoxp3-Cre conditional KO mice, gratefully received from Professor Stephen 
Anderton, have been described previously (McPherson et al. 2015). Mice were housed 
in accordance with UK Home Office regulations, and isolator-bred before being housed 
in filter-top cages for the duration of experiments. 
2.1.2 Tumour Induction, Diphtheria Toxin Administration and Tumour Monitoring 
For tumour induction, Foxp3DTR mice, T-betfl/flFoxp3-Cre conditional KO mice, or 
Wild-Type C57BL/6 mice, aged 8 to 15 weeks, were anesthetized and injected 
subcutaneously with 400µg of 3-methylcholanthrene carcinogen (MCA; Sigma-Aldrich) 
suspended in 100µl olive oil into the left hind leg, as previously described (Hindley et 
al. 2011). Following MCA injection, mice were monitored for tumour development 
weekly for up to 18 months. Tumour-bearing mice were sacrificed before their tumours 
reached 1.5cm in diameter, or if tumours caused apparent discomfort.  
For in vivo depletion of Foxp3+ Tregs, 0.1µg of diphtheria toxin (DT; Sigma-
Aldrich) diluted in 100µl sterile phosphate buffered saline (PBS) was administered by 
intra-peritoneal (i.p.) injection every other day, after development of a palpable tumour.  
Tumour size, in mm, was measured using calipers, every other day. The 
following measurements were taken: tumour leg width, non-tumour leg width, tumour 
width and tumour height. Tumour growth rate (k, days-1) was calculated using the 
difference between the tumour and non-tumour leg diameters, using the statistical 
software package Prism 5 (GraphPad) by the following equation for exponential 
growth: Y= Y0 x exp (k x X).  
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2.1.3 Depletion of Immune Cells or Blocking of Signalling Molecule Activity 
Hybridomas secreting CD4- and CD8- specific monoclonal antibodies (mAb) 
have been described previously (Qin et al. 1987; Cobbold et al. 1984). Depleting CD4- 
and CD8- specific antibodies were produced and purified in house as previously 
described (Jones 2002). To achieve depletion of CD4+ or CD8+ T cells, or simultaneous 
depletion of CD4+ and CD8+ T cells, 100µg of anti-CD4+ (clones YTS-191 & YTA-3) 
and/or anti-CD8+ (clones YTS-156 & YTS-169) mAb were administered by i.p. injection 
in sterile PBS, alongside DT treatment, at amounts and times stated in Figure 2.1. 
Anti-mouse CD20 mAb (clone 18B12 m2a) was gratefully received from 
Professor Martin Glennie and has been described previously (Williams et al. 2013). To 
achieve depletion of B cells, a single i.p. injection of 250µg of anti-CD20 was 
administered on Day 0, after which DT treatments were given every other day starting 
on Day 1, according to the protocol in Figure 2.1. 
For in vivo blockade of Lymphotoxin (LT)β receptor (LTβR) signalling, a mouse 
LT-βR decoy fusion protein (LTβR.Ig) was gratefully received from Dr Jane Grogan or 
Professor Carl Ware, and has been described previously (Chiang et al. 2009; Benedict 
et al. 2001; Rooney et al. 2000). LTβR.Ig was administered by i.p. injection every other 
day, at a dose of 10mg per kg of body weight, according to the protocol in Figure 2.1. 
For in vivo blockade of Tumour Necrosis Factor (TNF) Receptor (TNFR) signalling, 
clinical grade Etanercept (trade name Enbrel®, Amgen/Wyeth, Cambridge, UK), 
consisting of a dimeric fusion protein of human TNFR2 (TNFRII) fused to human IgG1 
(TNFRII.Ig), gratefully received from Dr Anwen Williams, was dissolved in the supplied 
vehicle according to the manufacturers’ instructions and diluted using sterile PBS. The 
agent was administered by i.p. injection either every day, at a dose of 2.5mg per kg of 
body weight, or every other day, at a dose of 5mg per kg of body weight, according to 
the protocol in Figure 2.1. For an alternative method of in vivo blockade of TNFR 
signalling, an antagonistic rat anti-mouse TNF-α mAb (clone MP6-XT22) was 
administered by i.p. injection in sterile PBS at amounts and times in Figure 2.1.  
	 76 
Figure 2.1 | Immune Cell Depletion and Cytokine Blockade Treatment Regimes. 
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2.1.4 Administration of Anti-IL-2 or Anti-IL-2 / IL-2 Complexes 
To neutralise IL-2 in vivo, 200µg of anti-IL-2 mAb (JES6-1A12; Bio-Xcell) was 
administered by i.p. injection on 3 consecutive days prior to sacrifice. Control mice 
were treated with an equal volume of sterile PBS. For treatment with Anti-IL-2/IL-2 
complexes, complexes were prepared by incubating 5µg recombinant murine IL-2 
(PeproTech) with 50µg of an anti-IL-2 mAb (JES6-1A12 or S4B6-1; Bio-Xcell) for 10 
minutes at room temperature (RT), prior to i.p. injection in 200µl of solution on 3 
consecutive days prior to sacrifice.  
2.1.5 Dissection of Tissues 
Spleen, inguinal Lymph Nodes (LN) and occasionally mesenteric LN, were 
carefully removed from naïve or tumour-bearing mice upon dissection. When required, 
blood was taken directly from the heart upon dissection and pipetted into Microvette® 
lithium heparin containing tubes, which were then centrifuged at 13,000 rpm in a 
microfuge for 5 minutes at RT for plasma isolation. Plasma was stored at -80°C until 
required. The inguinal LN on the tumour (left) side of tumour-bearing mice was 
analysed as a ‘tumour draining lymph node’ (DLN). The inguinal LN on the non-tumour 
(right) side of tumour-bearing mice was analysed as a ‘non-tumour draining lymph 
node’ (NDLN). For naïve (control) mice, the left and right inguinal LN were pooled for 
analysis. Tumours were carefully resected from tumour bearing mice avoiding local 
muscle, other normal tissues, and in particular, the local popliteal LN. 
2.2 Flow Cytometry 
2.2.1 Preparation of Single Cell Suspensions from Tissues 
Spleen and LN were homogenized in a multiwell plate using the back of a 
syringe plunger. Tumours were diced into small pieces in a petri dish, almost to a pulp, 
using a scalpel blade, before being forced through a 70µm cell strainer (BD 
Biosciences) using the back of a syringe plunger. Homogenized tissues were 
resuspended in complete RPMI (RPMI [Invitrogen] supplemented with 2mM L-
glutamine, 1mM sodium pyruvate, 50µg/ml penicillin streptomycin and 10% foetal calf 
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serum) before being passed through a 70µm cell strainer. The single cell suspension 
was washed by pelleting the cells via centrifugation at 1,500rpm (approx. 450 X G) for 
5 minutes, aspirating the supernatant, and resuspending the pellet in complete RPMI. 
Prior to antibody staining, red blood cells in tumour and spleen cell pellets were lysed 
by resuspending pellets in 5ml of RBC lysis buffer (Biolegend) for 90 seconds at RT. 
20ml of complete RPMI was then added to stop the reaction, and cells were pelleted 
once more at 1,500rpm for 5 minutes, after which the supernatant was discarded. 
2.2.2 Cell Surface Staining  
Single cell suspensions were plated out in a 96 round-bottomed well plate at a 
density of 0.5-1 million cells per well. Cells were washed twice in PBS prior to staining 
for dead cells using a fixable dead cell staining kit (LIVE/DEAD Aqua; Invitrogen), by 
adding 3µl (or 6µl for tumour cells) of diluted (1:10 in PBS) LIVE/DEAD Aqua to the cell 
pellet and mixing. Cells were stained for 15 minutes in the dark prior to washing twice 
with FACS buffer. Fc Receptors were blocked by adding diluted anti-CD16/32 (93; 
eBioscience) antibody directly to the cells and incubating for 10 minutes at 4°C in the 
dark. After another two washes in FACS buffer, cells were stained with a surface stain 
panel by adding 25-50µl of diluted (in FACS buffer) antibody master mix to the cells, 
and incubating at 4°C in the dark for 10-15 minutes. Surface antibodies are listed in 
Table 2.1 below.  
2.2.3 Intracellular Antigen and Cytokine Staining 
For intracellular cytokine analysis, single cell suspensions (0.5-1 million cells 
per well) were stimulated in 24 well plates with complete RPMI containing 20 nM 
phorbol myristate acetate (PMA; Sigma-Aldrich) and 1µg/ml ionomycin (Sigma-Aldrich), 
at 37°C for 4 hours, prior to surface staining.  After 1 hour of incubation, 1µl/ml of 
GolgiStop (containing monensin; BD Bioisciences) was added to each well. Surface 
stained cells were subsequently stained for intracellular antigen following 40 minutes to 
16 hours of Fixation/Permeabilisation (Foxp3-staining kit, eBiosciences). Intracellular 
antibodies are listed in Table 2.1 below. For flow cytometric analysis, samples were 
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acquired on a FACS Canto II flow cytometer (BD Biosciences). Unless stated 
otherwise, numbers presented in example flow cytometric histograms and dot plots 
included in Figures represent ‘proportion of parent population’ statistics. In some 
cases, absolute number of cells in the daughter population gate per x number of total 
live cells is presented: this statistic was calculated using the number of acquired events 
in total and daughter population gates on the flow cytometer. 
2.2.4 Flow Cytometric Analysis 
 Flow cytometric data were analysed using FlowJo software. As a large 
proportion of data were gathered surrounding expression of markers by conventional 
CD4+ Foxp3- T cells (Tconv) and CD4+ Foxp3+ Regulatory T cells (Tregs), an example 
gating strategy is shown in Figure 2.2. Additionally, the gating strategy for analysis of 
CD19+ B220+ CD21hi CD23lo CD1dhi Marginal Zone (MZ) B cells in the spleen is shown 
in Figure 2.3. 
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Table 2.1 | Flow Cytometry Antibodies 
Antigen Conjugate Clone Isotype Company Final 
Concentration 
(µg/ml) 
Surface Antibodies 
CD1d 
(CD1.1,  
Ly-38) 
Pacific Blue 1B1 Rat IgG2b, κ Biolegend 10 
CD3 PE-Cy5 17A2 Rat IgG2b, κ BD 
Biosciences 
2  
CD4 APC-eFluor 
780 
RM4-5 Rat IgG2a, κ eBioscience 2 
CD8a Pacific Blue 53-6.7 Rat IgG2a, κ BD 
Biosciences 
4 
CD8a APC 53-6.7 Rat IgG2a, κ eBioscience 2 
CD19 PerCP-
Cy5.5 
1D3 Rat IgG2a, κ BD 
Biosciences 
2 
CD21/CD35 APC 7G6 Rat IgG2b, κ BD 
Biosciences 
2 
CD23 PE B3B4 Rat IgG2a, κ Biolegend 2 
CD25 PE PC61 Rat IgG1, λ BD 
Biosciences 
4 
CD45R/ 
B220 
FITC RA3-6B2 Rat IgG2a, κ Biolegend 5 
CD69 APC H1.2F3 Armenian 
Hamster IgG 
Biolegend 10 
CD69 FITC H1.2F3 Armenian 
Hamster IgG1, 
λ3 
BD 
Biosciences 
2.5 
CD127 (IL-
7Rα) 
Brilliant 
Violet 605 
A7R34 Rat IgG2a, κ Biolegend 1.2 
CD183 
(CXCR3) 
APC CXCR3-
173 
Armenian 
Hamster IgG 
eBioscience 4 
CD183 
(CXCR3) 
Brilliant 
Violet 421 
CXCR3-
173 
Armenian 
Hamster IgG 
Biolegend 4 
Intracellular Antibodies 
Foxp3 PE-Cy7 FJK-16s Rat IgG2a, κ eBioscience 4 
Ki67 Brilliant 
Violet 421 
16A8 Rat IgG2a, κ Biolegend 2.5 
Ki67 FITC B56 Mouse IgG1 BD 
Biosciences 
2 
T-bet PerCP-
Cy5.5 
eBio4B10 Mouse IgG1 eBioscience 2 
TNFα FITC MP6-
XT22 
Rat IgG1, κ eBioscience 5 
Isotype control antibodies 
Mouse 
IgG1, κ 
PerCP-
Cy5.5 
MOPC-21 - Biolegend (matched to 
primary) 
Armenian 
Hamster 
IgG1, κ 
FITC - - BD 
Biosciences 
(matched to 
primary) 
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Figure 2.2 | Gating Strategy for CD4+ Foxp3- Tconv and CD4+ Foxp3+ Treg  
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Figure 2.3 | Gating Strategy for Marginal Zone B cells of the Spleen 
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2.3 Immunohistochemistry 
2.3.1 Paraffin Sections 
Portions of tumours and spleens collected from Foxp3DTR mice were fixed in 
neutral-buffered formalin solution (NBFS) and embedded in paraffin. 5µm thick 
sections were cut on a microtome and mounted on glass slides, and then dewaxed in 
xylene (3 x 5 minutes) and rehydrated via an alcohol gradient (2 x 3 minutes at 100% 
Methanol (MeOH); 1 x 3 minutes at 90% MeOH; 1 x 3 minutes at 70% MeOH; 1 x 5 
minutes in running tap water). Slides were then washed in distilled H2O. For antigen 
retrieval, slides were microwaved for 8 minutes in pre-warmed 10mmol/L Tris, 1mmol/L 
EDTA buffer (pH9), cooled for 30 minutes and equilibrated in 1x PBS. Endogenous 
peroxidase activity was quenched by incubation in Peroxidase Suppressor (Thermo 
Scientific) for 10-15 minutes at RT. After 3x 3 minute washes in 1x PBS, non-specific 
antibody binding was blocked by incubating slides in 2.5% Normal Horse Serum 
Blocking Solution (VectorLabs) for 30 minutes at RT. Slides were incubated in the 
primary antibody diluted to the appropriate concentration in 1% Bovine Serum Albumin 
(BSA) in PBS overnight at 40C. Primary antibodies are listed in Table 2.2 below. The 
following day, after 3x 3 minute washes in 1x PBS, primary antibodies were detected 
via a 30 minute incubation using the relevant ImmPRESSTM Horseradish Peroxidase 
(HRP) Polymer Detection Kit, and subsequently visualized by brief incubation in either 
Impact DAB (3, 3’-diaminobenzidine; brown) or Vector very intense purple (VIP; purple) 
HRP substrate (all VectorLabs). Following detection, slides were rinsed briefly in dH2O 
before counterstain in haematoxylin for 1 minute. Following a 2 minute wash in running 
tap water, sections were dehydrated via the following alcohol series: 1x 3 minutes at 
70% MeOH; 1x 3 minutes at 90% MeOH; 2x 3 minutes at 100% MeOH; 3x 5 minutes in 
Xylene. Sections were then mounted in mounting medium (distyrene, a plasticizer, and 
xylene; DPX) and glass coverslips and allowed to dry in a 600C oven overnight. 
Sections were analysed using a Nikon microscope, and then scanned for quantification 
as detailed below.  
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2.3.2 Frozen Sections 
Portions of tumours, spleens and LNs were embedded in optimum cutting 
temperature (OCT) compound (RA Lamb) and frozen on dry ice. 5µm thick sections 
were cut using a cryostat machine and fixed in ice-cold acetone for 10 minutes before 
being aired dried at RT. Slides were washed in 1x PBS (3x 3 minutes). If biotinylated 
antibodies were to be used, endogenous biotin, biotin receptors and avidin binding 
sites were blocked by incubation in Avidin D solution for 15 minutes at RT, followed by 
a brief rinse in 1x PBS, and incubation in Biotin solution for a further 15 minutes at RT. 
Non-specific antibody binding was blocked by incubating in 2.5% Normal Horse Serum 
Blocking Solution (VectorLabs) for 30 minutes at RT. Slides were incubated in the 
primary antibody diluted to the appropriate concentration in 1% BSA in PBS overnight 
at 40C. The following day, after 3x 3 minute washes in 1x PBS, primary antibodies were 
detected by incubation in a fluorophore-conjugated secondary antibody diluted to the 
appropriate concentration in 1% BSA in PBS, for 60 minutes at RT. Primary and 
secondary antibodies are listed in Table 2.2 below. When sections were double or 
triple stained with more than one unconjugated primary antibody of the same isotype, 
the first primary antibody was detected with a secondary antibody, prior to fixation in 
1% paraformaldehyde (PFA) for 10 minutes at RT. Slides were incubated in the second 
primary antibody for 60 minutes at RT before detection of this antibody using an 
appropriate secondary antibody. After 3x 3 minute washes in 1x PBS, slides were fixed 
in 1% PFA for 10 minutes. Slides were washed a further 2 times in 1xPBS, before 
excess unreacted PFA on the sections was quenched by a 3 minute wash in 0.3Molar 
Glycine in PBS. After a final wash in 1x PBS, sections were mounted using Vectashield 
mounting medium with DAPI (4, 6-diamidino-2-phenylindole; VectorLabs) and glass 
coverslips, and sealed with nail varnish. Sections were imaged using a Zeiss LSM5 
Pascal confocal microscope and serial images assembled using Adobe Photoshop 
software.  
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Table 2.2 | Immunohistochemistry Antibodies 
Antigen Conjugate Clone Isotype Company Final 
Concentration 
(µg/ml) 
Primary antibodies 
CD4 Purified RM4-5 Rat IgG2a, κ Biolegend 1 
CD8a (Ly-2) Purified 53-6.7 Rat IgG2a, κ eBioscience 1 
CD21/CD35 APC 7G6 Rat IgG2b, κ BD 
Biosciences 
2 
CD31 
(PECAM-1) 
FITC 390 Rat IgG2a, κ eBioscience 2 
CD35 Purified 8C12 Rat IgG2a, κ BD 
Biosciences 
1 
CD45R/ B220 Biotin RA3-6B2 Rat IgG2a, κ eBioscience 1 
CD45R/B220 Purified RA3-6B2 Rat IgG2a, κ eBioscience 2 
PNAd Purified MECA-79 Rat IgM, κ Biolegend 2.5 
PNAd Biotinylated MECA-79 Rat IgM, κ Biolegend 1 
MAdCAM-1 Purified MECA-
367 
Rat IgG2a, κ eBioscience 1 
Secondary antibodies 
Rat IgG Alexa Fluor® 
488 
- Donkey IgG Life 
Technologies 
2 
Rat IgG Alexa Fluor® 
568 
- Goat IgG Life 
Technologies 
2 
Streptavidin Alexa Fluor® 
555 
- - Life 
Technologies 
1 
Streptavidin FITC - - Biolegend 1 
Isotype control antibodies 
Rat IgG2a Biotinylated MRG2a-
83 
Mouse IgG Biolegend (matched to 
primary) 
Rat IgM κ Biotinylated RTK2118 - Biolegend (matched to 
primary) 
Rat IgG2a, κ Purified RTK2758 - Biolegend (matched to 
primary) 
Rat IgM, κ Purified RTK2118 - Biolegend (matched to 
primary) 
Rat IgG2a κ FITC RTK2758 - Biolegend (matched to 
primary) 
Rat IgG2b κ APC - - eBioscience (matched to 
primary) 
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2.4 Quantification of T cells in Tumour Tissue 
 Immunofluorescently stained frozen tumour sections were used to quantify 
numbers of CD4+ and / or CD8+ T cells within tumour tissue. Using a fluorescent 
microscope, numbers of T cells were counted per high power field of view by eye. The 
average of 10 high power fields of view was calculated for each section. 
2.5 Quantification of High Endothelial Venules in Tumour Tissue 
Paraffin-embedded tumour sections stained using the anti-mouse PNAd (clone 
MECA-79) antibody were scanned using a high-resolution digital Zeiss Axio Scan.Z1 
slide scanner. Absolute numbers of PNAd+ vessels present within total tumour area, 
calculated in µm2, were quantified per slide using Zeiss Zen software, and the density 
of HEV (HEV density/µm2) was calculated for each sample. Each individual tumour 
HEV vessel was drawn around using measurement tools in Zen software, to obtain the 
vessel area, so that average tumour HEV area could be calculated per sample (see 
Figure 2.4). Tumours with zero vessels were excluded from the calculation of average 
vessel area. Calculation of the area occupied by each individual vessel in each tumour 
enabled the ‘total HEV area’ to also be calculated, as a proportion of the total tumour 
area. A summary of the parameters measured is shown in Table 2.3 below. 
2.6 Quantification of Lymph Node Cellularity by Haemocytometer Count 
 20µl of a single cell suspension generated from mashed lymph nodes, as 
described above, was mixed with 20µl of 0.4% Trypan Blue solution (Thermo Scientific) 
by pipetting. 20µl of mixed solution was pipetted into one chamber of a disposable 
haemocytometer. Viable cells, which had not taken up the blue dye, were counted in a 
block of 16 (4x4) squares by eye under a light microscope, and the number of cells per 
ml of solution was calculated by: count x 2 x 104/ml. 
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Figure 2.4 | Example of High Endothelial Venule Quantification 
 
Table 2.3 | High Endothelial Venule Parameters Measured  
Parameter Calculation 
HEV Density (per 106 µm2) (Absolute HEV number / Total tumour area (µm2)) x 106 
Total HEV area (%) (Total HEV area (µm2) / Total tumour area (µm2)) x 100 
Average HEV area (µm2) Total HEV area (µm2) / Absolute HEV number 
2.7 TNFα Enzyme Linked ImmunoSorbent Assay 
Enzyme Linked Immunosorbent assay (ELISA) for quantification of TNFα in 
plasma was performed using the eBioscience Mouse TNF alpha ELISA Ready-Set-
Go!® kit, according to the manufacturers specifications. Briefly, the plate was coated 
Figure 2.4 | High Endothelial Venules (HEV) were quantified in stained paraffin embedded 
tumour sections by drawing around individual vessels using a graphics tool in Zen software 
(blue lines). In addition, the total tumour area (µm2) was calculated by drawing around the 
entire tumour mass using the same graphics tool (also blue line, around perimeter). A) Low 
power image of a quantified tumour section. B) Higher power image of part of a quantified 
tumour section. Some blue lines are encapsulating HEV vessels while other blue lines are 
highlighting areas of the tissue that are not tumour tissue and will be exluded from final 
analysis. C & D) High power images of parts of a quantified tumour section, showing some 
HEV vessels, and some parts of the tissue to be excluded from analysis (D). 
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with 100µl / well of capture antibody and incubated overnight at 4°C. Wells were 
washed 3x before blocking with 200µl / well of 1x Assay Diluent for 1 hour at RT. 
Standards were diluted in Assay Diluent by two-fold serial dilution; samples were 
diluted three-fold and added at 50-100µl / well. The plate was incubated for 2 hours at 
RT, and then washed 5x. 100µl / well of Detection Antibody diluted in Assay Diluent 
was added per well and the plate incubated for 1 hour at RT. The plate was washed 5x 
prior to adding 100µl / well of Avidin-HRP diluted in Assay Diluent and incubating for 30 
minutes. The plate was washed 7x before adding 50µl / well of Substrate solution and 
incubating for 15 minutes. 50µl / well of Stop Solution (1Molar H3PO4) was added prior 
to reading the plate at 450nm on a FLUOstar OPTIMA Microplate Reader. 
2.8 Gene Expression Analysis 
Data previously generated by gene expression profiling were analysed for 
statistically significant differences in expression of TNF superfamily genes between 
groups (Hindley et al. 2012). Briefly, gene expression profiling was carried out using 
MouseRef-8v2.0 whole genome expression bead chip (Illumina) as recommended by 
the manufacturer. Probe intensity values were corrected by background subtraction in 
GenomeStudio software and subsequently log2 and baseline (median) transformed 
using Genespring software (Agilent) before analysis of genes. Data are therefore 
presented as relative gene expression, calculated as log2-fold change relative to the 
global median of genes.  
2.9 In vitro Treg Suppression Assay 
Spleen and NDLN were a source of effector T cells, and NDLN and DLN, 
Spleen and Tumour were a source of CD69- and CD69+ Tregs. Single cell suspensions 
were prepared as above. Cell suspensions were stained in a 96 well round bottomed 
plate using LIVE/DEAD Aqua, anti-CD3, anti-CD4, anti-CD25 and anti-CD127 mAb. 
CD3+ CD4+ CD25lo Tconvs, CD3+ CD4+ CD25hi CD127lo CD69+ Tregs and CD3+ CD4+ 
CD25hi CD127lo CD69- Tregs were sorted using a customized 20-parameter FACSAria 
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II flow cytometer (BD Biosciences). Post-sort purity checks on practice cell sorts using 
the same panel of antibodies 2 days earlier revealed greater than 98% purity.  
Following sorting, Tconvs were washed in Hank’s Balanced Salt Solution 
(HBSS) and pelleted cells resuspended in warm complete RPMI, at a concentration of 
1 x 106 cells per ml. 0.4µl of 2.5mM CellTrace stock solution prepared in Dimethyl 
sulfoxide (DMSO; Invitrogen) was added per ml of cell suspension, and cells incubated 
for 20 minutes at RT, away from light. 5x the original staining volume of complete RPMI 
was added and the cells were incubated for 5 minutes at RT. Cells were pelleted by 
centrifugation (5 minutes, 1500rpm), and resuspended in warm complete RPMI at a 
concentration of 2.8 x 105 cells per ml, to deliver 14,000 effector cells in 50µl.  
Sorted Treg populations were washed once in HBSS, pelleted and 
resuspended in warm complete RPMI culture medium (complete RPMI supplemented 
with β-Mercaptoethanol, Minimal Essential Media Non Essential Amino Acids (MEM 
NEAA 100X; gibco) and 5mM N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid 
(HEPES buffer solution; gibco)). 14,000 Tconvs per well were incubated with anti-
mouse CD3/CD28 dynabeads (Invitrogen) at a ratio of 1:2 (beads:Tconvs), with 
titrating numbers of Tregs, in complete RPMI culture medium for 120 hours. After 72 
hours, 100µl of fresh, warm complete RPMI culture medium was added to each well. At 
the end of culture, cells were stained with LIVE/DEAD Aqua, and Fc Receptors were 
blocked prior to cell surface staining with anti-CD3, anti-CD4 and anti-CD25. Dilution of 
the CellTrace Violet dye was measured by flow cytometry on a FACS Canto II flow 
cytometer (BD Biosciences). Addition of the CD25 antibody enabled exclusion of the 
CellTrace Violet negative, CD25hi Tregs present in some samples.  
2.10 Statistical Analyses 
 All statistical analyses were performed using GraphPad Prism software, except 
for Linear Models, which were performed in R-statistics software with the help of an in-
house biostatistician. Details of statistical tests used are shown in Figure legends and / 
or in text (footnotes). 
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1 One-Way ANOVA with Tukey’s multiple comparison test 2 Mantel-Cox log rank test  
3 Mann Whitney test 
Chapter Three 
3 Results: Mechanisms of Foxp3+ Treg Enrichment in Tumours 
3.1 Introduction 
The observation that Foxp3+ Tregs are enriched in tumours has been made in 
numerous mouse models and human cancer patients (Ondondo et al. 2013). In fact, 
Tregs can represent up to 40-50% of the CD4+ T cell pool in the MCA-induced 
fibrosarcomas studied herein (Betts et al. 2007). Our lack of knowledge concerning 
mechanisms of Treg enrichment significantly impedes the design of therapies to 
prevent the accumulation of these immunosuppressive cells in tumours.  
Several mechanisms could explain the accumulation of Tregs in tumours (see 
Section 1.6.2 in Chapter One). One idea involves preferential migration of Tregs in 
response to chemokines expressed by tumour cells and/or the surrounding tumour 
stroma (Ondondo et al. 2013). Our recently published study investigated the 
chemokine profile of MCA-induced tumours and compared chemokine receptor 
expression profiles between tumour infiltrating Foxp3- Tconv and Foxp3+ Treg. Whilst 
both Foxp3- and Foxp3+ T cells employ multiple, overlapping chemokine receptors to 
migrate to the tumour, a site characterised by expression of type-1 inflammatory 
chemokines, specific recruitment of Foxp3+ Tregs does not occur via a distinct 
chemokine axis (Ondondo et al. 2014a).  
Mouse and human CD4+ Tregs in peripheral lymphoid organs including LNs 
and spleen demonstrate more active proliferation than CD4+ Tconv under normal 
physiological conditions (Hori et al. 2002; Fisson et al. 2003; Attridge & Walker 2014; 
Pierson et al. 2013). However, our recently published data indicate that the difference 
between the proportions of proliferating Tconv and Treg cells is significantly greater 
within the tumour compared to LNs and spleen. This difference is due to a significant 
increase in the percentage of proliferating Tregs within the tumour (approximately 
45%), compared to normal lymphoid tissue (approximately 20%) (Colbeck et al. 2015). 
The vast majority of proliferating Foxp3+ T cells in MCA tumours also express Helios, 
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which is expressed predominantly in tTregs (Thornton et al. 2010).  These data confirm 
that Tregs in MCA tumours are highly proliferative, and thymus-derived. These findings 
are in support of previous data published by our group demonstrating the largely 
distinct TCR clonotypes of Foxp3- and Foxp3+ CD4+ tumour-infiltrating T cell sub-
populations, suggesting a minimal contribution by conversion of Tconv into Tregs in 
Treg enrichment (Hindley et al. 2011). 
Under normal physiological conditions, the considerable cellular proliferation 
demonstrated by Tregs in vivo is coupled to enhanced cell death: Tregs exhibit an 
enhanced propensity to undergo apoptosis relative to Foxp3- CD4+ T cells (Pandiyan & 
Lenardo 2008; Vukmanovic-Stejic et al. 2006; Taams et al. 2001). Cytokine-withdrawal 
induced apoptosis in fact plays a key role in setting the size of the peripheral Treg pool 
during homeostasis (Pierson et al. 2013). In line with these data, we have previously 
observed that a lower proportion of Tregs than Tconv express the anti-apoptotic factor 
Bcl-2 in LNs and spleen of tumour-bearing animals. However, the proportion of tumour 
infiltrating Treg and Tconv expressing Bcl-2 is almost equal. Furthermore, whilst Tregs 
incorporate higher levels of the dead cell exclusion dye 7AAD than Tconvs in lymphoid 
tissues, a significantly lower proportion of intra-tumoural Tregs take up 7AAD than 
intra-tumoural Tconv (unpublished data). These data corroborate the notion that Tregs 
within the tumour are less prone to death by apoptosis than their counterparts in 
lymphoid tissues. Taken together, these data indicate that enhanced proliferation and 
survival of tumour infiltrating Tregs cooperatively promote enrichment of Tregs in 
tumours. We have found that Tregs also demonstrate enhanced activation relative to 
Tconvs in MCA tumours, by virtue of their heightened expression of a number of cell 
surface activation markers (Colbeck et al. 2015). 
I aimed to investigate further the mechanisms underlying accumulation of 
Foxp3+ Tregs in tumours, using the well-established mouse model of MCA-induced 
carcinogenesis. I hypothesised that in addition to heightened proliferation and 
activation, and enhanced survival, Tregs ensure dominance over Tconv in the tumour 
microenvironment by expression of particular cell surface and/ or intracellular markers, 
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perhaps facilitating their retention, and by exploitation of limited resources within the 
tumour microenvironment (Figure 3.1). Specifically, I investigated: 
• expression of early activation and retention markers on intra-tumoural 
Foxp3+ Tregs; 
• a role for competition for limited IL-2 with conventional T cells in 
enrichment of intra-tumoural Foxp3+ Tregs within the tumour; 
• expression of the TH1-associated transcription factor T-bet on intra-
tumoural Foxp3+ Tregs. 
 
 
Figure 3.1 | Hypothesis of Treg Enrichment in MCA-Induced Tumours. 
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3.2 Results: Tumour-infiltrating CD4+ T cells are Enriched for Inflammation-
Seeking TH1-like Tregs  
Previous studies have reported that Tregs can express the TH1 associated 
chemokine receptor CXCR3 in response to TH1 polarising cues, and that these 
CXCR3+ Tregs accumulate at peripheral sites of inflammation to specifically suppress 
TH1 and CTL responses (Campbell & Koch 2011; Redjimi et al. 2012; Koch et al. 2009; 
O'Connor et al. 2012). Considering the multitude of studies highlighting a crucial role 
for TH1 and CTL cells in the anti-tumour response to MCA induced fibrosarcomas, I 
explored the possibility that the enriched pool of intra-tumoural Tregs reflect this TH1 
orientated immune response (Koebel et al. 2007; Ondondo et al. 2013). When I 
analysed tumour-infiltrating T cells for CXCR3 expression, a high proportion of tumour-
infiltrating Tregs were CXCR3+ (Figure 3.2). In fact, the majority of intra-tumoural Tregs 
expressed CXCR3  (56.34% mean ± 6.267 SD; Figure 3.3 A). Furthermore, the 
majority of Ki67+ proliferating Tregs in the tumour expressed CXCR3 (59.54% mean  ± 
5.231 SD), as was true for intra-tumoural Tconvs (Figure 3.3 B). The proportion of 
either total or Ki67+ proliferating Tregs expressing CXCR3 was significantly greater in 
the tumour relative to the spleen and LNs, and in the tumour draining LN (DLN) relative 
to the non-draining LN (NDLN)1 (Figure 3.3 A-B). 
Several studies have reported that CXCR3+ Tregs are “TH1-like” by virtue of 
transient expression of T-bet, the master regulator of TH1 cells (Szabo et al. 2000; 
Koch et al. 2009; Campbell & Koch 2011; Redjimi et al. 2012; O'Connor et al. 2012). In 
line with these data, I consistently found T-bet expression in a proportion of both intra-
tumoural Foxp3- and Foxp3+ CD4+ T cells (Figure 3.4). Significantly higher proportions 
of intra-tumoural Foxp3- and Foxp3+ CD4+ T cells expressed T-bet than those cells in 
other compartments1 (Figure 3.5 A). Collectively these data are compatible with the 
hypothesis that in MCA-induced tumours, the accumulating Tregs are so-called TH1-
like Tregs mirroring the TH1-orientated immune response targeted for suppression. 
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Figure 3.2 | The majority of tumour infiltrating Foxp3+ Treg express CXCR3. 
Representative flow cytometry plots showing proportion of T cells expressing CXCR3 (y axis) 
and Ki67 (x axis) in Spleen, tumour non-draining lymph nodes (NDLN), tumour draining lymph 
node (DLN) and tumour of one animal. Cells are gated on live CD4+ Foxp3- conventional T cells 
(Tconv; left column), or live CD4+ Foxp3+ regulatory T cells (Treg; right column). Numbers 
represent proportion of cells in each quadrant. 
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Figure 3.3 | A large proportion of total and Ki67+ proliferating Tconv and Treg express CXCR3 in 
tumour. 
Bar charts showing the proportion of total CD4+ Foxp3- conventional T cells (Tconv; white bars), 
and total CD4+ Foxp3+ regulatory T cells (Tregs; grey bars) (A), and those expressing Ki67 (B), 
that also express CXCR3, in spleen, tumour non-draining lymph node (NDLN), tumour draining 
lymph node (DLN), and tumour. N = 5. Data are presented as mean ± standard deviation (SD). 
Statistical significance was determined by One-way ANOVA with Tukey’s multiple comparison 
tests to compare pairs of means (* = P≤0.05, ** = P≤0.01, *** = P≤0.001). 
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Figure 3.4 | A large proportion of Tconv and Treg express T-bet in tumour. 
Representative flow cytometry plots showing proportion of T cells expressing T-bet (x axis) in 
spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN), and 
tumour of one animal. Cells are gated on live CD4+ Foxp3- conventional T cells (Tconv; left 
column), or live CD4+ Foxp3+ regulatory T cells (Treg; right column). Numbers represent 
proportion of cells positive for T-bet expression. Stained samples are shown in red; samples 
stained using the isotype control are shown in blue. 
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Figure 3.5 | T-bet expression by Treg is dispensable for Treg-mediated suppression of anti-
tumour immune responses. 
(A) Bar chart showing the proportion of total CD4+ Foxp3- conventional T cells (Tconv; white 
bars) and total CD4+ Foxp3+ regulatory T cells (Treg; grey bars) that express T-bet in spleen, 
tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN) and tumour. N = 5. 
Data are presented as mean ± standard deviation (SD). Statistical significance was determined 
by One-way ANOVA with Tukey’s multiple comparison tests to compare pairs of means (* = 
P≤0.05, ** = P≤0.01, *** = P≤0.001). (B) A representative flow cytometry plot showing the 
proportion of CD4+ Foxp3+ Tregs  (gated on live CD4+ Foxp3+ lymphocytes) that express 
CXCR3 in blood of Wild Type C57BL/6 (red) and T-betfl/flFoxp3-Cre conditional knock out (cKO) 
animals (purple). The number represents the proportion of Tregs expressing CXCR3 in Wild 
Type. (C) Incidence of MCA-induced tumours (per cent of animals tumour free X days after 
MCA injection) for Wild Type C57BL/6 mice (red) and T-betfl/flFoxp3-Cre cKO mice (purple). N = 
4. Statistical significance was determined by a log rank (Mantel-Cox) test. 
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I hypothesised that if T-bet expression is necessary for the ability of Tregs to 
suppress TH1 responses, as is suggested in the literature (Campbell & Koch 2011; 
Koch et al. 2009), and promote tumour growth, then tumour development should be 
better controlled in the absence of T-bet expressing Tregs. I used mice genetically 
engineered to lack T-bet expression specifically in Foxp3+ cells (T-betfl/flFoxp3-Cre 
conditional KO mice) (McPherson et al. 2015). As CXCR3 expression is under the 
control of T-bet in Treg cells, Treg in T-betfl/flFoxp3-Cre conditional KO mice also 
display abolished CXCR3 expression (Koch et al. 2009; McPherson et al. 2015). The 
lack of CXCR3 expression in Foxp3+ Tregs in T-betfl/flFoxp3-Cre conditional KO mice 
was confirmed by flow cytometric analysis of blood from the conditional KO animals 
relative to that from control Wild Type C57BL/6 animals (Figure 3.5 B). To test the 
hypothesis, I compared the incidence of MCA-induced tumours in T-betfl/flFoxp3-Cre 
conditional KO and WT C57BL/6 mice and found that tumour incidence was 
comparable between the groups as there was no statistically significant difference2 
(Figure 3.5 C). Thus, whilst these data show that in MCA-induced tumours, 
approximately 50% of tTregs are “TH1-like”, I have no evidence that T-bet is required 
for Treg-mediated suppression in the tumour environment.  
 
 
 
 
 
 
 
 
 
 
	1 One-Way ANOVA with Tukey’s multiple comparison test 2 Mantel-Cox log rank test  
3 Mann Whitney test 
99 
3.3 Results: Competition for IL-2 does not account for the Enrichment of Intra-
Tumoural Foxp3+ Tregs 
The ratio of Tregs to Tconvs under homeostatic conditions is tightly controlled 
by bioavailability of IL-2. Tregs are unable to synthesize IL-2 but constitutively express 
CD25, part of the high affinity IL-2 receptor, suggesting they may have the ability to 
exploit the IL-2 resource provided by other T cells (Boyman & Sprent 2012). Tregs 
have been shown to indirectly induce apoptosis of conventional CD4+ T cells via 
deprivation of pro-survival cytokines that signal through the common cytokine γ-chain 
receptor, such as IL-2 (Pandiyan et al. 2007). Furthermore, Tregs have been shown in 
vitro and in vivo to out-compete Tconvs for IL-2, particularly under conditions where its 
production is limited (Almeida et al. 2006).  
I postulated that competition for a limited resource of IL-2 in the tumour 
represents a key component of intra-tumoural Treg proliferation and subsequent 
enrichment. Studies in our lab have shown that a lower proportion of Tconvs within 
MCA tumours express intracellular IL-2 compared to those in spleen and LNs (Colbeck 
et al. 2015). Analysis of intracellular IL-2 expression by intra-tumoural Tconvs 
represents a surrogate measure of the available IL-2 present in the tumour 
microenvironment.  
I therefore hypothesised that IL-2 is limited in the tumour and that Tregs out-
compete Tconvs for this limited resource by virtue of CD25 expression. To test this 
hypothesis I injected tumour-bearing mice with anti-IL-2 monoclonal antibodies (JES6-
1A12) for three consecutive days and analysed T cell proportions and marker 
expression by flow cytometry. Whilst IL-2 neutralisation resulted in a significant 
decrease in the proportion of Ki67+ proliferating CD4+ Tconv, CD4+ Treg and CD8+ T 
cells in lymphoid organs, the observed trend towards a decrease in proliferation of 
these cell subsets in the tumour failed to reach significance3 (Figure 3.6). Furthermore, 
neutralisation of IL-2 did not affect the ratio of Treg to Tconv in any of the 
compartments studied including the tumour3: this was observed when data were 
analysed as either percentage of CD4+ T cells (Figure 3.7) or absolute number of 
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Tconv and Treg (data not shown). These data suggest that limited IL-2 is not 
responsible for dictating the perturbed ratio of Treg to effector T cells in tumour 
microenvironments. IL-2 neutralisation did significantly decrease the proportion of CD4+ 
Tregs expressing CD25 in all compartments studied, including the tumour, in 
corroboration of previous data showing that IL-2 directly regulates CD25 gene 
expression3 (Figure 3.8) (Kim et al. 2001). The proportion of CD8+ T cells expressing 
CD25 was also significantly decreased in LNs3 (Figure 3.8). These CD25 data confirm 
that the antibody successfully accessed the tumour microenvironment.  
To further explore the potential role of IL-2 in maintenance of an altered Treg: 
Tconv ratio in tumours, I injected anti-IL-2/IL-2 complexes into tumour-bearing hosts 
and again analysed T cell proportions and marker expression by flow cytometry. I used 
two different anti-IL-2 monoclonal antibody-IL-2 complexes, which exhibit functional 
dichotomy in terms of the cellular subsets they expand or restrict in vivo. The JES6-
1A12 antibody binds IL-2 in such a way that precludes the interaction of this cytokine 
with low affinity IL-2 receptors, so that the JES6-1A12-IL-2 complex favours stimulation 
of cells expressing the high affinity IL-2 receptor, namely Foxp3+ Tregs. Conversely, 
binding of a second anti-IL-2 monoclonal antibody, S4B6, apparently occludes 
interactions between IL-2 and the high affinity IL-2 receptor but allows interactions with 
the lower affinity receptor. Complexes formed between this antibody and IL-2 therefore 
favour preferential stimulation of CD8+ T cells and other low affinity IL-2 receptor 
bearing cells such as Foxp3- Tconvs, over Foxp3+ Tregs (Boyman et al. 2006; Boyman 
& Sprent 2012; Rojas et al. 2014). 
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 Figure 3.6 | Neutralisation of IL-2 results in significant reductions in the proportions of proliferating T cells in lymphoid organs, but only modest reductions in tumour. 
Bar charts showing the proportion of CD4+ Foxp3- conventional T cells (Tconv; white bars), 
CD4+ Foxp3+ regulatory T cells (Treg; grey bars) and CD8+ T cells (dashed bars) expressing 
Ki67 in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN) 
and tumour of PBS-treated control animals or experimental animals treated with the JES6-1A12 
anti-IL-2 monoclonal antibody. N = 3 experimental; 6 control. Data are presented as median ± 
interquartile range (IQR). Statistical significance was determined by individual Mann Whitney t 
tests between each cell type in control and treated groups. 
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Figure 3.7 | Neutralisation of IL-2 does not alter the Tconv : Treg ratio in lymphoid organs or in 
tumour. 
Bar charts showing the proportion of CD4+ T cells that are Foxp3- (Tconv; white bars) or Foxp3+ 
(Treg; grey bars) in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph 
node (DLN) and tumour of PBS-treated control animals or experimental animals treated with the 
JES6-1A12 anti-IL-2 monoclonal antibody. N = 3 experimental; 6 control. Data are presented as 
median ± interquartile range (IQR). Statistical significance was determined by Mann Whitney t 
tests between each cell type in control and treated groups. 
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Figure 3.8 | Neutralisation of IL-2 alters CD25 expression by T cells in lymphoid organs and in 
tumour. 
Bar charts showing the proportion of CD4+ Foxp3- conventional T cells (Tconv; white bars), 
CD4+ Foxp3+ regulatory T cells (Treg; grey bars) and CD8+ T cells (dashed bars) expressing 
CD25 in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN) 
and tumour of PBS-treated control animals or experimental animals treated with the JES6-1A12 
anti-IL-2 monoclonal antibody. N = 3 experimental; 6 control. Data are presented as median ± 
interquartile range (IQR). Statistical significance was determined by Mann Whitney t tests 
between each cell type in control and treated groups. 
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Injection of pre-formed JES6-1A12/IL-2 complexes into tumour-bearing hosts 
resulted in a significant increase in proliferation of Tregs in all lymphoid organs studied, 
and also Tconvs and CD8+ T cells in the spleen3. However, no significant increase in 
proliferation in any of these cellular subsets was observed in the tumour3 (Figure 3.9). 
The observed change in cellular proliferation resulted in a net effect of increasing the 
ratio of Treg to Tconv in lymphoid organs, whilst no change in the Treg to Tconv ratio 
was observed in the tumour, again, when data were analysed as either percentage of 
CD4+ T cells (Figure 3.10) or absolute number of Tconv and Treg (data not shown)3. 
This complex also resulted in significantly increased proportions of Tregs expressing 
CD25 in lymphoid organs, and Tconv and CD8+ T cells expressing CD25 in the spleen, 
but no alteration in CD25 expression was observed in cells isolated from tumour3 
(Figure 3.11). 
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Figure 3.9 | Administration of IL-2/anti-IL-2 (JES6-1A12) complexes results in increased T cell 
proliferation in lymphoid organs but not in tumour. 
Bar charts showing the proportion of CD4+ Foxp3- conventional T cells (Tconv; white bars), 
CD4+ Foxp3+ regulatory T cells (Treg; grey bars) and CD8+ T cells (dashed bars) expressing 
Ki67 in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN) 
and tumour of PBS-treated control animals or experimental animals treated with the IL-2/JES6-
1A12 anti-IL-2 complex. N = 4 experimental; 6 control. Data are presented as median ± 
interquartile range (IQR). Statistical significance was determined by Mann Whitney t tests 
between each cell type in control and treated groups. 
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Figure 3.10 | Administration of IL-2/anti-IL-2 (JES6-1A12) complexes alters the Tconv : Treg 
ratio in lymphoid organs but not in tumour. 
Bar charts showing the proportion of CD4+ T cells that are Foxp3- (Tconv; white bars) or Foxp3+ 
(Treg; grey bars) in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph 
node (DLN) and tumour of PBS-treated control animals or experimental animals treated with the 
IL-2/JES6-1A12 anti-IL-2 complex. N = 4 experimental; 6 control. Data are presented as median 
± interquartile range (IQR). Statistical significance was determined by Mann Whitney t tests 
between each cell type in control and treated groups. 
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Figure 3.11 | Administration of IL-2/anti-IL-2 (JES6-1A12) complexes alters CD25 expression by 
T cells in lymphoid organs but not in tumour. 
Bar charts showing the proportion of CD4+ Foxp3- conventional T cells (Tconv; white bars), 
CD4+ Foxp3+ regulatory T cells (Treg; grey bars) and CD8+ T cells (dashed bars) expressing 
CD25 in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN) 
and tumour of PBS-treated control animals or experimental animals treated with the IL-2/JES6-
1A12 anti-IL-2 complex. N = 4 experimental; 6 control. Data are presented as median ± 
interquartile range (IQR). Statistical significance was determined by Mann Whitney t tests 
between each cell type in control and treated groups. 
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Administration of preformed S4B6-IL2 complexes also resulted in a highly 
significant increase in proliferation of CD4+ Tconv, CD4+ Treg and CD8+ T cells to a 
comparable degree in secondary lymphoid tissues3. Again, a significant increase in 
proliferation of CD4+ Tconv and CD4+ Treg was not observed in the tumour3 (Figure 
3.12). However, in line with previous reports, the S4B6-IL2 complex resulted in 
preferential and considerable expansion of CD8+ T cells in the tumour, confirming 
successful tumour access by the complex3 (Boyman et al. 2006; Boyman & Sprent 
2012). The S4B6-IL-2 complex increased the proportion of Tregs and CD8+ T cells, and 
sometimes CD4+ Tconv, expressing CD25 in lymphoid organs3 (Figure 3.13). 
Furthermore, the proportion of Tregs expressing CD25 was also significantly increased 
in the tumour following S4B6-IL-2 complex administration3 (Figure 3.12). However, 
whilst S4B6/IL-2 administration resulted in an increased ratio of Treg to Tconv in 
lymphoid tissues, the ratio of Treg to effector T cells, including both Tconv and CD8+ T 
cells, remained unchanged in the tumour, when data were analysed as either 
percentage of CD4+ T cells (Figure 3.14) or absolute number (data not shown).   
These data collectively indicate that increasing the availability of IL-2 has no 
impact on the ratio of Tregs to Tconvs at the tumour site.  
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Figure 3.12 | Administration of IL-2/anti-IL-2 (S4B6) complexes results in increased T cell 
proliferation in lymphoid organs and in tumour. 
Bar charts showing the proportion of CD4+ Foxp3- conventional T cells (Tconv; white bars), 
CD4+ Foxp3+ regulatory T cells (Treg; grey bars) and CD8+ T cells (dashed bars) expressing 
Ki67 in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN) 
and tumour of PBS-treated control animals or experimental animals treated with the IL-2/S4B6 
anti-IL-2 complex. N = 4 experimental; 6 control. Data are presented as median ± interquartile 
range (IQR). Statistical significance was determined by Mann Whitney t tests between each cell 
type in control and treated groups. 
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Figure 3.13 | Administration of IL-2/anti-IL-2 (S4B6) complexes alters CD25 expression by T 
cells in lymphoid organs and in tumour. 
Bar charts showing the proportion of CD4+ Foxp3- conventional T cells (Tconv; white bars), 
CD4+ Foxp3+ regulatory T cells (Treg; grey bars) and CD8+ T cells (dashed bars) expressing 
CD25 in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN) 
and tumour of PBS-treated control animals or experimental animals treated with the IL-2/S4B6 
anti-IL-2 complex. N = 4 experimental; 6 control. Data are presented as median ± interquartile 
range (IQR). Statistical significance was determined by Mann Whitney t tests between each cell 
type in control and treated groups. 
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Figure 3.14 | Administration of IL-2/anti-IL-2 (S4B6) complexes alters the Tconv : Treg ratio in 
lymphoid organs but not in tumour. 
Bar charts showing the proportion of CD4+ T cells that are Foxp3- (Tconv; white bars) or Foxp3+ 
(Treg; grey bars) in spleen, tumour non-draining lymph node (NDLN), tumour draining lymph 
node (DLN) and tumour of PBS-treated control animals or experimental animals treated with the 
IL-2/S4B6 anti-IL-2 complex. N = 4 experimental; 6 control. Data are presented as median ± 
interquartile range (IQR). Statistical significance was determined by Mann Whitney t tests 
between each cell type in control and treated groups. 
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3.4 Results: CD69 is highly Expressed on Intra-Tumoural Foxp3+ Tregs  
CD69 is classically described as a marker of early T cell activation (González-
Amaro et al. 2013). In recent years however, it has become apparent that through 
reciprocal regulation of sphingosine 1-phosphate receptor 1 (S1P1), CD69 also plays a 
role in retaining T cells at the site of antigen (Shiow et al. 2006; Matloubian et al. 2004; 
Chu et al. 2003; Bankovich et al. 2010; Mackay et al. 2015). I compared CD69 
expression on MCA tumour-derived Foxp3- and Foxp3+ CD4+ T cells and found a 
striking difference (Figure 3.15). A significantly greater proportion of intra-tumoural 
Foxp3+ T cells expressed CD69, than tumour derived conventional Foxp3- T cells1 
(Figure 3.16 A). The proportion of Foxp3+ Tregs expressing CD69 was also statistically 
greater than the proportion of CD69-expressing Foxp3- T cells in LNs and spleen1. 
Furthermore, the proportion of CD69-expressing Foxp3+ Tregs in the tumour was 
statistically greater than in any lymphoid tissue1 (Figure 3.16 A).  
To investigate the relevance of this finding in the context of another tumour 
model, I also compared CD69 expression in Foxp3- and Foxp3+ CD4+ T cells isolated 
from tumours induced by injection of the 4T1 mammary carcinoma cell line (Figure 
3.17) (Miller et al. 1983; Miller 1983). These data strongly corroborated my findings in 
the MCA-induced fibrosarcomas, as I observed that a significantly greater proportion of 
tumour derived Foxp3+ CD4+ T cells expressed CD69 relative to tumour derived Foxp3- 
CD4+ T cells, and Foxp3+ Tregs in all other lymphoid compartments1 (Figure 3.16 B). 
Again, a greater proportion of Foxp3+ Tregs than Foxp3- CD4+ T cells expressed CD69 
in lymphoid compartments, as observed in the MCA-induced model, although this did 
not reach statistical significance here1 (Figure 3.16 B). Collectively, these data from two 
different tumour models strongly support the notion that Tregs are far more likely than 
Foxp3- T cells to remain tumour-resident by virtue of their heightened expression of 
CD69, thereby contributing to their accumulation within the tumour-infiltrating T cell 
pool (Figure 3.18). 
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Figure 3.15 | Intra-tumoural Tregs of MCA fibrosarcomas express high levels of CD69. 
Representative flow cytometry plots showing proportion of T cells expressing CD69 (x axis) in 
spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN), and 
tumour of one animal model of MCA-induced fibrosarcoma. Cells are gated on live CD4+ Foxp3- 
conventional T cells (Tconv; left column), or live CD4+ Foxp3+ regulatory T cells (Treg; right 
column). Numbers represent proportion of cells positive for CD69. Stained samples are shown 
in red; samples stained using the isotype control are shown in blue. 
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Figure 3.16 | Tregs express higher levels of CD69 than Tconv in lymphoid organs and tumours 
of two separate tumour models.  
Bar charts showing the proportion of CD4+ Foxp3- conventional T cells (Tconv; white bars) and 
CD4+ Foxp3+ regulatory T cells (Treg; grey bars) that express CD69 in spleen, tumour non-
draining lymph node (NDLN), tumour draining lymph node (DLN) and tumour, expressed as 
Mean Fluorescence Intensity (MFI) in animal models of MCA-induced fibrosarcoma (A), or 4T1 
breast carcinoma (B). N = 3 (A), N = 8 (B). Data are presented as mean ± standard deviation 
(SD). Statistical significance was determined by One-way ANOVA with Tukey’s multiple 
comparison tests to compare pairs of means (* = P≤0.05, ** = P≤0.01, *** = P≤0.001). 
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Figure 3.17 | Intra-tumoural Tregs of 4T1 mammary carcinomas express high levels of CD69. 
Representative flow cytometry plots showing proportion of T cells expressing CD69 (x axis) in 
spleen, tumour non-draining lymph node (NDLN), tumour draining lymph node (DLN), and 
tumour of one animal model of 4T1 breast carcinoma. Cells are gated on live CD4+ Foxp3- 
conventional T cells (Tconv; left column), or live CD4+ Foxp3+ regulatory T cells (Treg; right 
column). Numbers represent proportion of cells positive for CD69. Stained samples are shown 
in red; samples stained using the –FITC fluorescence minus one control are shown in blue. 
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Figure 3.18 | MCA induced fibrosarcomas and 4T1 mammary carcinomas demonstrate a 
significant enrichment of Helios+ thymus-derived Foxp3+ Tregs, which express heightened levels 
of Ki67 and CD69 relative to those in Spleen. Spice diagrams showing proportions of CD4+ T 
cells expressing certain markers in one representative spleen and tumour of the MCA-induced 
fibrosarcoma model (top) and the 4T1 mammary carcinoma model (bottom). Each arc denotes a 
marker as detailed in the key.  
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3.5 Results: CD69 Expression Confers Superior Suppressive Capacity on 
Foxp3+ T cells  
CD69 is a well-established marker of early leukocyte activation (González-
Amaro et al. 2013) yet CD69-/- animals paradoxically display enhanced anti-tumour 
immunity and enhanced susceptibility to autoimmune diseases (Esplugues et al. 2003; 
Sancho et al. 2003). These data indicate that CD69 could also therefore act as a 
negative regulator of T cell activation somehow. A recent study indicated that Foxp3+ 
Tregs could indirectly mediate this negative regulatory effect, as CD69+ Foxp3+ Tregs 
were found to be more efficient at limiting inflammation than CD69- counterparts 
(Cortés et al. 2014).  
Having found a significant population of CD69+ Foxp3+ Tregs in MCA-induced 
tumours, I next sought to assess the suppressive capacity of this population of Foxp3+ 
Treg. CD4+ CD25lo Tconvs were sorted from lymphoid tissue and co-cultured in the 
presence of anti-CD3 and anti-CD28 beads with either CD69+ or CD69- Tregs sorted 
from DLN or NDLN, at varying Tconv : Treg ratios. Treg were sorted as CD4+ CD25hi 
CD127lo (CD69+ or CD69-) cells: low cell surface expression of the IL-7 receptor α-
chain (CD127) is used to discriminate and isolate live Tregs by cell sorting as intra-
cellular Foxp3 staining cannot be used (Liu et al. 2006). After 120 hours of culture, 
proliferation of labelled Tconvs was measured by flow cytometry.  
Strikingly, CD69+ Tregs, recovered from DLN and NDLN, were more 
suppressive of Tconv proliferation than their CD69- counterparts (Figure 3.19). I 
observed that CD69+ Tregs are 2 x and 1.3 x more suppressive than CD69- Tregs at a 
Tconv : Treg ratio of 8 : 1 in the DLN and NDLN, respectively. Similarly, CD69+ Tregs 
are 1.2 x and 1.3 x more suppressive than CD69- Tregs at a Tconv : Treg ratio of 4 : 1 
in the DLN and NDLN, respectively (Figure 3.19). These data are indicative of a 
superior ability of CD69+ Foxp3+ Tregs to not only be retained at the site of antigen, but 
to suppress proliferation of anti-tumour Tconv cells, in relation to CD69- Foxp3+ Tregs. 
Collectively, these data might point to a role for CD69 in retaining highly proliferative, 
super-suppressive Tregs at the tumour site. 
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Figure 3.19 | CD69+ Tregs from Lymph Nodes demonstrate heightened suppression of Tconv 
proliferation relative to CD69- Tregs in vitro.  
Representative flow cytometry plots showing proportion of divided Tconv cells according to 
dilution of CellTrace Violet dye (x axis) with no CD3/CD28 stimulation (filled in red peak), with 
stimulation (purple peak), with stimulation and CD69- Tregs (green peak), and with stimulation 
and CD69+ Tregs (blue peak). Data are shown for CD4+ CD25hi CD127lo CD69+ or CD69- Tregs 
from tumour draining lymph nodes (DLN) and tumour non-draining lymph nodes (NDLN).  
 
	1 One-Way ANOVA with Tukey’s multiple comparison test 2 Mantel-Cox log rank test  
3 Mann Whitney test 
119 
3.6 Discussion 
It is clear that TH1 cells and CTL are the key cells involved in immune control of 
MCA-induced tumours (Koebel et al. 2007). I have found that the proliferating Tregs in 
MCA tumours express both the chemokine receptor CXCR3 and the transcription 
factor T-bet, in-keeping with a “TH1-like” lineage. Redjimi and colleagues reported that 
CXCR3+ T-bet+ Tregs are prevalent in human ovarian tumours. These data imply that 
‘mirroring’ of the anti-tumour TH1-orientated immune response may be required for 
effective immunosuppression by Tregs in tumours (Redjimi et al. 2012). Indeed, Koch 
and colleagues previously observed that T-bet deficient Tregs were inferior to wild-type 
Tregs during control of TH1-mediated multi-organ autoimmunity (Koch et al. 2009). 
However, several studies have reported either no alteration in suppressive capacity of 
Tregs when T-bet is absent, or even superior suppressive function of T-bet deficient 
Tregs (Neurath et al. 2002; Bettelli et al. 2004; Finotto et al. 2005). A recent study of 
experimental autoimmune encephalomyelitis (EAE) reported that lack of T-bet 
expression in Foxp3+ Tregs did not hinder their infiltration of the inflamed central 
nervous system, which is important for EAE resolution. T-bet deficient Tregs were also 
capable of preventing the development of T cell-driven colitis (McPherson et al. 2015). 
My studies provide no evidence that T-bet expression defines Tregs with a superior 
capacity to suppress anti-tumour TH1-orientated immune responses. These data also 
corroborate recent data from our laboratory that excluded a role for CXCR3 in 
preferential homing of Tregs to the tumour (Ondondo et al. 2014a). 
I postulated that as IL-2 might be a limiting resource in the tumour environment, 
preferential proliferation and accumulation of Tregs in the tumours could be due to 
competition for IL-2. IL-2 serves to promote both tolerance and immunity. Whilst it is 
needed to potentiate differentiation and expansion of both TH1 cells and CD8+ CTL, 
Tregs also depend on IL-2 for their expansion and survival (Malek 2008). Although high 
doses of IL-2 have proven an effective component of immunotherapy against renal cell 
cancer in some patients (< 20%), its administration is associated with high levels of 
toxicity and may result in a significant increase in Treg numbers (Fyfe et al. 1995; 
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Ahmadzadeh & Rosenberg 2006; Cesana et al. 2006; van der Vliet et al. 2007). My 
data indicate that while IL-2 is a limiting factor for proliferation of Tregs, Tconvs and 
CD8+ T cells in lymphoid compartments and tumour, as evidenced by changes in Ki67 
expression following anti-IL-2 or IL-2/anti-IL-2 administration, altering the availability of 
IL-2 has no significant impact on the ratio of Tregs to Tconvs or Tregs to CD8+ effector 
T cells at the tumour site.  
I found that a significantly higher proportion of intra-tumoural Tregs express 
CD69 than intra-tumoural Tconvs and Tconvs in other, lymphoid tissues. Furthermore, 
intra-tumoural Tregs consistently expressed the highest levels of CD69 relative to 
Tregs in lymphoid organs. Lastly, my data indicate that CD69-expressing Tregs in 
lymphoid organs are more suppressive of CD4+ Tconv proliferation than their CD69- 
counterparts. However, these are preliminary data from one experiment, and would 
need to be repeated before firm conclusions regarding the suppressive capacity of 
CD69+ and CD69- Tregs could be drawn.  
CD69 is a type-II C-lectin transmembrane receptor, up-regulated on T cells 
upon antigen stimulation via the TCR (González-Amaro et al. 2013). It has also 
become apparent that CD69 plays a role in retaining T cells at the site of antigen, 
through preventing expression of S1P1, thereby stopping lymphocyte egress from the 
site of antigen recognition (Shiow et al. 2006). Furthermore, it is now known that lack of 
expression of S1P1 in resident memory T cells is responsible for their retention in non-
lymphoid tissues (Skon et al. 2013).  
Although CD69 is considered a classical marker of T cell activation, CD69-/- 
paradoxically mice exhibit enhanced tumour immunity and heightened susceptibility to 
autoimmune disease and allergic inflammation, raising the possibility that the molecule 
could act as a negative regulator of T cell activation (Esplugues et al. 2003; Sancho et 
al. 2003; Martin et al. 2010). It is possible that this effect of CD69 expression is 
mediated by Foxp3+ Tregs. Several recent studies in mouse and human have provided 
data linking CD69 expression to the generation and suppressive function of Foxp3+ 
Tregs (González-Amaro et al. 2013). Double positive thymocytes expressing high 
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levels of CD69 represent the precursors to Foxp3+ tTregs in human (Martín-Gayo et al. 
2010). Consistent with these data, peripheral CD69-expressing Tregs in mice differ 
from CD69 negative Tregs in terms of expression levels of Treg associated markers 
such as glucocorticoid-induced TNFR family related gene (GITR), CTLA-4 and 
inducible co-stimulator (ICOS), supporting the idea that CD69+ Treg represent a distinct 
subset of Treg (Cortés et al. 2014). Compromised Foxp3+ Treg suppressive function in 
systemic sclerosis patients is associated with diminished CD69 expression on Tregs 
(Radstake et al. 2009). A more recent study has demonstrated that mouse CD69+ 
Foxp3+ Tregs limit inflammation more efficiently than CD69- Tregs (Cortés et al. 2014). 
S1P1 signalling has also been shown to up-regulate the Akt-mTOR signalling pathway, 
which results in diminished suppressor activity in Tregs (Liu et al. 2009). Hence, CD69 
expression on Tregs following TCR activation may not only serve to retain Tregs at the 
site of antigen but may also, through repression of S1P1 signalling, favour strong 
suppressor activity by the retained CD69+ Tregs. Thus, in the case of the tumours 
described herein, the consequence of CD69 expression on Tregs may be the retention 
of tumour-infiltrating super-suppressive Tregs at the site of antigen, thereby ensuring 
Treg dominance within the local tumour microenvironment.  
CD69 expression on intra-tumoural Tregs could of course be a simple reflection 
of heightened activation status. To tease apart activation and suppressive capacity of 
Tregs in future experiments would be challenging, as these are intricately linked in 
Foxp3+ Tregs. However, the fact that most T cells inside the tumour are highly 
activated (unpublished data) argues for a fundamental difference in the functional 
activity of CD69+ Tregs. 
In conclusion, I have eliminated competition for a limited IL-2 resource as a 
means by which Tregs become significantly enriched in tumours. Despite the discovery 
of an accumulation of TH1-like Tregs in tumours, this feature did not contribute to the 
functional ability of Tregs to control anti-tumour immune responses. Instead, my 
observations highlight that as well as increased proliferation with superior survival, 
retention of highly suppressive Tregs within the tumour microenvironment by virtue of 
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CD69 expression is a key mechanism by which Tregs exert dominance over intra-
tumoural Tconvs (Figure 3.20). Further analyses investigating the relevance of these 
observations in different tumour models will enable more successful manipulation of 
these immunosuppressive cells in cancer immunotherapy regimes. 
 Figure 3.20 | Modified Hypothesis of Treg Enrichment in MCA Tumours. 
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Chapter Four 
4 Results: Cellular Subsets Responsible for Directing High Endothelial 
Venule Neogenesis in Tumours 
4.1 Introduction 
 HEV develop during ontogeny as part of the pre-programmed process of SLO 
development, which is kick-started by interactions between stromal LTo and 
haematopoietic LTi cells (Mebius 2003). Previous immunohistochemical analyses 
conducted in our lab revealed an absence of canonical CD3- CD4+ IL-7Rα+ RORγt+ LTi 
cells in HEV positive and negative tumours of Treg depleted Foxp3DTR animals (Hindley 
et al. 2012). These data indicate that HEV neogenesis in MCA tumours proceeds along 
a distinct molecular pathway to that observed during normal lymphoid organ 
development.  
The precise mechanisms and cellular subsets directing HEV development 
within LNs remain incompletely defined. Recent evidence has pointed to a crucial role 
for CD11c+ DCs in modulation and maintenance of the specialised HEV phenotype in 
LNs (Moussion & Girard 2011). There is also evidence that DCs regulate the overall 
size of the HEV vascular tree, possibly via LTβR-induced VEGF expressed by FRCs, 
suggesting an additional role for DCs in control of HEV growth (Wendland et al. 2011; 
Webster et al. 2006; Chyou et al. 2008; Ager & May 2015).  
Whether LTi-like cells or DCs dictate HEV neogenesis in solid human tumours 
remains unknown (Ager & May 2015). Recent studies have implicated LTβ-producing 
mature DC-LAMP+ DCs in the process of HEV neogenesis in human breast tumours. 
Martinet and colleagues observed that clusters of mature DCs surround HEV in tumour 
tissue and that DCs were the major producers of LTβ in tumours. Furthermore, DC 
abundance correlated positively with density of tumour-associated HEV (Martinet et al. 
2013; Martinet & Girard 2013). However, direct evidence for involvement of DCs in 
HEV neogenesis in tumours is still lacking. Considering Treg depletion in Foxp3DTR 
mice results in a profound increase in both numbers and activation status of DCs (Kim 
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et al. 2007), it is possible that DCs could be instrumental in driving HEV neogenesis in 
MCA tumours of Treg depleted Foxp3DTR mice. Current ongoing work in our lab is 
aimed at determining whether these immune cells regulate HEV neogenesis in this 
scenario.  
 Due to the complete absence of HEV in Treg replete tumours of our MCA-
Foxp3DTR model, it is entirely possible that other immune cells, which become highly 
activated as a result of Treg depletion (Kim et al. 2007; Hindley et al. 2012), coordinate 
HEV formation in these tumours. T and B lymphocytes, as well as DCs, are capable of 
producing TNF superfamily cytokines involved in HEV development during ontogeny 
(Ware 2005), and therefore represent strong candidates for ‘HEV-initiator’-type cells in 
tumours. Under this premise, I aimed to determine whether there is a role for: 
• B cells,  
• CD4+ T cells, and / or 
• CD8+ T cells,  
in HEV neogenesis in Treg depleted tumours.  
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4.2 Results: HEV in Tumours of Treg Depleted Animals Share Similarities with 
but also Differ from Lymph Node HEV 
 HEV in tumours of Treg depleted Foxp3DTR animals were detected by 
immunohistochemical staining of paraffin embedded sections or immunofluorescence 
staining of frozen sections using the MECA-79 monoclonal antibody that detects PNAd 
expressed on endothelial cells (Figure 4.1). MECA-79 staining co-localised with the 
pan-endothelial marker CD31, confirming the detection of vascular endothelial cells. 
However, the vast majority of CD31+ blood vessels in the tumour did not express PNAd 
(data not shown).  
 PNAd+ HEV within tumours of Treg depleted Foxp3DTR animals differed from 
HEV within LNs of Treg replete Foxp3DTR mice according to several criteria (Figure 
4.2). While LN HEV are composed of endothelial cells with a characteristic and 
distinctive cuboidal, or ‘high’ morphology (Figure 4.2) (Gowans & Knight 1964; Rosen 
2004), endothelial cells lining PNAd+ HEV in tumours seemed much less plump: 
vessels were often lined by flat endothelial cells (Figure 4.1). LN HEV are situated 
within the post-capillary network, and increase in size from the cortical-paracortical 
junction, where they are smallest, to the paracortex, where they are largest. HEV 
therefore conform to an orderly and uniform architectural organisation within LNs (Ager 
& May 2015). In contrast, HEV within the tumours described herein displayed varying 
degrees of uniformity in relation to morphology and size, with no apparent pattern of 
distribution within the tumour mass (Figures 4.1 and 4.2).  
Mature LN HEV are characterised by luminal expression of PNAd. When 
analysing the pattern of PNAd distribution in tumour HEV, there looked to be PNAd 
staining throughout the vessel wall (Figure 4.1). However, it was not possible to 
definitively determine the contribution of luminal versus abluminal PNAd expression, as 
this was not directly measured here. Interestingly, in contrast to HEV reported in some 
human cancers (see Table 1.2 in Chapter One), development of HEV within the 
fibrosarcomas described herein was not accompanied by the formation of isolated 
lymphoid aggregates (Figure 4.1). While PNAd+ HEV were often observed in close 
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proximity to clusters of lymphocytes within the tumour mass, the vessels were certainly 
not embedded within discrete lymphoid follicles.  
Tumour HEV also differed from classical LN HEV by co-expression of 
MAdCAM-1, an addressin normally restricted to mucosal lymphoid organs such as 
mesenteric LNs in adult animals (Figure 4.1) (Girard et al. 2012). MAdCAM-1 is 
expressed by endothelial cells of HEV in all LNs early in development, after which it is 
rapidly downregulated concurrent with the upregulation of PNAd expression on HEV 
(Mebius et al. 1996). Dedifferentiation of HEV in LNs involves reversion from a mature 
(MECA-79hi MAdCAM-1lo) phenotype to an immature (MECA-79lo MAdCAM-1hi) 
phenotype (Mebius et al. 1993; Mebius et al. 1991; Swarte et al. 1998). MAdCAM-1 
expression is therefore associated with an immature HEV phenotype (Drayton et al. 
2006), and could reflect an early developmental status of HEV in tumours of Treg 
depleted animals. However, upon antigen challenge, HEV in reactive LNs undergo 
extensive remodelling during which they re-express MAdCAM-1 and downregulate 
PNAd (Liao & Ruddle 2006; Herzog et al. 2013). MAdCAM-1 expression on HEV is 
hence indicative of two entirely divergent biological scenarios: dedifferentiation 
concurrent with reversion to an immature phenotype, or robust activation of the 
endothelium. Some intra-tumoural vessels expressed MAdCAM-1 but not PNAd, 
suggesting the existence of a range of vessels at various states of differentiation and / 
or activation in the tumour (Figure 4.1). Interestingly, the anti-MAdCAM-1 antibody also 
reacted with PNAd+ HEV in LNs of Treg replete Foxp3DTR animals, in contrast to 
reports of HEV in inguinal LN being MAdCAM-1 negative (Figure 4.2) (Girard et al. 
2012). Further study, including functional analyses, will be required to determine the 
relevance of MAdCAM-1 expression on both tumour HEV and HEV of inguinal LNs in 
Foxp3DTR animals. 
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Figure 4.1 | High Endothelial Venules present in a range of morphologies in MCA-induced 
tumours in the absence of Tregs. 
High power confocal images of High Endothelial Venules (HEV) within tumours of Treg 
depleted Foxp3DTR animals. Endothelial cells of HEV were detected by immunofluorescence 
staining using a biotinylated rat anti-PNAd primary antibody (clone MECA-79) and streptavidin 
Alexa Fluor® 555 secondary antibody (red). Tumour sections were dual-stained for PNAd and 
either CD31 (rat anti-CD31-FITC; green; top panels) or MAdCAM-1 (rat anti-MAdCAM-1 
antibody followed by donkey anti-rat Alexa Fluor® 488 secondary antibody; green; bottom 
panels). Merged images include the nuclear stain DAPI (blue). Scale bars are shown.  	
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Figure 4.2 | High Endothelial Venules in peripheral Lymph Nodes conform to a uniform 
morphology and size. 
High power confocal images of High Endothelial Venules (HEV) within Lymph Nodes of Treg 
replete Foxp3DTR animals. Endothelial cells of HEV were detected by immunofluorescence 
staining using a biotinylated rat anti-PNAd primary antibody (clone MECA-79) and streptavidin 
Alexa Fluor® 555 secondary antibody (red). Lymph Node sections were dual-stained for PNAd 
and either CD31 (rat anti-CD31-FITC; green; top panels) or MAdCAM-1 (rat anti-MAdCAM-1 
antibody followed by donkey anti-rat Alexa Fluor® 488 secondary antibody; green; bottom 
panels). Merged images include the nuclear stain DAPI (blue). Scale bars are shown.  	
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In addition to the profound splenomegaly and lymphadenopathy induced by 
Treg depletion in Foxp3DTR animals (Kim et al. 2007), I noted significant disruption to 
the general organisation and morphology of LN microarchitecture, including HEV, after 
depletion of Tregs (Figures 4.3 and 4.4). Demarcation between T and B cell zones was 
almost completely lost; instead T cells could be found throughout the swollen LN. HEV 
had lost their distinctive orderly and uniform organisation within the LN: vessels of 
varying sizes were located randomly throughout the node (Figure 4.3). Furthermore, 
HEV were generally larger in size, with particularly open lumen, relative to LN HEV of 
Treg replete Foxp3DTR animals. However, HEV maintained PNAd and MAdCAM-1 
expression, which could on occasion be seen to be upregulated, relative to HEV of 
Treg replete animals (Figure 4.4). The observed alterations to the LN HEV network 
following Treg depletion are reminiscent of previous reports of expansion of HEV in 
peripheral LN following depletion of Treg in the Foxp3DTR model (Kumar et al. 2012). By 
optical projection tomography analysis, Kumar and colleagues reported increases in 
HEV segment length, number of branching points and overall HEV length following 
Treg depletion, although it remains unknown whether the observed vascular expansion 
was a result of the autoinflammatory lymphadenopathy induced by Treg depletion, or 
direct Treg activity on the LN vasculature.  
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Figure 4.3 | Treg depletion induces profound microarchitectural changes in peripheral Lymph 
Nodes. 
Low power confocal images of High Endothelial Venules (HEV) and T cells within Lymph Nodes 
of Treg replete (upper panels) and Treg depleted (lower panels) Foxp3DTR animals. Lymph node 
sections were immunofluorescently co-stained using a biotinylated rat anti-PNAd primary 
antibody (clone MECA-79), which was detected using a streptavidin Alexa Fluor® 555 secondary 
antibody (red), and rat anti-CD4 and rat anti-CD8a primary antibodies, which were detected 
using a donkey anti-rat Alexa Fluor® 488 secondary antibody (green). Merged images include 
the nuclear stain DAPI (blue). Scale bars are shown.  	
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Figure 4.4 | Treg depletion induces significant alterations in High Endothelial Venule morphology 
in peripheral Lymph Nodes. 
High power confocal images of High Endothelial Venules (HEV) within Lymph Nodes of Treg 
depleted Foxp3DTR animals. Endothelial cells of HEV were detected by immunofluorescence 
staining using a biotinylated rat anti-PNAd primary antibody (clone MECA-79) and streptavidin 
Alexa Fluor® 555 secondary antibody (red). Lymph Npde sections were dual-stained for PNAd 
and either CD31 (rat anti-CD31-FITC; green; top panels) or MAdCAM-1 (rat anti-MAdCAM-1 
antibody followed by donkey anti-rat Alexa Fluor® 488 secondary antibody; green; bottom 
panels). Merged images include the nuclear stain DAPI (blue). Scale bars are shown.  	
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4.3 Results: HEV Density Correlates with Increased T cell Infiltration and 
Reduced Tumour Growth Rate in Treg Depleted Tumours 
Tumours of Treg depleted Foxp3DTR animals that contain HEV contain 
significantly increased numbers of CD8+ T cells and display significantly reduced 
tumour growth rates, relative to HEV negative tumours of Treg depleted animals, and 
tumours of Treg replete mice (Hindley et al. 2012). However, delineating tumours into 
“HEV positive” or “HEV negative” categories over-simplified the biological scenario: 
“HEV positive” tumours varied greatly in terms of numbers of vessels per unit area. In 
order to more accurately represent the observed variation, I developed a method of 
quantitating HEV in tumours. Using Zen software and scanned images of 
immunohistochemically stained tumour sections (Figure 4.5 A), I obtained quantitative 
measures of number of PNAd+ HEV per unit area of tumour (HEV density), average 
area of HEV vessels per tumour (Average HEV area) and proportion of tumour area 
occupied by HEV vessels (Total HEV area; see Table 4.1 below). By quantifying HEV, I 
obtained measures by which to assess the impact of various treatments on HEV 
neogenesis in tumours, as described in the following Results sections. 
Table 4.1 | Quantitative Parameters of Tumour HEV 
Parameter Calculation 
HEV Density (per 106 µm2) (Absolute HEV number / Total tumour area (µm2)) x 106 
Total HEV area (%) (Total HEV area (µm2) / Total tumour area (µm2)) x 100 
Average HEV area (µm2) Total HEV area (µm2) / Absolute HEV number 
 Both HEV density and total HEV area data fit a bifurcated pattern of distribution, 
whereby, within the dataset, one group of data points is very low or null, and the other 
group of data points is above this threshold and demonstrate positivity for the measure 
(Figure 4.5 B and D). These data corroborate the observation that approximately 50% 
of Treg depleted tumours contain HEV (Hindley et al. 2012). The average area of HEV 
of Treg depleted tumours varied significantly, ranging from less than 50 µm2 to over 
450 µm2 (Figure 4.5 C). 
	1 Spearman’s correlation 2 Mann Whitney non-parametric t test 3 Kruskal-Wallis One-
Way ANOVA with Dunn’s multiple comparisons test 4 Linear Regression 
133 
I found a striking statistically significant positive correlation between HEV 
density and number of T cells in tumours of Treg depleted animals (r = 0.4781, 
*P=0.0284 for CD4+ T cells1; r = 0.6221, **P=0.0026 for CD8+ T cells1; Figure 4.6 A-B). 
There was also a positive correlation between total HEV area and number of T cells in 
tumours (r = 0.3806, nsP=0.0887 for CD4+ T cells1; r = 0.6286, **P=0.0023 for CD8+ T 
cells1; data not shown). These data support my hypothesis stating that T cells access 
the tumour via HEV following Treg depletion. Of note, those tumours with high 
numbers of CD4+ T cells generally also contained high numbers of CD8+ T cells.  
Number of CD4+ T cells and CD8+ T cells negatively correlated with tumour 
growth rate, which did not reach statistical significance for CD4+ T cells (r = -0.3384, 
nsP=0.1335 for CD4+ T cells1; r = 5481, *P=0.0101 for CD8+ T cells1; Figure 4.6 C-D). 
These data indicate that following Treg depletion, infiltration of T cells, particularly 
CD8+ T cells, contributes towards tumour growth control. Interestingly, HEV density 
and total HEV area both displayed highly statistically significant negative correlations 
with tumour growth rate (r = -0.6519, **P=0.0014 for HEV density1; r = -0.7390, 
***P=0.0001 for total HEV area1; Figure 4.6 E-F). The greater association between total 
HEV area and tumour growth rate than between HEV density and tumour growth rate 
suggests that not only number but relative area of HEV in tumours is important for 
dictating HEV-mediated tumour control.  Furthermore, the more striking correlation 
between measures of HEV and tumour growth rate than between number of tumour 
infiltrating T cells and tumour growth rate suggests that HEV-mediated tumour control 
is a function not only of T cell infiltration via HEV, but also perhaps infiltration of other 
anti-tumour immune cells. For instance, HEV density also displays a weak positive 
correlation with number of CD45R+ B cells in tumours of Treg depleted animals (r = 
0.4659, nsP=0.12751; Figure 4.7). Collectively, these data support my hypothesis 
stated in Chapter One: intra-tumoural HEV facilitate control of tumour growth and 
tumour rejection by enabling infiltration of high numbers of anti-tumour T cells. 
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Figure 4.5 | MCA-induced tumours develop ectopic High Endothelial Venules following Treg 
depletion. 
Quantitative measures of High Endothelial Venules (HEV) in tumours of Treg depleted Foxp3DTR 
animals. (A) Representative microscope images of HEV in paraffin embedded tumours. The 
anti-PNAd antibody (clone MECA-79) was detected using DAB chromogen (brown staining). 
Sections were counterstained using haematoxylin. Scale bars are shown. (B) HEV density was 
calculated per unit area of tumour (µm2). The insert shows an enlarged version of the boxed 
area. (C) Average area of HEV vessels calculated in µm2. (D) Total HEV area as a proportion of 
total tumour area, calculated as a percentage. Data are presented as individual datapoints plus 
median. Statistical significance was determined by Mann Whitney t tests. N = 21 (20 in C). 	
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Figure 4.6 | Intra-tumoural High Endothelial Venules correlate with higher numbers of infiltrating 
T cells and reduced tumour growth rate. 
Correlations between numbers of intra-tumoural CD4+ and CD8+ T cells, High Endothelial 
Venule (HEV) density and total HEV area, and tumour growth rates for Treg depleted Foxp3DTR 
animals. (A-B) Numbers of intra-tumoural CD4+ and CD8+ T cells plotted against tumour HEV 
density; CD4+ T cells (A; purple); CD8+ T cells (B; blue). (C-D) Numbers of intra-tumoural CD4+ 
and CD8+ T cells plotted against tumour growth rates (k, days-1); CD4+ T cells (C; purple); CD8+ 
T cells (D; blue). (E-F) HEV density (E) and total HEV area (as proportion of total tumour area; 
F) plotted against tumour growth rate (k, days-1). Statistical significance was determined by the 
non-parametric Spearman’s correlation coefficient test, and the r statistic and P values are 
shown. N = 21. 	
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4.4 Depletion of B cells does not Abrogate HEV Neogenesis in Tumours 
 Foxp3+ Tregs are capable of direct suppression of B cell proliferation and 
Immunoglobulin (Ig) production, and B cell killing (Lim et al. 2005; Zhao et al. 2006; 
Wang & Zheng 2013). In line with this, Treg depletion results in a significant increase in 
numbers of CD45R+ B cells in LN and spleen and dysregulated antibody production 
(Morgan et al. 2003; Kim et al. 2007). CD45R+ B cells are detectable in tumours of 
Foxp3DTR mice (unpublished data), and numbers of B cells in Treg depleted tumours 
correlates with HEV density (Figure 4.7). Furthermore, B cells are prolific producers of 
TNF superfamily cytokines involved in development of HEV-containing LN when 
activated (Ware 2005), raising the possibility that these cells could contribute to HEV 
formation in tumours following Treg depletion. For this reason, I set out to determine 
whether B cells are important for HEV neogenesis in tumours. I injected tumour-
bearing animals with an anti-CD20 antibody to deplete B cells according to the protocol 
in Chapter Two and analysed tumour sections for HEV presence by 
immunohistochemistry.  
Figure 4.7 | High Endothelial Venule density correlates with numbers of CD45R+ B cells inside 
tumours.  
Correlation between number of intra-tumoural CD45R+ B cells and High Endothelial Venule 
(HEV) density, in Treg depleted Foxp3DTR animals. Statistical significance was determined by 
the non-parametric Spearman’s correlation coefficient test, and the r statistic and P values are 
shown. N = 12. 	
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 To confirm efficacy of the anti-CD20 antibody, proportions of CD45R+ B cells 
were analysed in tumour draining LN (DLN) and non-draining LNs (NDLN), and spleen 
by flow cytometry, and in tumour by counting of immunofluorescently stained frozen 
sections. A single administration of the anti-CD20 antibody at the beginning of the Treg 
depletion regime resulted in a significant decrease in both the proportion and absolute 
number of CD45R+ B cells in spleen and lymph nodes, and absolute number of B cells 
in tumour (Figure 4.8).  
PNAd+ HEV were easily detectable in frozen tumour sections of Treg depleted 
animals in the absence of B cells (Figure 4.9). PNAd staining co-localised with CD31, 
confirming detection of vascular endothelial cells of vessels (data not shown). PNAd+ 
HEV were also readily detectable in paraffin embedded tumour sections of the same B 
cell depleted, Treg depleted tumours (Figure 4.10 A). Quantification of PNAd+ HEV 
demonstrated that there was no significant difference in HEV density in anti-CD20 
treated Treg depleted tumours relative to Treg depleted tumours, despite a slight 
decrease in anti-CD20 tumours (nsP=0.16042, Figure 4.10 B). There was also no 
significant difference in the total HEV area between anti-CD20 treated Treg depleted 
tumours and Treg depleted tumours (nsP=0.42092, Figure 4.10 D). However, there was 
a highly significant increase in the average HEV area in anti-CD20 treated Treg 
depleted tumours relative to Treg depleted control tumours (***P=0.00072, Figure 4.10 
C).  
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Figure 4.8 | Treatment with an anti-CD20 monoclonal antibody depletes CD45R+ B cells from 
lymphoid organs and tumour. 
Proportion and absolute number of CD45R+ B cells in spleen, non tumour-draining lymph node 
(NDLN), tumour-draining lymph node (DLN) and tumour, determined by flow cytometry or 
counting of immunofluorescently stained tumour sections, in Treg depleted and anti-CD20 
treated, Treg depleted Foxp3DTR animals, at the end of treatment. Data shown are: proportion of 
total live lymphocytes expressing CD45R (left), absolute number of CD45R+ B cells (middle) or 
counts of CD45R+ B cells per high power field of view for tumour (bottom left). Data are 
presented as median ± Interquartile range. Statistical significance was determined by Mann 
Whitney t tests. N = 6 (anti-CD20 treated Treg depleted); N = 3 (Treg depleted; lymphoid 
organs); N = 12 (anti-CD20 treated, Treg depleted and Treg depleted Foxp3DTR animals; 
tumours).  	
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Figure 4.9 | High Endothelial Venules are found in tumours in the absence of CD45R+ B cells. 
Confocal images of High Endothelial Venules (HEV) within tumours of Treg depleted (top) and 
anti-CD20 treated, Treg depleted (bottom) Foxp3DTR animals. Endothelial cells of HEV were 
detected by immunofluorescence staining using a biotinylated rat anti-PNAd primary antibody 
(clone MECA-79) and streptavidin Alexa Fluor® 555 secondary antibody (red). Tumour sections 
were dual-stained for PNAd and B cells (rat anti-CD45R detected using donkey anti-rat Alexa 
Fluor® 488 secondary antibody; green). Merged images include the nuclear stain DAPI (blue). 
Scale bars are shown.  	
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Figure 4.10 | Measures of High Endothelial Venule density and total area are not significantly 
altered in the absence of B cells. 
Quantitative measures of High Endothelial Venules (HEV) in tumours of anti-CD20 treated, Treg 
depleted Foxp3DTR animals. (A) Representative microscope images of HEV in paraffin 
embedded tumours. The anti-PNAd antibody (clone MECA-79) was detected using either DAB 
chromogen (top; brown staining) or VIP chromogen (bottom; purple staining). Sections were 
counterstained using haematoxylin. Scale bars are shown. (B) HEV density was calculated per 
unit area of tumour (µm2). The insert shows an enlarged version of the boxed area. (C) Average 
area of HEV vessels calculated in µm2. (D) Total HEV area as a proportion of total tumour area, 
calculated as a percentage. Data are presented as individual datapoints plus median. Statistical 
significance was determined by Mann Whitney t tests. N = 12 anti-CD20 treated, Treg- tumours 
(10 in C); N = 21 Treg- tumours (20 in C). 	
	1 Spearman’s correlation 2 Mann Whitney non-parametric t test 3 Kruskal-Wallis One-
Way ANOVA with Dunn’s multiple comparisons test 4 Linear Regression 
141 
To assess functionality of HEV in anti-CD20 treated Treg depleted tumours, I 
correlated HEV density or total HEV area with numbers of tumour infiltrating T cells and 
tumour growth rates (Figure 4.11). I found a weak positive correlation between HEV 
density and number of tumour infiltrating CD8+ T cells in anti-CD20 treated tumours (r = 
0.6305, *P=0.03231; Figure 4.11 A). The number of CD4+ T cells also appeared to 
correlate positively with HEV density, although statistical significance was not reached 
(r = 0.5639, nsP=0.05911; Figure 4.11 B).  
 There was a weak negative correlation between numbers of CD4+ and CD8+ T 
cells and tumour growth rate, although this did not reach statistical significance for 
either type of T cell (r = -0.3217, nsP=0.3085 for CD4+ T cells1; r = -0.2657, 
nsP=0.4042 for CD8+ T cells1; Figure 4.11 C-D). Furthermore, there was a very weak 
correlation between measures of HEV density and total HEV area and tumour growth 
rate, which were far from reaching statistical significance (r = -0.1681, nsP=0.6039 for 
HEV density1; r = -0.0070, nsP=0.9910 for total HEV area1; Figure 4.11 E-F). These 
data suggested that despite no significant change in HEV density or total HEV area in 
anti-CD20 treated tumours relative to Treg depleted tumours, the functionality of HEV 
that developed during anti-CD20 treatment was significantly compromised relative to 
HEV in Treg depleted tumours, in terms of facilitating anti-tumour lymphocyte 
extravasation into tumours and subsequent tumour growth control. 
 Collectively, these data show that, whilst depletion of B cells results in a 
modest, insignificant decrease in HEV density in tumours, there is no difference in total 
HEV area in tumours. Therefore, HEV neogenesis can proceed uninterrupted in the 
absence of these cells. These data suggest that B cells do not represent a key LTi-like 
‘HEV-initiator’ cell type in this system. However, the average size of HEV was 
significantly increased in the absence of B cells. Furthermore, the data suggest a 
function of B cells in the maintenance of a fully functional HEV phenotype in tumours, 
as the infiltration of high numbers of T cells via HEV and an association with reduced 
tumour growth rate was abrogated in the absence of B cells.  
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Figure 4.11 | Functionality of High Endothelial Venules in B cell-depleted tumours is significantly 
compromised.  
Correlations between number of intra-tumoural CD4+ and CD8+ T cells, High Endothelial Venule 
(HEV) density and total HEV area, and tumour growth rates for anti-CD20 treated, Treg 
depleted Foxp3DTR animals. (A-B) Numbers of intra-tumoural CD4+ and CD8+ T cells plotted 
against tumour HEV density; CD4+ T cells (A; purple); CD8+ T cells (B; blue). (C-D) Numbers of 
intra-tumoural CD4+ and CD8+ T cells plotted against tumour growth rates (k, days-1); CD4+ T 
cells (C; purple); CD8+ T cells (D; blue). (E-F) HEV density (E) and total HEV area (as 
proportion of total tumour area; F) plotted against tumour growth rate (k, days-1). Statistical 
significance was determined by the non-parametric Spearman’s correlation coefficient test, and 
the r statistic and P values are shown. N = 12. 	
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4.5 Results: Depletion of Both CD4+ and CD8+ T cells Significantly Abrogates 
HEV Neogenesis in Tumours 
 Depletion of Tregs in Foxp3DTR animals results in a significant increase in 
number, proliferation and activation of both CD4+ and CD8+ T cells (Kim et al. 2007; 
Hindley et al. 2012). Furthermore, there is a highly significant increase in numbers of 
tumour-infiltrating CD4+ and CD8+ T cells following Treg depletion, which confer a 
significant reduction in tumour growth rate (Hindley et al. 2012). Our hypothesis states 
that neogenesis of HEV in tumours facilitates high numbers of both CD4+ and CD8+ T 
cells to infiltrate the tumour mass, which then ensure an effective anti-tumour immune 
response, resulting in tumour growth control. It is entirely possible that T cells 
themselves, which are highly activated following Treg depletion, also represent the 
initiator cell type in the process of HEV neogenesis.  
T cells, like B cells, are prolific producers of TNF Superfamily cytokines involved 
in organogenesis of HEV-containing lymphoid organs (Ware 2005). T cells could 
therefore form part of a positive feedback loop, in which they produce cytokines 
necessary for development of HEV in tumours, which, once formed, allow entry of vast 
numbers of activated T cells constituting a robust anti-tumour immune response. I 
aimed to first establish whether either CD4+ or CD8+ T cells were required for HEV 
neogenesis in tumours by injecting tumour-bearing Treg depleted Foxp3DTR animals 
with a cocktail of anti-CD4 and anti-CD8 antibodies, according to the protocol in 
Chapter Two, and analysing tumour sections for HEV by immunohistochemistry. To 
deplete T cells, I used a combination of two different anti-CD4 monoclonal antibody 
clones (YTS-191 & YTA-3), and a combination of two different anti-CD8 monoclonal 
antibody clones (YTS-169 & YTS-156); each pair of antibodies has been shown to 
synergize in vivo, resulting in more efficient CD4+ or CD8+ T cell depletion, 
respectively, than when a single clone is administered alone (Qin et al. 1987; Qin et al. 
1989; Cobbold et al. 1984). 
 Efficacy of the anti-CD4/ anti-CD8 antibody cocktail was examined by flow 
cytometric analysis of CD4+ and CD8+ T cell proportions and numbers in spleen, NDLN 
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and DLN, and tumour, as well as counting of T cells in immunofluorescently stained 
tumour sections. These analyses confirmed that the antibody cocktail resulted in a 
significant reduction in both the proportion and absolute number of both CD4+ and 
CD8+ T cells in spleen, LNs and tumour (Figure 4.12). Of note, the antibody cocktail 
resulted in the loss of the majority but not all T cells; absolute depletion of CD4+ T cells 
was particularly difficult to achieve.  
 PNAd+ staining could be found on occasion in frozen tumour sections (Figure 
4.13). However, the vast majority of tumours from anti-CD4/CD8 treated animals 
contained no PNAd+ staining. Where it could be found, PNAd staining co-localised with 
CD31 (data not shown).  
PNAd+ vessels were also incredibly scarce in paraffin embedded tumour 
sections from anti-CD4/CD8 treated animals (Figure 4.14 A). Those vessels that were 
present in anti-CD4/CD8 treated tumours appeared more fragile, with weaker PNAd+ 
staining, and the endothelial cells even less plump than those in Treg depleted 
tumours. When PNAd+ vessels in anti-CD4/CD8 treated tumours were quantified, I 
found a striking difference; despite incomplete depletion of T cells from tumours (Figure 
4.12), anti-CD4/CD8 treated tumours contained significantly lower numbers of PNAd+ 
HEV per unit tumour area than Treg depleted tumours (***P=0.00072; Figure 4.14 B). 
There was no significant difference in average HEV area that formed in anti-CD4/CD8 
treated tumours and Treg depleted tumours (nsP=0.41092, Figure 4.14 C). In 
corroboration of the striking reduction in HEV density, there was also a highly 
significant decrease in the total HEV area of anti-CD4/CD8 treated tumours relative to 
Treg depleted tumours (**P=0.00312; Figure 4.14 D). These data show that even a 
partial reduction in T cell numbers in tumours severely abrogates the process of HEV 
neogenesis. 
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Figure 4.12 | Treatment with a cocktail of anti-CD4 and anti-CD8 monoclonal antibodies 
depletes CD4+ and CD8+ T cells from lymphoid organs and tumour. 
Proportion and absolute number of T cells in spleen, non tumour-draining lymph node (NDLN), 
tumour-draining lymph node (DLN) and tumour, determined by flow cytometry or counting of 
immunofluorescently stained tumour sections, in Treg depleted and anti-CD4/CD8 treated, Treg 
depleted Foxp3DTR animals, at the end of treatment. Data shown are: proportion of total live 
lymphocytes expressing CD4 or CD8 (left), absolute number of CD4+ or CD8+ T cells (middle) or 
counts of CD4+ or CD8+ T cell per high power field of view in tumour (bottom right). CD4+ T cells 
(purple); CD8+ T cells (blue). Data are presented as median ± Interquartile range. Statistical 
significance was determined by Mann Whitney t tests. N = 3 for anti-CD4/CD8 treated Treg 
depleted, N = 6 for Treg depleted Foxp3DTR animals (proportion and absolute number by flow 
cytometry); N = 16 for anti-CD4/CD8 treated Treg depleted, N = 21 for Treg depleted Foxp3DTR 
animals (counting of immunofluorescently stained tumour sections).  	
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Figure 4.13 | High Endothelial Venules are found in tumours in the absence of T cells. 
Confocal images of High Endothelial Venules (HEV) within tumours of Treg depleted (top) and 
anti-CD4/CD8 treated, Treg depleted (bottom) Foxp3DTR animals. Endothelial cells of HEV were 
detected by immunofluorescence staining using a biotinylated rat anti-PNAd primary antibody 
(clone MECA-79) and streptavidin Alexa Fluor® 555 secondary antibody (red). Tumour sections 
were dual-stained for PNAd and CD4+ T cells (rat anti-CD4 detected using donkey anti-rat Alexa 
Fluor® 488 secondary antibody; green). Merged images include the nuclear stain DAPI (blue). 
Scale bars are shown.  	
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Figure 4.14 | Measures of High Endothelial Venule density and total area are significantly 
decreased in the absence of T cells. 
Quantitative measures of High Endothelial Venules (HEV) in tumours of anti-CD4/CD8 treated, 
Treg depleted Foxp3DTR animals. (A) Representative microscope images of HEV in paraffin 
embedded tumours. The anti-PNAd antibody (clone MECA-79) was detected using VIP 
chromogen (purple staining). Sections were counterstained using haematoxylin. Scale bars are 
shown. (B) HEV density was calculated per unit area of tumour (µm2). The insert shows an 
enlarged version of the boxed area. (C) Average area of HEV vessels calculated in µm2. (D) 
Total HEV area as a proportion of total tumour area, calculated as a percentage. Data are 
presented as individual datapoints plus median. Statistical significance was determined by 
Mann Whitney t tests. N = 16 anti-CD4/CD8 treated, Treg- tumours (14 in C); N = 21 Treg- 
tumours (20 in C). 	
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A weak positive correlation between numbers of CD4+ T cells and HEV density 
was observed for anti-CD4/CD8 treated tumours; the association between numbers of 
CD8+ T cells and HEV density was stronger than that for CD4+ T cells, but neither 
association reached statistical significance (r = 0.2246, nsP=0.4030 for CD4+ T cells1; r 
= 0.4580, nsP=0.0744 for CD8+ T cells1; Figure 4.15 A-B). These data could indicate 
that either 1) HEV that develop in anti-CD4/CD8 treated tumours are at least partially 
functional in allowing T cell entry, or 2) HEV can only form in tumours in which 
CD4/CD8 depletion is not absolute. These data do not distinguish between these two 
possibilities, as it is impossible to delineate cause from effect here.  
 There was a weak positive correlation between numbers of CD4+ T cells and 
tumour growth rate that did not reach statistical significance (r = 0.3870, nsP=0.13861), 
and no association between numbers of CD8+ T cells and tumour growth rate for anti-
CD4/CD8 treated tumours (r = -0.0250, nsP=0.92671; Figure 4.15 C-D). These data 
suggest the existence of a threshold of number of intra-tumoural T cells, which must be 
reached before an association with tumour growth rate can be recognised. In this case, 
there are too few T cells within the tumour to confer a reduction in growth rate. In 
corroboration of these data, the observed association between both HEV density and 
total HEV area and tumour growth rate in Treg depleted tumours is completely lost 
upon CD4/CD8 depletion (r = 0.0191, nsP=0.9439 for HEV density1; r = 0.0133, 
nsP=0.9612 for total HEV area1; Figure 4.15 E-F). These data support my hypothesis 
that HEV neogenesis confers a reduction in tumour growth via facilitating infiltration of 
high numbers of anti-tumour T cells: in the case of CD4/CD8 T cell depleted tumours 
described here, any residual HEV can no longer confer a reduction in growth due to the 
absence of such T cell populations.  
 Collectively, these data indicate that the mechanism of HEV neogenesis in 
tumours following Treg depletion is reliant on CD4+ and / or CD8+ T cells. The finding 
that HEV neogenesis is severely abrogated in the absence of T cells suggests that T 
cells could represent an LTi-like ‘HEV-initiator’ cell type in the tumours studied here.  
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Figure 4.15 | Functionality of High Endothelial Venules in T cell-depleted tumours is significantly 
compromised.  
Correlations between number of intra-tumoural CD4+ and CD8+ T cells, High Endothelial Venule 
(HEV) density and total HEV area, and tumour growth rates for anti-CD4/CD8 treated, Treg 
depleted Foxp3DTR animals. (A-B) Numbers of intra-tumoural CD4+ and CD8+ T cells plotted 
against tumour HEV density; CD4+ T cells (A; purple); CD8+ T cells (B; blue). (C-D) Numbers of 
intra-tumoural CD4+ and CD8+ T cells plotted against tumour growth rates (k, days-1); CD4+ T 
cells (C; purple); CD8+ T cells (D; blue). (E-F) HEV density (E) and total HEV area (as 
proportion of total tumour area; F) plotted against tumour growth rate (k, days-1). Statistical 
significance was determined by the non-parametric Spearman’s correlation coefficient test, and 
the r statistic and P values are shown. N = 16. 	
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4.6 Results: Depletion of CD4+ T cells Modestly Abrogates HEV Neogenesis in 
Tumours 
Considering the striking findings described in Section 4.5 above, it was 
important to establish whether one or the other, or both of these two populations of T 
cells were instrumental in HEV neogenesis. To address this aim, I injected tumour-
bearing Treg depleted Foxp3DTR animals with either anti-CD4 or anti-CD8 antibodies, 
as described in Chapter Two. The results of the anti-CD4 experiments are detailed 
here: for the results of the anti-CD8 experiments, see Section 4.7 below. 
Efficacy of the anti-CD4 antibody was examined by flow cytometric analysis of T 
cell proportions and numbers in spleen, NDLN and DLN, and tumour, as well as 
counting of T cells in immunofluorescently stained tumour sections. These analyses 
confirmed that the anti-CD4 antibody resulted in a significant reduction in both the 
proportion and absolute number of CD4+ T cells in spleen, LNs and tumour (Figure 
4.16). As for the experiments in which both CD4+ and CD8+ T cells were depleted, the 
anti-CD4 antibody resulted in the loss of the majority but not all T cells in all 
compartments.  
Interestingly, depletion of CD4+ T cells resulted in a significant increase in not 
only the proportion (in LNs) but also the absolute number of CD8+ T cells in spleen and 
LNs (Figure 4.16). This affect of CD4+ T cell depletion on CD8+ T cell numbers using 
these specific monoclonal antibodies has been previously reported (Cobbold et al. 
1992)(S. Cobbold communication). The underlying mechanism remains unknown, 
although it has been suggested that this affect is a result of compensatory homeostatic 
repopulation of the naïve T cell pool: naïve T cell homeostasis does not discriminate 
between CD4 and CD8 T cell populations and due to the considerably higher numbers 
of CD4+ than CD8+ T cells in normal animals, CD8 depletion allows little room for 
repopulation by CD4 but CD4 depletion creates significant room for repopulation by 
CD8 T cells (S. Cobbold communication).  
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Figure 4.16 | Treatment with an anti-CD4 monoclonal antibody depletes CD4+ T cells from 
lymphoid organs and tumour. 
Proportion and absolute number of T cells in spleen, non tumour-draining lymph node (NDLN), 
tumour-draining lymph node (DLN) and tumour, determined by flow cytometry or counting of 
immunofluorescently stained tumour sections, in Treg depleted and anti-CD4 treated, Treg 
depleted Foxp3DTR animals, at the end of treatment. Data shown are: proportion of total live 
lymphocytes expressing CD4 or CD8 (left), absolute number of CD4+ or CD8+ T cells (middle) or 
counts of CD4+ or CD8+ T cell per high power field of view in tumour (bottom right). CD4+ T cells 
(purple); CD8+ T cells (blue). Data are presented as median ± Interquartile range. Statistical 
significance was determined by Mann Whitney t tests. N = 3 for anti-CD4 treated Treg depleted, 
N = 6 for Treg depleted Foxp3DTR animals (proportion and absolute number by flow cytometry); 
N = 11 for anti-CD4 treated Treg depleted, N = 21 for Treg depleted Foxp3DTR animals (counting 
of immunofluorescently stained tumour sections).  	
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PNAd+ staining could be found in frozen tumour sections of some anti-CD4 
treated animals (Figure 4.17), but, similarly to the anti-CD4/CD8 treated cohort, the 
majority of tumours from anti-CD4 treated animals contained no PNAd+ staining. Where 
it could be found, PNAd staining again co-localised with CD31 (data not shown).  
PNAd+ vessels were also relatively scarce in paraffin embedded tumour 
sections from anti-CD4 treated animals (Figure 4.18 A). Anti-CD4 treated tumours 
demonstrated a modestly reduced HEV density relative to Treg depleted tumours 
(*P=0.04692; Figure 4.18 B). The difference between anti-CD4 treated tumours and 
Treg depleted tumours was not as striking as that between anti-CD4/CD8 treated 
tumours and Treg depleted tumours, as described in Section 4.5. There was a highly 
significant increase in average HEV area in anti-CD4 treated tumours relative to Treg 
depleted tumours (***P=0.00052; Figure 4.18 C). In line with the slight reduction in HEV 
density, total HEV area demonstrated a modest, statistically insignificant decrease in 
tumours of anti-CD4 treated tumours relative to Treg depleted tumours (nsP=0.23312; 
Figure 4.18 D).  
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Figure 4.17 | High Endothelial Venules are found in tumours in the absence of CD4+ T cells. 
Confocal images of High Endothelial Venules (HEV) within tumours of Treg depleted (top) and 
anti-CD4 treated, Treg depleted (bottom) Foxp3DTR animals. Endothelial cells of HEV were 
detected by immunofluorescence staining using a biotinylated rat anti-PNAd primary antibody 
(clone MECA-79) and streptavidin Alexa Fluor® 555 secondary antibody (red). Tumour sections 
were dual-stained for PNAd and CD4+ T cells (rat anti-CD4 detected using donkey anti-rat Alexa 
Fluor® 488 secondary antibody; green). Merged images include the nuclear stain DAPI (blue). 
Scale bars are shown.  	
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Figure 4.18 | Measures of High Endothelial Venule density and total area are modestly 
decreased in the absence of CD4+ T cells. 
Quantitative measures of High Endothelial Venules (HEV) in tumours of anti-CD4 treated, Treg 
depleted Foxp3DTR animals. (A) Representative microscope images of HEV in paraffin 
embedded tumours. The anti-PNAd antibody (clone MECA-79) was detected using VIP 
chromogen (purple staining). Sections were counterstained using haematoxylin. Scale bars are 
shown. (B) HEV density was calculated per unit area of tumour (µm2). The insert shows an 
enlarged version of the boxed area. (C) Average area of HEV vessels calculated in µm2. (D) 
Total HEV area as a proportion of total tumour area, calculated as a percentage. Data are 
presented as individual datapoints plus median. Statistical significance was determined by 
Mann Whitney t tests. N = 11 anti-CD4/CD8 treated, Treg- tumours (7 in C); N = 21 Treg- 
tumours (20 in C). 	
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Plotting HEV density as a function of the number of remaining CD4+ T cells in 
tumours of anti-CD4 treated animals revealed that, in contrast to Treg depleted control 
tumours, HEV density only weakly correlated with numbers of CD4+ T cells (r = 0.5583, 
nsP=0.07611; Figure 4.19 A). These data could suggest that HEV that form in the 
absence of CD4+ T cells are dysfunctional in their ability to allow infiltration of residual 
CD4+ T cells into tumours. This scenario is unlikely, considering the weak but 
significant positive correlation between HEV density and numbers of infiltrating CD8+ T 
cells (r = 0.7118, *P=0.01621; Figure 4.19 B). Thus, HEV that form in the absence of 
CD4+ T cells are at least partly functional in facilitating T cell trafficking into tumours. 
Number of tumour infiltrating CD4+ T cells demonstrated a weak negative 
correlation with tumour growth rate, suggesting residual CD4+ T cells were efficient in 
conferring a degree of anti-tumour efficacy (r = -0.6000, nsP=0.09681; Figure 4.19 C). 
Number of tumour infiltrating CD8+ T cells demonstrated a statistically significant 
negative correlation with tumour growth rate, corroborating the idea that HEV in CD4-
depleted tumours were functional in terms of supporting CD8+ T cell trafficking (r = -
0.7500, *P=0.02551; Figure 4.19 D). Furthermore, there was a weak negative 
correlation between both HEV density and total HEV area and tumour growth rate, 
despite neither association reaching statistical significance (r = -0.4686, nsP=0.2125 
for HEV density1; r = -0.3849, nsP=0.3125 for total HEV area1; Figure 4.19 E-F). 
Collectively, these data suggest CD4+ T cells play a minor role in HEV 
neogenesis, as HEV formation is modestly abrogated after loss of these cells. 
However, development of HEV in tumours in which depletion of CD4+ T cells was 
almost absolute suggests the presence of other cell types capable of directing HEV 
neogenesis. The difference in HEV density and total HEV area between tumours of 
anti-CD4/CD8 treated and anti-CD4 treated tumours suggests CD8+ T cells may play 
an important role in this process. The slight decrease in functionality of HEV that 
formed in the absence of CD4+ T cells relative to HEV in control Treg depleted tumours 
could reflect a requirement for CD4+ T cell help by anti-tumour CD8+ T cells. 
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Figure 4.19 | Functionality of High Endothelial Venules in CD4+ T cell-depleted tumours is 
modestly compromised.  
Correlations between number of intra-tumoural CD4+ and CD8+ T cells, High Endothelial Venule 
(HEV) density and total HEV area, and tumour growth rates for anti-CD4 treated, Treg depleted 
Foxp3DTR animals. (A-B) Numbers of intra-tumoural CD4+ and CD8+ T cells plotted against 
tumour HEV density; CD4+ T cells (A; purple); CD8+ T cells (B; blue). (C-D) Numbers of intra-
tumoural CD4+ and CD8+ T cells plotted against tumour growth rates (k, days-1); CD4+ T cells 
(C; purple); CD8+ T cells (D; blue). (E-F) HEV density (E) and total HEV area (as proportion of 
total tumour area; F) plotted against tumour growth rate (k, days-1). Statistical significance was 
determined by the non-parametric Spearman’s correlation coefficient test, and the r statistic and 
P values are shown. N = 11 (9 C-F). 	
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4.7 Results: Depletion of CD8+ T cells Phenocopies Depletion of Both CD4+ and 
CD8+ T cells in Severely Abrogating HEV Neogenesis 
In parallel to treating tumour-bearing Foxp3DTR animals with anti-CD4 depleting 
antibodies, I treated a separate group of animals with the anti-CD8 antibody alone. The 
anti-CD8 antibody resulted in a significant reduction in both the proportion and absolute 
number of CD8+ T cells in spleen and LNs, and absolute number in tumour (Figure 
4.20). The anti-CD8 antibody resulted in the loss of the majority but not all T cells in all 
compartments. In support of previous reports, the anti-CD8 antibody resulted in a 
selective effect upon CD8+ T cells only, with no reciprocal increase in numbers of CD4+ 
T cells (Figure 4.20) (Cobbold et al. 1992)(S. Cobbold communication). 
Reminiscent of tumours of anti-CD4/CD8 treated animals, PNAd+ HEV could on 
occasion be found in tumours of anti-CD8 treated animals, but were extremely scarce 
(Figure 4.21). The infrequent PNAd+ staining once again colocalised with CD31 (data 
not shown). Paraffin embedded tumour sections of anti-CD8 treated animals also 
contained very few PNAd+ HEV: the majority of tumours contained no vessels 
whatsoever, in a similar manner to tumours of anti-CD4/CD8 treated animals (Figure 
4.22 A). Indeed, there was a highly significant reduction in HEV density in treated 
tumours relative to Treg depleted tumours (**P=0.00542; Figure 4.22 B). The few HEV 
within CD8 depleted tumours demonstrated a slightly significant increase in average 
area (*P=0.02292; Figure 4.22 C). Total HEV area was also significantly reduced in 
tumours of anti-CD8 treated tumours relative to Treg depleted tumours (*P=0.01462; 
Figure 4.22 D). These data combined with those from the anti-CD4/CD8 and anti-CD4 
experiments described above collectively suggest that CD8+ T cells are crucial in the 
process of intra-tumoural HEV neogenesis.  
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 Figure 4.20 | Treatment with an anti-CD8 monoclonal antibody depletes CD8
+ T cells from 
lymphoid organs and tumour. 
Proportion and absolute number of T cells in spleen, non tumour-draining lymph node (NDLN), 
tumour-draining lymph node (DLN) and tumour, determined by flow cytometry or counting of 
immunofluorescently stained tumour sections, in Treg depleted and anti-CD8 treated, Treg 
depleted Foxp3DTR animals, at the end of treatment. Data shown are: proportion of total live 
lymphocytes expressing CD4 or CD8 (left), absolute number of CD4+ or CD8+ T cells (middle) or 
counts of CD4+ or CD8+ T cell per high power field of view in tumour (bottom right). CD4+ T cells 
(purple); CD8+ T cells (blue). Data are presented as median ± Interquartile range. Statistical 
significance was determined by Mann Whitney t tests. N = 4 for anti-CD8 treated Treg depleted, 
N = 6 for Treg depleted Foxp3DTR animals (proportion and absolute number by flow cytometry); 
N = 8 for anti-CD8 treated Treg depleted, N = 21 for Treg depleted Foxp3DTR animals (counting 
of immunofluorescently stained tumour sections).  	
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Figure 4.21 | High Endothelial Venules are found in tumours in the absence of CD8+ T cells. 
Confocal images of High Endothelial Venules (HEV) within tumours of Treg depleted (top) and 
anti-CD8 treated, Treg depleted (bottom) Foxp3DTR animals. Endothelial cells of HEV were 
detected by immunofluorescence staining using a biotinylated rat anti-PNAd primary antibody 
(clone MECA-79) and streptavidin Alexa Fluor® 555 secondary antibody (red). Tumour sections 
were dual-stained for PNAd and CD8+ T cells (rat anti-CD8 detected using donkey anti-rat Alexa 
Fluor® 488 secondary antibody; green). Merged images include the nuclear stain DAPI (blue). 
Scale bars are shown.  	
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Figure 4.22 | Measures of High Endothelial Venule density and total area are significantly 
decreased in the absence of CD8+ T cells. 
Quantitative measures of High Endothelial Venules (HEV) in tumours of anti-CD8 treated, Treg 
depleted Foxp3DTR animals. (A) Representative microscope images of HEV in paraffin 
embedded tumours. The anti-PNAd antibody (clone MECA-79) was detected using VIP 
chromogen (purple staining). Sections were counterstained using haematoxylin. Scale bars are 
shown. (B) HEV density was calculated per unit area of tumour (µm2). The insert shows an 
enlarged version of the boxed area. (C) Average area of HEV vessels calculated in µm2. (D) 
Total HEV area as a proportion of total tumour area, calculated as a percentage. Data are 
presented as individual datapoints plus median. Statistical significance was determined by 
Mann Whitney t tests. N = 8 anti-CD8 treated, Treg- tumours (5 in C); N = 21 Treg- tumours (20 
in C). 	
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I found a weak positive correlation between HEV density and both CD4+ and 
CD8+ T cells in tumours of anti-CD8 treated animals, although neither association 
reached statistical significance (r = 0.1464, nsP=0.7520 for CD4+ T cells1; r = 0.4636, 
nsP=0.2431 for CD8+ T cells1; Figure 4.23 A-B). These data suggest that HEV that 
form during anti-CD8 treatment are functional in terms of facilitating high numbers of T 
cells to enter the tumour. These data could also be interpreted to suggest that HEV 
density is a function of the number of CD8+ T cells present in the tumour, as HEV are 
only present in those tumours containing higher numbers of CD8+ T cells. 
There was no significant correlation between either numbers of CD4+ T cells or 
CD8+ T cells and tumour growth rate for anti-CD8 treated animals (r = 0.0476, 
nsP=0.9349 for CD4+ T cells1; r = -0.0952, nsP=0.8401 for CD8+ T cells1; Figure 4.23 
C-D). These data support the idea of the existence of a threshold of number of intra-
tumoural T cells, which must be reached before an association with tumour growth rate 
is observed. As is the case in anti-CD4/CD8 treated tumours, there are too few T cells 
within the tumour mass of anti-CD8 treated animals to confer a reduction in tumour 
growth rate. However, there remains a slight negative correlation between both 
measures of HEV density and total HEV area and tumour growth rate for anti-CD8 
treated animals, suggesting maintenance of HEV functionality to a degree (r = -0.5855, 
nsP=0.1323 for HEV density and total HEV area1; Figure 4.23 E-F).  
Collectively these data imply a significant role for CD8+ T cells in HEV 
neogenesis in tumours, as this process is severely abrogated in the absence of these 
cells. However, the phenotype is less absolute than that observed in tumours of anti-
CD4/CD8 treated animals, supporting the data in Section 4.6 showing a partial 
phenotype after depletion of only CD4+ T cells. In contrast to the anti-CD4 treated 
tumours, tumours of CD8+ T cell depleted animals demonstrated HEV neogenesis only 
in the situation where a residual number of CD8+ T cells remained, highlighting a 
superior requirement for CD8+ T cells over CD4+ T cells in the process of HEV 
formation. 
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Figure 4.23 | Functionality of High Endothelial Venules in CD8+ T cell-depleted tumours is 
compromised.  
Correlations between number of intra-tumoural CD4+ and CD8+ T cells, High Endothelial Venule 
(HEV) density and total HEV area, and tumour growth rates for anti-CD8 treated, Treg depleted 
Foxp3DTR animals. (A-B) Numbers of intra-tumoural CD4+ and CD8+ T cells plotted against 
tumour HEV density; CD4+ T cells (A; purple); CD8+ T cells (B; blue). (C-D) Numbers of intra-
tumoural CD4+ and CD8+ T cells plotted against tumour growth rates (k, days-1); CD4+ T cells 
(C; purple); CD8+ T cells (D; blue). (E-F) HEV density (E) and total HEV area (as proportion of 
total tumour area; F) plotted against tumour growth rate (k, days-1). Statistical significance was 
determined by the non-parametric Spearman’s correlation coefficient test, and the r statistic and 
P values are shown. N = 8. 	
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4.8 Results: Comparison of T cell Infiltration, HEV Neogenesis and Tumour 
Growth across all Cell Depletion Treatments 
 To compare the impact of different cell depletion treatments on T cell infiltration 
and HEV neogenesis in the tumour, and overall tumour growth, I plotted these data 
altogether (Figures 4.24-4.26). To compare parameters for each treatment group to 
Treg depleted control tumours that contain either high or low densities of HEV, I 
separated the Treg depleted control tumours into “HEVlo” and “HEVhi” categories, by 
selecting 6 Treg depleted tumours with the lowest HEV density and 6 Treg deleted 
tumours with the highest HEV density. Plotting numbers of intra-tumoural CD4+ or 
CD8+ T cells for each treatment group once again demonstrated the efficacy of the T 
cell depleting antibodies, and highlighted the previously observed slight increase in 
CD8+ T cells in tumours of anti-CD4 treated animals (Figure 4.24). As the number of 
intra-tumoural CD8+ T cells function as a surrogate marker of HEV neogenesis, these 
data corroborate the data illustrating no change in total HEV area in these tumours, 
signifying functional HEV are able to form in the absence of CD4+ T cells  (Figure 4.24).  
Indeed, when HEV density and total HEV area were plotted for all treatments, 
only treatments in which T cells were depleted resulted in a significant decrease in 
HEV density relative to HEVhi controls, with treatments in which CD8+ T cells were 
depleted having the most significant effect on HEV density3 (Figure 4.25 A). 
Furthermore, only the treatments in which CD8+ T cells were depleted resulted in a 
significant decrease in total HEV area, relative to HEVhi controls3 (Figure 4.25 B). 
These data support the conclusion that CD8+ T cells are an essential cell population in 
the process of HEV neogenesis in tumours following Treg depletion, in which CD4+ T 
cells also play a minor role; CD20+ B cells play no role in HEV neogenesis following 
Treg depletion. 
Simultaneous depletion of CD4+ and CD8+ T cells resulted in a significant 
increase in tumour growth rate, relative to Treg depleted controls (Figure 4.26 A). 
Moreover, simultaneous loss of both populations of T cells resulted in a significant 
increase in tumour growth rate relative to HEVhi Treg depleted controls, but not HEVlo 
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Treg depleted controls, suggesting a causal link between intra-tumoural HEV, T cell 
infiltration and tumour control (Figure 4.26 B). The significant increase in tumour 
growth rate in anti-CD4/CD8 treated animals relative to anti-CD4 treated animals 
signifies the importance of CD8+ CTLs in the anti-tumour immune response to MCA-
induced fibrosarcomas following Treg depletion, supporting previous data (Betts et al. 
2007; Ondondo et al. 2013; Teng et al. 2010; Koebel et al. 2007). The difference in 
tumour growth rate between anti-CD4/CD8 treated and anti-CD8 treated mice could 
signify either a requirement for CD4+ T cells for effective tumour control, or simply 
reflect the observed less efficient depletion of CD8+ T cells in the single depletion 
group. The lack of a difference in tumour growth rate between Treg depleted controls 
and anti-CD4 treated animals supports the latter hypothesis, in suggesting that CD4+ T 
cells are not required for tumour control.  
To determine whether tumour growth could be explained by HEV density and / 
or treatment regime, I used a linear model with fixed effects to analyse the relationship 
between tumour growth and each independent variable one-by-one, by statistically 
controlling for the variation introduced by each independent variable. These analyses 
revealed that while treatment had a far more profound effect on tumour growth 
(***P<0.001), HEV density, as an independent variable, indeed had a significant impact 
on tumour growth (*P=0.0111). These data emphasize that while treatment could be 
having an overall impact on tumour growth rate via multiple various mechanisms, HEV 
density alone is a significant biological variable that influences the growth of tumours. 
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Figure 4.24 | Immune cell depletion treatments did or did not alter absolute numbers of CD4+ 
and / or CD8+ T cells inside tumours.  
Number of intra-tumoural CD4+ (A) and CD8+ (B) T cells for each of the following treatment 
groups: Treg depleted (Treg-) HEVlo, N = 6; Treg- HEVhi, N = 6; anti-CD20 treated, Treg-, N = 12; 
anti-CD4/CD8 treated, Treg-, N = 16; anti-CD4 treated, Treg-, N = 11; and anti-CD8 treated, 
Treg-, N = 8. Data are presented as individual datapoints plus median. Statistical significance 
was determined by Kruskal-Wallis One-Way ANOVA and Dunn’s multiple comparisons tests (* = 
P≤0.05, ** = P≤0.01, *** = P≤0.001).  	
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Figure 4.25 | Immune cell depletion treatments did or did not alter High Endothelial Venule 
density and / or total area inside tumours.  
HEV density (A) and total HEV area (B) for each of the following treatment groups: Treg 
depleted (Treg-) HEVlo, N = 6; Treg- HEVhi, N = 6; anti-CD20 treated, Treg-, N = 12; anti-
CD4/CD8 treated, Treg-, N = 16; anti-CD4 treated, Treg-, N = 11; and anti-CD8 treated, Treg-, N 
= 8. HEV density was calculated per unit area of tumour (µm2) and total HEV area was 
calculated as a percentage of total tumour area. Data are presented as individual datapoints 
plus median. Statistical significance was determined by Kruskal-Wallis One-Way ANOVA and 
Dunn’s multiple comparisons tests (* = P≤0.05, ** = P≤0.01). 	
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Figure 4.26 | Immune cell depletion treatments did or did not alter growth rate of tumours.  
Tumour growth rate (k, days-1) data for each of the following treatment groups: Treg depleted 
control group  (Treg-; N = 21 (A); Treg- HEVlo; N = 6; Treg- HEVhi; N = 6 (B)), anti-CD20 treated, 
Treg-, N = 12; anti-CD4/CD8 treated, Treg-, N = 16; anti-CD4 treated, Treg-, N = 9; and anti-CD8 
treated, Treg-, N = 8. Data are presented as individual datapoints plus median. Statistical 
significance was determined by Kruskal-Wallis One-Way ANOVA and Dunn’s multiple 
comparisons tests (** = P≤0.01, *** = P≤0.001). 	
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4.9 Discussion 
 The data presented here show no role for B lymphocytes in neogenesis of 
PNAd+ HEV in tumours following Treg depletion. Instead, density and total area of HEV 
are significantly reduced following depletion of T cells. Thus, T lymphocytes play an 
essential role in development of PNAd+ HEV in tumours (Figure 4.27).  
My data further define that CD8+ T lymphocytes are required for HEV 
neogenesis: this process is severely compromised in the absence of CD8+ T cells. The 
difference in HEV measures between tumours of anti-CD4/CD8 and anti-CD8 treated 
animals suggests a role for CD4+ T cells also. This difference could be explained by the 
less efficient CD8+ T cell depletion in anti-CD8 treated animals relative to anti-
CD4/CD8 treated animals. However, depletion of CD4+ T cells alone results in a 
modest abrogation in HEV neogenesis, implying a minor role for CD4+ T cells. This 
could be a direct role for CD4+ T cells in HEV neogenesis, or an indirect, accessory 
role via CD8+ T cell support.  
While initial formation of HEV structure and abluminal PNAd expression on HEV 
endothelium during lymphoid organ formation proceeds in the absence of T or B cells, 
the development of a fully mature HEV phenotype requires lymphocytes (Liao & 
Ruddle 2006). While this study implies a degree of lymphocyte dependency for 
development of a mature HEV phenotype, a separate study demonstrated unimpaired 
L-selectin-dependent lymphocyte trafficking to peripheral LNs in RAG-1 deficient mice 
(Galkina et al. 2003). Our model of HEV neogenesis in Treg depleted MCA tumours 
could therefore represent a significant departure from normal LN HEV development, 
which seems to proceed mostly uninterrupted in the absence of lymphocytes. 
HEV neogenesis in tumours in the context Treg depletion can perhaps instead 
be likened to HEV formation during chronic inflammation. DCs have been implicated in 
regulation of PNAd+ HEV in TLOs of inflamed lungs in mouse models 
(GeurtsvanKessel et al. 2009; Halle et al. 2009). However, a series of studies have 
instead implicated lymphocytes in HEV neogenesis and / or TLO development during 
inflammation. HEV in chronic inflammation-associated TLOs in the RIP-LTα mouse 
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display only abluminal PNAd expression, presumably due to the lack of LTβ 
overexpression (Kratz et al. 1996). However, RIP-LTα RAG2 deficient littermates lack 
all PNAd expression on TLO-associated HEV, suggesting that lymphocyte-derived 
factors in addition to LTα are required for basal abluminal PNAd expression on HEV 
endothelium (Kratz et al. 1996).  
Marinkovic and colleagues demonstrated the absolute requirement for CD3+ 
CD4+ T lymphocytes, rather than canonical RORγt+ LTi cells, in TLO generation in the 
thyroid driven by CCL21 over-expression (Marinkovic et al. 2006). Furthermore, TH17 
cells are responsible for inducing CXCL13 expression that drives iBALT development 
following inflammatory insult in the lung (Rangel-Moreno et al. 2011). A recent study 
strongly implicated TH17 cells in the formation of synovial ELS in both experimental and 
clinical rheumatoid arthritis (RA) (Jones et al. 2015). This study identified IL-27, a 
cytokine often elevated in serum and synovia of patients, as a key regulator of TH17 
cells and thereby inhibitor of ectopic lymphoid neogenesis. Interestingly, the TH17 cells 
associated with organised ELS development in the absence of IL-27 signalling 
appeared to be gp38-expressing, Tfh-cell like cells, which have been implicated in ELS 
formation in autoimmunity elsewhere (Jones et al. 2015; Peters et al. 2011). Perhaps, 
in the context of the chronic autoimmunity induced by Treg depletion and tumour 
immunity as described herein, effector T lymphocytes compensate for the lack of 
canonical LTi-like cells to induce the formation of isolated PNAd-expressing HEV, 
much as for TLO induction in other inflammatory models. 
The cells involved in driving HEV neogenesis specifically in tumours remain to 
be defined. Martinet and colleagues suggested that LTβ-producing DCs initiate HEV 
development in breast tumours (Martinet et al. 2013; Martinet & Girard 2013). 
However, a direct functional link between DCs and PNAd+ vasculature in tumours has 
yet to be defined. In corroboration of my data, a recently published study described that 
development of “LN-like” PNAd+ vasculature in tumours of both melanoma and lung 
carcinoma mouse models is reliant upon endogenous effector CD8+ T cells (Peske et 
al. 2015). Peske and colleagues noted the presence of PNAd+ HEV expressing CCL21 
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located within organised aggregates of B lymphocytes and gp38-expressing stromal 
cells, within tumours of WT animals. In contrast, there was a distinctive lack of PNAd+ 
tumour vasculature in gene-targeted animals specifically devoid of CD8+ T cells, and 
RAG2 deficient animals. Furthermore, PNAd-expressing vessels were restored to 
levels observed in WT animals upon adoptive transfer of CD8+ T cells to RAG2 
deficient mice. The authors suggested that although NK cells could induce PNAd+ 
vasculature in some tumour settings in a redundant fashion, CD8+ T lymphocytes were 
primarily responsible for HEV induction in tumours (Peske et al. 2015). 
 My hypothesis states that T cell infiltration represents a significant bottleneck in 
control of tumour growth following Treg depletion: this bottleneck can be overcome by 
formation of HEV (Hindley et al. 2012). However, my data shown here indicate an early 
role for T lymphocytes in development of HEV, which poses some important questions: 
are T cells acting locally to induce HEV in tumours, and if so, how do ‘HEV-initiator’ T 
cells reach the tumour site without HEV?  Considering LN HEV are induced by physical 
interactions between LTαβ-expressing LTi cells and LTβR-expressing vascular 
endothelial cells (Onder et al. 2013), I hypothesise that similar proximal signals are 
required for HEV development in tumours. The phenotype of ‘HEV-initiator’ T cells 
could mean they do not require HEV to infiltrate tumours (i.e. L-selectinlo), and can 
instead access tumour via endothelium, which is highly activated following Treg 
depletion (Li et al. 2010). It is also possible that ‘HEV-initiator’ T cells access tumour by 
use of chemokine aided migration (Ondondo et al. 2014a). These ‘HEV-initiator’ T cells 
then provide signals to kick-start HEV neogenesis, which then facilitate entry of anti-
tumour T cells: these could also act as further HEV-initiator cells, thereby establishing 
a self-amplifying loop to underpin effective tumour control. It will be important to define 
the specific phenotype of CD8+ T lymphocytes capable of initiating HEV neogenesis, if 
therapies aimed at promoting HEV development in tumours are to be designed. 
The data presented in this Chapter pose an important question: What factors 
could T lymphocytes be producing that are capable of directing HEV neogenesis in 
tumours after Treg depletion? I address this question in the following results chapter. 
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Figure 4.27 | Updated hypothesis of HEV Neogenesis in Carcinogen-Induced 
Tumours after Treg Depletion. 
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Chapter Five 
5 Results: Cytokines and signalling pathways involved in High Endothelial 
Venule neogenesis in tumours 
5.1 Introduction 
 The nature of the communication between LTi and LTo cells that directs 
lymphoid organ development is firmly established: LTα1β2 expressing LTi cells interact 
with LTβR expressing LTo cells (Mebius 2003). LTβR signalling is also required for 
maintenance of HEV structure and function in adult lymphoid organs (Browning et al. 
2005; Liao & Ruddle 2006; Lu & Browning 2014). LTβR expression by vascular 
endothelial cells also seems necessary specifically for HEV development within 
lymphoid organs (Onder et al. 2013). However, there remains a considerable gap in 
our knowledge surrounding HEV development during ontogeny. 
TNFR signalling has also been implicated in LN development. Mice genetically 
deficient for TNFα, TNFRI or TNFRII demonstrate relatively normal development of 
most LN, except PP (Pfeffer et al. 1993; Neumann et al. 1996; Pasparakis et al. 1996; 
Pasparakis et al. 1997; Körner et al. 1997; Erickson et al. 1994; Kuprash et al. 2005). 
However, while in utero treatment with an LTβR.Ig fusion protein was permissive for 
mesenteric, sacral, cervical and lumbar LN development, administration of a TNFRI.Ig 
fusion protein or anti-TNFα antibody in combination with LTβR.Ig treatment, resulted in 
complete blockade of all LN development. This key study suggested a contribution by 
TNFα-TNFRI signalling to LN development, even if in a redundant fashion to LTβR 
signalling (Rennert et al. 1998).  
Additionally, animals deficient in both LTβ and TNFRI lack all LN and PP in 
contrast to LTβ-/- mice, which retain some LNs (Koni & Flavell 1998; Koni et al. 1997; 
Alimzhanov et al. 1997; Kuprash et al. 1999). Furthermore, TNFα over-expression can 
compensate for the lack of LTi cells in LN and TLO development to a certain degree, 
as TNF/Rorc(γt)-/- mice develop TLOs and several SLOs. Within LNs of TNF/Rorc(γt)-/- 
mice, PNAd+ HEV were present and indistinguishable from those in wild-type LNs 
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(Furtado et al. 2014). These data lend support to the idea that TNFR signalling also 
plays an important role in normal development of HEV-containing lymphoid organs. 
 Martinet and colleagues have proposed that LTβR signalling, initiated by LTβ-
expressing DCs, drives HEV neogenesis in human breast tumours (Martinet et al. 
2013; Martinet & Girard 2013). The mechanisms driving HEV neogenesis in the context 
of chronic autoimmunity induced by the depletion of Tregs could represent a significant 
departure from any of the above scenarios. If novel immunotherapeutic approaches to 
drive intra-tumoural HEV neogenesis are to be designed, it is absolutely necessary to 
first delineate the molecular mechanisms underpinning HEV formation in tumours.  
 I therefore aimed to establish the role of: 
• LTβR signalling, and 
• TNFR signalling  
in HEV neogenesis in tumours following Treg depletion. 
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5.2 Results: TNF Superfamily members are differentially regulated in HEV 
containing Treg depleted MCA tumours 
 To ascertain whether mechanisms underpinning HEV neogenesis in tumours 
relied upon similar signalling pathways and cytokines as development of HEV-
containing SLOs, I analysed genetic data previously acquired in my host lab. 
Microarray analyses had been performed on RNA extracted from whole tumour tissue 
of either Treg replete animals (whose tumours are consistently HEV negative), Treg 
depleted animals whose tumours contained HEV, or Treg depleted animals whose 
tumours were HEV negative. I focused my analysis on the immediate TNF Superfamily 
genes, as ligands and receptors of this family play a crucial role in development of 
HEV-containing LNs during ontogeny and therefore represented strong candidates for 
controlling HEV neogenesis in tumours (Mebius 2003; van de Pavert & Mebius 2014; 
van de Pavert & Mebius 2010). 
 Several ligands and receptors of the immediate TNF Superfamily were 
significantly differentially expressed in tumour tissue of HEV positive, Treg depleted 
tumours relative to HEV negative, Treg depleted tumours and HEV negative, Treg 
replete tumours (Figure 5.1). Of particular interest, gene expression of LTβ but not LTα 
or LTβR, was significantly increased in HEV positive tumours relative to HEV negative 
tumours and tumours of Treg replete animals1. Interestingly, gene expression of TNFα 
and TNFR2 was also significantly increased in HEV positive tumours relative to the two 
other groups; TNFR1 expression, on the other hand, was significantly down-regulated 
in HEV positive tumours1. Expression of LIGHT, another ligand capable of signalling 
via the LTβR, was significantly upregulated in HEV positive tumours, relative to other 
groups, whilst no change was observed in HVEM expression1. Collectively, these data 
indicate involvement of immediate TNFSF members in HEV neogenesis in tumours, as 
for normal development of HEV-containing LNs.		
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Figure 5.1 | Several members of the Tumour Necrosis Superfamily of ligands and receptors are 
differentially regulated in HEV+ tumours of Treg depleted animals relative to HEV- tumours of 
Treg depleted and Treg replete tumours. 
Bar charts showing relative gene expression of ligands and receptors of the immediate TNFSF 
in tumours of Treg replete animals (black bars), HEV negative tumours of Treg depleted 
animals (grey bars), and HEV positive tumours of Treg depleted animals (white bars), as 
determined by microarray analysis. N = 5 per group. Data are presented as mean ± Standard 
Deviation (SD). Relative gene expression was calculated following normalisation to internal 
control house-keeping genes. Statistical significance was determined by One-Way ANOVA with 
Tukey’s multiple comparison tests to compare pairs of means (* = P≤0.05, ** = P≤0.01, *** = 
P≤0.001). HEV, High Endothelial Venule; TNFSF, Tumour Necrosis Factor Superfamily. 	
	1 One-Way ANOVA with Tukey’s multiple comparison test 2 Paired t test 3 Mann Whitney 
test 4 Spearman’s correlation 5 Welch’s unequal variance t test 6 Kruskal-Wallis One-
Way ANOVA with Dunn’s multiple comparisons test 7 Linear Regression 
176 
5.3 Results: Lymphotoxin β Receptor antagonism does not prevent HEV 
neogenesis in tumours 
 Given the crucial role of the LTα1β2-LTβR signalling pathway in development of 
HEV-containing SLOs (Mebius 2003; van de Pavert & Mebius 2014; van de Pavert & 
Mebius 2010), the implied role for this pathway specifically in formation of HEV within 
LNs (Onder et al. 2013), and the increased expression of the gene encoding LTβ in 
HEV positive tumours of our model (Figure 5.1), I explored the relevance of LTαβ-
LTβR signalling for intra-tumoural HEV formation. I treated tumour-bearing Foxp3DTR 
animals with DT and an LTβR.Ig fusion protein, according to the protocol in Chapter 2. 
My primary readouts for these experiments were HEV presence and morphology in 
tumours, T cell numbers in tumours and tumour growth rates.  
 Efficacy of LTβR.Ig treatment was confirmed by examination of CD45R+ CD19+ 
CD21hi CD23lo Marginal Zone (MZ) B cells in the spleen by flow cytometry. MZ B cell 
development and maintenance is reliant upon both LT and TNF signalling (Fu & 
Chaplin 1999; Mackay & Browning 1998) and a reduction in the proportion of splenic 
MZ B cells is a hallmark of LTβR antagonism (Mackay et al. 1997). I observed a 
significant decrease in both the proportion and absolute number of splenic MZ B cells 
following LTβR.Ig treatment, in both Treg replete and Treg depleted animals2 (Figure 
5.2).  
Interestingly, I observed a significant decrease in the proportion and absolute 
number of MZ B cells upon Treg depletion alone, even in the absence of LTβR.Ig 
treatment1 (Supplemental Figure 5.1 A-B). This effect was also observed in LTβR.Ig-
treated animals, so that Treg depletion and LTβR.Ig treatment synergised to further 
decrease the proportion and number of MZ B cells. There was no significant difference 
in the proportion or absolute number of splenic MZ B cells between Wild-Type C57BL/6 
animals and C57BL/6 animals treated with DT2: these data confirm that the observed 
reduction in MZ B cells is a direct consequence of the loss of Tregs rather than a result 
of DT administration (Supplemental Figure 5.1 C-D). 
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Figure 5.2 | Antagonism of LTβ Receptor signalling results in a significant reduction in 
proportions and absolute numbers of Marginal Zone B cells in the Spleen.  
Efficacy of the LTβR.Ig reagent, as assessed by a decrease in Marginal Zone (MZ) B cells in 
spleen of Treg replete or Treg depleted Foxp3DTR animals. (A) Representative flow cytometry 
plots showing the proportion of CD19+ CD45R+ B cells that are CD21hi CD23lo MZ B cells, in the 
spleen of Treg replete (top), Treg replete LTβR.Ig treated (second down), Treg depleted (third 
down) and Treg depleted LTβR.Ig treated (bottom) Foxp3DTR animals. Cells are gated on 
CD19+, CD45R+. Numbers represent MZ B cells (gated), as a proportion of live CD19+ CD45R+ 
B cells. Expression of CD23 is shown on the y axis; expression of CD21 is shown on the x axis. 
(B-C) Proportion of CD19+ CD45R+ B cells that are CD21hi CD23lo MZ B cells (left hand graphs) 
and absolute number of CD21hi CD23lo MZ B cells per 100 total live cells (right hand graphs) in 
spleen of Treg replete and Treg replete LTβR.Ig treated Foxp3DTR animals (B) or Treg depleted 
and Treg depleted LTβR.Ig treated Foxp3DTR animals (C). Data are presented as individual 
datapoints and mean ± Standard Deviation (SD). Statistical significance was determined by 
unpaired t tests. N = 3 per group. 
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FDCs, a unique population of stromal cells located in the centre of B cell 
follicles in SLOs, require both LT and TNF signalling via B cells for their maturation and 
maintenance. FDCs are characterised by high expression of surface complement 
receptors CR1 (CD35) and CR2 (CD21) (Heesters et al. 2014; Allen & Cyster 2008). 
Loss of splenic FDC upon LTβR.Ig treatment is well documented (Mackay & Browning 
1998; Chiang et al. 2009).  
By immunofluorescence staining using CD45R, MAdCAM-1 and CD35/CD21 
specific antibodies, I noticed a profound loss of splenic FDC upon LTβR.Ig treatment in 
both Treg replete and Treg depleted animals (Figures 5.3-5.4). Blockade of LTβR 
signalling using LTβR.Ig also results in overall disruption to normal stromal cell 
networks in the spleen, including decreased or absent MAdCAM-1 expression by 
marginal sinus-lining stromal cells (Fu & Chaplin 1999; Ware 2005; Mackay et al. 
1997). A loss of MAdCAM-1 staining of sinus-lining cells was observable in spleen 
sections of Treg replete and Treg depleted animals following LTβR.Ig treatment 
(Figures 5.3-5.4). Of note, the affect of LTβR.Ig treatment on FDCs was not always 
easily detectable by visual inspection of immunofluorescently stained spleen sections 
from Treg depleted animals: Treg depletion alone often resulted in significant disruption 
to overall splenic microarchitecture, including loss of FDCs and sometimes MAdCAM-1 
staining of sinus-lining cells (Supplemental Figure 5.2). Furthermore, some Splenic B 
cell follicles of animals treated with the combined therapy (LTβR.Ig and DT) maintained 
relatively normal FDC cell compartments and MAdCAM-1 staining of sinus-lining cells  
(Supplemental Figure 5.3).   
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Figure 5.3 | Antagonism of LTβ Receptor signalling results in a profound loss of CD35/CD21+ 
Follicular Dendritic Cells and MAdCAM-1+ marginal zone sinus lining cells in Treg+ Spleen. 
Representative confocal high power images showing loss of CD35/CD21+ Follicular Dendritic 
Cells (FDC) and MAdCAM-1+ staining of marginal sinus lining cells in spleen of Treg replete 
Foxp3DTR animals following treatment with LTβR.Ig. Images of a spleen from a Treg replete 
animal (top) and from an LTβR.Ig treated, Treg replete animal (bottom) are shown. Sections 
were co-stained using a rat anti-CD35/CD21-APC antibody (purple), a rat anti-MAdCAM-1 
antibody followed by goat anti-rat AlexaFluor-568 secondary antibody (red) and a biotinylated 
rat anti-CD45R antibody followed by streptaviding-FITC secondary antibody (green). Merged 
images include the nuclear stain DAPI (blue). Scale bars are shown. 	
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Figure 5.4 | Antagonism of LTβ Receptor signalling results in a profound loss of CD35/CD21+ 
Follicular Dendritic Cells and MAdCAM-1+ marginal zone sinus lining cells in Treg- Spleen. 
Representative confocal high power images showing loss of CD35/CD21+ Follicular Dendritic 
Cells (FDC) and MAdCAM-1+ staining of marginal sinus lining cells in spleen of Treg depleted 
Foxp3DTR animals following treatment with LTβR.Ig. Images of a spleen from a Treg depleted 
animal (top) and from an LTβR.Ig treated, Treg depleted animal (bottom) are shown. Sections 
were co-stained using a rat anti-CD35/CD21-APC antibody (purple), a rat anti-MAdCAM-1 
antibody followed by goat anti-rat AlexaFluor-568 secondary antibody (red) and a biotinylated 
rat anti-CD45R antibody followed by streptaviding-FITC secondary antibody (green). Merged 
images include the nuclear stain DAPI (blue). Scale bars are shown. 	
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Whilst PNAd+ HEV were detectable in Inguinal LNs of LTβR.Ig treated animals, 
vessel morphology was significantly disrupted in a high proportion of samples: vessel 
distribution within the LN appeared less organised, and vessels appeared larger, often 
with more open lumen than those in LNs of Treg depleted Foxp3DTR animals (Figure 
5.5). Of note, not all LN HEV were disrupted following LTβR.Ig treatment: some HEV 
were indiscernible from those in LNs of Treg depleted animals. However, these data 
indicated a reduction in the fully differentiated status of HEV in LNs, a well-described 
consequence of LTβR.Ig treatment (Browning et al. 2005).  
LTβR.Ig treatment reduces PLN cellularity as a result of impaired lymphocyte 
trafficking via HEV due to dedifferentiation of vessels (Browning et al. 2005). The 
morphological disruption to HEV of inguinal LNs in LTβR.Ig treated Treg depleted 
animals was reflected by a significant reduction in inguinal LN cellularity1 (Figure 5.6 
A). The same trend, albeit not statistically significant, was observed for Treg replete 
animals (Figure 5.6 A). The profound lymphadenopathy induced by Treg depletion 
(Kim et al. 2007) (Figure 5.6 A & B), made the observed reduction in inguinal LN 
cellularity of Treg depleted mice upon LTβR.Ig treatment even more striking.  
Lymphocyte homing to mucosal lymphoid organs is dependent on the integrin 
α4β7–MAdCAM-1 adhesion cascade as well as the L-selectin–PNAd adhesion cascade 
(Butcher et al. 1999). Despite reports of reduced PNAd and MAdCAM-1 expression on 
HEV and decreased mesenteric LN cellularity upon LTβR.Ig treatment (Browning et al. 
2005), I observed no change in mesenteric LN cellularity after LTβR.Ig treatment of 
Treg replete or Treg depleted animals1, perhaps reflecting maintained MAdCAM-1 
expression and dominance of α4β7–MAdCAM-1 interactions for homing to mesenteric 
LN (Figure 5.6 B; data not shown).  In line with reports of inhibited lymphocyte entry 
into LNs resulting in increased numbers of lymphocytes in spleen, I observed an 
increase in splenic cellularity following LTβR.Ig treatment in Treg replete animals 
(Browning et al. 2005): the profound splenomegaly induced by Treg loss masked this 
affect of LTβR.Ig treatment in Treg depleted animals (Kim et al. 2007) (Figure 5.6 C).  
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Figure 5.5 | Antagonism of LTβ Receptor signalling results in a profound disruption to Lymph 
Node High Endothelial Venule morphology.  
Representative confocal microscope images showing disruption to PNAd+ HEV of lymph nodes 
in Treg depleted Foxp3DTR animals following treatment with LTβR.Ig. Low power (top) and high 
power (bottom) images of lymph node sections from a Treg depleted Foxp3DTR animal (left) and 
from an LTβR.Ig treated, Treg depleted Foxp3DTR animal (right) are shown. Sections were 
immunofluorescently co-stained using a biotinylated rat anti-PNAd primary antibody (clone 
MECA-79), which was detected using a streptavidin-555 secondary antibody (red), and rat anti-
CD4 and rat anti-CD8a primary antibodies, which were detected using an anti-rat donkey 
AlexFluor 488 secondary antibody (green). Merged images include the nuclear stain DAPI 
(blue). Scale bars are shown.  	
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Figure 5.6 | Antagonism of LTβ Receptor signalling results in a reduction in Inguinal Lymph 
Node cellularity with a concurrent increase in Splenic cellularity.  
Absolute numbers of cells in lymphoid organs of Treg replete and Treg depleted Foxp3DTR 
animals treated with or without LTβR.Ig, as assessed by haemocytometer count. Numbers of 
cells per 106 total cells are shown for Inguinal lymph node (A), Mesenteric lymph node (B) and 
Spleen (C), of Treg replete (closed shapes) Foxp3DTR animals treated with or without LTβR.Ig, 
and Treg depleted (open shapes) Foxp3DTR animals treated with or without LTβR.Ig. Statistical 
significance was determined by One-way ANOVA with Tukey’s multiple comparison tests to 
compare pairs of means (* = P≤0.05, ** = P≤0.01, *** = P≤0.001). N = 3 per group. 	
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To determine the affect of LTβR.Ig treatment on intra-tumoural HEV 
neogenesis, tumour sections were examined by immunohistochemistry. PNAd+ HEV 
were present in LTβR.Ig-treated Treg depleted frozen tumour sections (Figure 5.7). 
PNAd co-localised with CD31, as in control Treg depleted tumours, confirming the 
detection of vascular endothelial cells (Figure 5.7). PNAd+ HEV were also readily 
detectable in paraffin embedded tumour sections of LTβR.Ig-treated Treg depleted 
animals (Figure 5.8 A). Quantification of PNAd+ vessels in paraffin embedded tumour 
sections revealed no significant difference in HEV density of LTβR.Ig-treated Treg 
depleted tumours relative to control Treg depleted tumours (nsP=0.08253; Figure 5.8 
B). However, there was a noticeable trend towards an increase in HEV density in 
LTβR.Ig-treated tumours. Interestingly, the average HEV area in LTβR.Ig-treated Treg 
depleted tumours was significantly greater than that in control Treg depleted tumours 
(***P=0.00053; Figure 5.8 C). These findings were corroborated by the visual 
observation that HEV in LTβR.Ig-treated tumours often appeared larger, with more 
open lumen, than HEV of Treg depleted tumours (Figure 5.8 A). In support of the 
observed trend towards an increase in HEV density in LTβR.Ig-treated tumours, there 
was a modest increase in the total HEV area in LTβR.Ig-treated tumours relative to 
Treg depleted tumours (*P=0.03063; Figure 5.8 D).  
To assess functionality of intra-tumoural HEV in LTβR.Ig treated Treg depleted 
animals, I correlated measures of HEV density or total HEV area with numbers of 
tumour infiltrating T cells and tumour growth rates (Figure 5.9). There was a significant 
positive correlation between HEV density and number of tumour infiltrating T cells (r = 
0.8901, ***P<0.0001 for CD4+ T cells4; r = 0.6777, *P=0.0109 for CD8+ T cells4; Figure 
5.9 A-B). These data indicated that intra-tumoural HEV that developed following Treg 
depletion, during LTβR.Ig treatment, were functional in terms of facilitating lymphocyte 
trafficking into the tumour mass. Furthermore, numbers of tumour infiltrating T cells 
appeared to correlate negatively with tumour growth rate in LTβR.Ig-treated animals, 
as observed for the control Treg depleted group, although in this case, the trend did not 
reach statistical significance (r = -0.4121, nsP=0.1618 for CD4+ T cells4; r = -0.4904, 
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nsP=0.0889 for CD8+ T cells4; Figure 5.9 C-D). Similarly, both HEV density and total 
HEV area seemed to correlate negatively with tumour growth rate following LTβR.Ig 
treatment, although, again, statistical significance was not reached (r = -0.3022, 
nsP=0.3156 for HEV Density4; r = -0.3297, nsP=0.2713 for HEV Area4; Figure 5.9 E-F). 
The observed loss of a statistically significant correlation between HEV density or total 
HEV area and tumour growth rate in LTβR.Ig-treated animals relative to control Treg 
depleted animals indicates that LTβR.Ig treatment could be having some effect on HEV 
integrity or functionality. 
Collectively, these data indicate that LTβR antagonism does not interrupt HEV 
neogenesis in tumours following Treg depletion. These data suggest that signalling via 
the LTβR is not required for intra-tumoural HEV formation in this model, and that an 
alternative signalling circuitry drives this biological process. Interruption of LTβR 
signalling did however seem to have a partial effect upon functionality of tumour HEV, 
in terms of conferring a degree of tumour growth control. Collectively, these data imply 
that HEV neogenesis in tumours of Treg depleted animals represents a distinct 
molecular mechanism to that underpinning normal development of HEV-containing LNs 
in wild-type animals, which is critically dependent upon LTβR signalling.  
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Figure 5.7 | High Endothelial Venules are found in tumours following LTβ Receptor antagonism. 
Confocal images of High Endothelial Venules (HEV) within tumours of Treg depleted (top) and 
LTβR.Ig treated, Treg depleted (bottom) Foxp3DTR animals. Endothelial cells of HEV were 
detected by immunofluorescence staining using a biotinylated rat anti-PNAd primary antibody 
(clone MECA-79) and streptavidin Alexa Fluor® 555 secondary antibody (red). Tumour sections 
were dual-stained for PNAd and CD31 (rat anti-CD31-FITC; green). Merged images include the 
nuclear stain DAPI (blue). Scale bars are shown. 	
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Figure 5.8 | Measures of High Endothelial Venule density and total area are modestly increased 
when LTβ Receptor signalling is antagonised. 
Quantitative measures of High Endothelial Venules (HEV) in tumours of LTβR.Ig treated, Treg 
depleted Foxp3DTR animals. (A) Representative microscope images of HEV in paraffin 
embedded tumours. The anti-PNAd antibody (clone MECA-79) was detected using DAB 
chromogen (brown staining). Sections were counterstained using haematoxylin. Scale bars are 
shown. (B) HEV density was calculated per unit area of tumour (µm2). (C) Average area of HEV 
vessels calculated in µm2. (D) Total HEV area as a proportion of total tumour area, calculated 
as a percentage. Data are presented as individual datapoints plus median. Statistical 
significance was determined by Mann Whitney t tests. N = 13 LTβR.Ig treated, Treg- tumours; N 
= 21 Treg- tumours (20 in C). 	
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Figure 5.9 | Functionality of High Endothelial Venules in tumours in which LTβ Receptor 
signalling is blocked seems partially compromised.  
Correlations between number of intra-tumoural CD4+ and CD8+ T cells, High Ednothelial 
Venule (HEV) density and total HEV area, and tumour growth rates for LTβR.Ig treated, Treg 
depleted Foxp3DTR animals. (A-B) Numbers of intra-tumoural CD4+ and CD8+ T cells plotted 
against tumour HEV density; CD4+ T cells (A; purple); CD8+ T cells (B; blue). (C-D) Numbers 
of intra-tumoural CD4+ and CD8+ T cells plotted against tumour growth rates (k, days-1); CD4+ 
T cells (C; purple); CD8+ T cells (D; blue). (E-F) HEV density (E) and total HEV area (as 
proportion of total tumour area; F) plotted against tumour growth rate (k, days-1). Statistical 
significance was determined by the non-parametric Spearman’s correlation coefficient test, 
and the r statistic and P values are shown. N = 13. 	
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5.4 Results: TNFR antagonism using a TNFRII.Ig fusion protein reduces HEV 
density, total HEV area and average HEV area in tumours 
Having eliminated a role for LTβR signalling, I investigated a role for TNFR 
signalling in HEV neogenesis in our tumour model. In addition to an implied role in SLO 
development (Rennert et al. 1998), genes encoding TNFα and TNFR2 were 
significantly upregulated in HEV positive tumours of Treg depleted animals relative to 
HEV negative tumours of Treg depleted animals, and Treg replete animals (Figure 
5.1). I therefore treated tumour-bearing Foxp3DTR animals with DT and a TNFRII fusion 
protein (Enbrel® (Etanercept)), according to the protocol in Chapter 2.  
 Blockade of TNFR signalling using TNFRII.Ig results in similar splenic 
architectural disruption as observed following LTβR antagonism, including a loss of 
MAdCAM-1 staining on marginal sinus lining cells and splenic FDCs (Chiang et al. 
2009). Successful antagonism of TNFR signalling was confirmed by a profound loss of 
FDC and MAdCAM-1 staining following TNFRII.Ig treatment (Figure 5.10). The degree 
of disruption varied; some samples demonstrated maintained MAdCAM-1 expression 
(Supplemental Figure 5.4). However, loss of FDCs was a reliable, consistent surrogate 
marker of TNFR antagonism by TNFRII.Ig.  
Inguinal LNs of some TNFRII.Ig treated animals contained fewer PNAd+ HEV, 
and / or PNAd staining appeared weaker (Figure 5.11). These data are in contrast to a 
report where murine TNFRII.Ig failed to disrupt LN HEV (Browning et al. 2005). 
However, the disruption to LN architecture following Treg depletion signifies the 
magnitude of baseline systemic alterations in this system (Figures 4.2-4.4). As for 
LTβR.Ig, TNFRII.Ig treatment also disrupted LN HEV morphology: vessel distribution 
was less uniform, and vessels often had more open lumen than those in LNs of Treg 
depleted animals (Figure 5.11). Again, the degree of disruption varied, and some LN 
HEV of TNFRII.Ig treated mice were indiscernible from those of Treg depleted animals. 
However, these data indicated a reduction in the fully differentiated status of HEV in 
LNs, in a similar manner to that following LTβR.Ig treatment.  
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Figure 5.10 | Antagonism of TNF Receptor signalling results in a profound loss of CD35/CD21+ 
Follicular Dendritic Cells and MAdCAM-1+ marginal zone sinus lining cells in Treg- Spleen. 
Representative confocal high power images showing loss of CD35/CD21+ Follicular Dendritic 
Cells (FDC) and MAdCAM-1+ staining of marginal sinus lining cells in spleen of Treg depleted 
Foxp3DTR animals following treatment with TNFRII.Ig. Images of a spleen from a Treg depleted 
animal (top) and from an TNFRII.Ig treated, Treg depleted animal (bottom) are shown. Sections 
were co-stained using a rat anti-CD35/CD21-APC antibody (purple), a rat anti-MAdCAM-1 
antibody followed by goat anti-rat AlexaFluor-568 secondary antibody (red) and a biotinylated rat 
anti-CD45R antibody followed by streptaviding-FITC secondary antibody (green). Merged 
images include the nuclear stain DAPI (blue). Scale bars are shown. 	
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Figure 5.11 | Antagonism of TNF Receptor signalling results in a profound disruption to Lymph 
Node High Endothelial Venule morphology.  
Representative confocal microscope images showing disruption to PNAd+ HEV of lymph nodes 
in Treg depleted Foxp3DTR animals following treatment with TNFRII.Ig. Low power (top) and high 
power (bottom) images of lymph node sections from a Treg depleted Foxp3DTR animal (left) and 
from an TNFRII.Ig treated, Treg depleted Foxp3DTR animal (right) are shown. Sections were 
immunofluorescently co-stained using a biotinylated rat anti-PNAd primary antibody (clone 
MECA-79), which was detected using a streptavidin-555 secondary antibody (red), and rat anti-
CD4 and rat anti-CD8a primary antibodies, which were detected using an anti-rat donkey 
AlexFluor 488 secondary antibody (green). Merged images include the nuclear stain DAPI 
(blue). Scale bars are shown.  	
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PNAd+ CD31+ HEV were present in tumours of Treg depleted, TNFRII.Ig 
treated animals (Figure 5.12). However, PNAd staining of HEV appeared weaker in the 
majority of TNFRII.Ig treated tumours and the morphology of the endothelial cells lining 
HEV appeared deflated relative to Treg depleted control samples (Figure 5.12 & 5.13 
A). Furthermore, HEV appeared fewer in number and smaller in size, relative to 
vessels found in Treg depleted control tumours (Figure 5.13 A). Indeed, when HEV 
were quantified, there was a noticeable decrease in HEV density in Treg depleted, 
TNFRII.Ig treated tumours relative to control Treg depleted tumours, despite not 
reaching statistical significance (nsP=0.39463; Figure 5.13 B). In line with these data, 
there was a reduction in total HEV area in TNFRII.Ig treated tumours relative to control 
Treg depleted tumours, despite not reaching statistical significance (nsP=0.33263; 
Figure 5.13 D). Lastly, in support of observations, there was a decrease in average 
HEV area in TNFRII.Ig treated tumours, despite once again not reaching statistical 
significance (nsP=0.13943; Figure 5.13 C).	
There was a weak positive correlation between HEV density and number of 
tumour infiltrating CD4+ T cells in TNFRII.Ig treated tumours (r = 0.6016, *P=0.01064; 
Figure 5.14 A). The number of CD8+ T cells also appeared to correlate positively with 
HEV density, although statistical significance was not reached (r = 0.4491, 
nsP=0.07064; Figure 5.14 B). However, numbers of tumour infiltrating T cells did not 
correlate with tumour growth rate in TNFRII.Ig-treated animals, in contrast to the 
control Treg depleted group (r = -0.05770, nsP=0.8259 for CD4+ T cells4; r = -0.2074, 
nsP=0.4245 for CD8+ T cells4; Figure 5.14 C-D). In agreement with these data, both 
HEV density and total HEV area displayed very weak negative correlations with tumour 
growth rate following TNFRII.Ig treatment, which were far from reaching statistical 
significance (r = -0.3235, nsP=0.2052 for HEV Density4; r = -0.2304, nsP=0.3737 for 
HEV Area4; Figure 5.14 E-F). These data suggest that intra-tumoural HEV that 
developed during TNFRII.Ig treatment were compromised in terms of their ability to 
facilitate infiltration of lymphocytes capable of supporting an effective anti-tumour 
immune response. 
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Collectively, these data show that, whilst HEV neogenesis was not completely 
ablated in tumours of Treg depleted TNFRII.Ig treated animals, HEV density, total HEV 
area and average HEV area appear reduced. Furthermore, HEV functionality seems 
diminished, as correlation between HEV density and infiltrating T cells or tumour 
growth rate are mostly lost after TNFRII.Ig treatment. Therefore, HEV neogenesis in 
tumours following Treg depletion appears to be at least partially reliant upon TNFR 
signalling. 
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Figure 5.12 | High Endothelial Venules are found in tumours following TNF Receptor 
antagonism. 
Confocal images of High Endothelial Venules (HEV) within tumours of Treg depleted (top) and 
TNFRII.Ig treated, Treg depleted (bottom) Foxp3DTR animals. Endothelial cells of HEV were 
detected by immunofluorescence staining using a biotinylated rat anti-PNAd primary antibody 
(clone MECA-79) and streptavidin Alexa Fluor® 555 secondary antibody (red). Tumour sections 
were dual-stained for PNAd and CD31 (rat anti-CD31-FITC; green). Merged images include the 
nuclear stain DAPI (blue). Scale bars are shown. 	
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Figure 5.13 | Measures of High Endothelial Venule density and total area are profoundly 
decreased when TNF Receptor signalling is antagonised. 
Quantitative measures of High Endothelial Venules (HEV) in tumours of TNFRII.Ig treated, Treg 
depleted Foxp3DTR animals. (A) Representative microscope images of HEV in paraffin 
embedded tumours. The anti-PNAd antibody (clone MECA-79) was detected using DAB 
chromogen (brown staining). Sections were counterstained using haematoxylin. Scale bars are 
shown. (B) HEV density was calculated per unit area of tumour (µm2). The insert shows an 
enlarged version of the boxed area. (C) Average area of HEV vessels calculated in µm2. (D) 
Total HEV area as a proportion of total tumour area, calculated as a percentage. Data are 
presented as individual datapoints plus median. Statistical significance was determined by 
Mann Whitney t tests. N = 17 TNFII.Ig treated, Treg- tumours; N = 21 Treg- tumours (20 in C). 	
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Figure 5.14 | Functionality of High Endothelial Venules in tumours in which TNF Receptor 
signalling is blocked seems severely compromised.  
Correlations between number of intra-tumoural CD4+ and CD8+ T cells, High Endothelial Venule 
(HEV) density and total HEV area, and tumour growth rates for TNFRII.Ig treated, Treg depleted 
Foxp3DTR animals. (A-B) Numbers of intra-tumoural CD4+ and CD8+ T cells plotted against 
tumour HEV density; CD4+ T cells (A; purple); CD8+ T cells (B; blue). (C-D) Numbers of intra-
tumoural CD4+ and CD8+ T cells plotted against tumour growth rates (k, days-1); CD4+ T cells 
(C; purple); CD8+ T cells (D; blue). (E-F) HEV density (E) and total HEV area (as proportion of 
total tumour area; F) plotted against tumour growth rate (k, days-1). Statistical significance was 
determined by the non-parametric Spearman’s correlation coefficient test, and the r statistic and 
P values are shown. N = 17. 	
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5.5 Results: TNFR antagonism using an anti-TNFα antibody reduces HEV 
density and total HEV area but increases average HEV area in tumours 
 Having identified a putative role for TNFR signalling in HEV neogenesis in 
tumours, I investigated the affect of another method of TNFR signalling blockade on 
intra-tumoural HEV neogenesis. I treated tumour-bearing Foxp3DTR animals with DT 
together with an anti-TNFα monoclonal antibody (clone XT22-MP6), according to the 
protocol in Chapter 2.  
 As for both LTβR.Ig and TNFRII.Ig treatments, efficacy of anti-TNFα treatment 
was confirmed by immunohistochemical staining of spleen sections using CD45R, 
MAdCAM-1 and CD21/CD35 specific antibodies. As for TNFRII.Ig treatment, Treg 
depleted animals displayed a profound loss of FDCs and a partial loss of MAdCAM-1 
staining following anti-TNFα treatment (Figure 5.15). As for previous treatments, the 
degree of disruption to splenic stromal cell compartments varied, mainly with regard to 
expression of MAdCAM-1 on sinus lining cells (Supplemental Figure 5.5). However, as 
for TNFRII.Ig treatment, marked loss of FDCs following anti-TNFα treatment was a 
consistent surrogate marker of TNFR signalling blockade. 
As for LNs of TNFRII.Ig treated animals, LNs of anti-TNFα treated animals 
seemed to contain fewer HEV, and / or PNAd staining of HEV appeared weaker 
(Figure 5.16).  Reminiscent of previous treatments, anti-TNFα resulted in less 
organised vessel distribution, and vessels appeared to have more open lumen than 
those in LNs of Treg depleted Foxp3DTR animals (Figure 5.16). Again, although the 
degree of disruption varied between samples, these data indicated a degree of 
dedifferentiation of LN HEV, in a similar manner to that following either LTβR.Ig or 
TNFRII.Ig treatments.  
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Figure 5.15 | Neutralisation of TNFα results in a profound loss of CD35/CD21+ Follicular 
Dendritic Cells and MAdCAM-1+ marginal zone sinus lining cells in Treg- Spleen. 
Representative confocal high power images showing loss of CD35/CD21+ Follicular Dendritic 
Cells (FDC) and MAdCAM-1+ staining of marginal sinus lining cells in spleen of Treg depleted 
Foxp3DTR animals following treatment with anti-TNFα. Images of a spleen from a Treg depleted 
animal (top) and from an anti-TNFα treated, Treg depleted animal (bottom) are shown. Sections 
were co-stained using a rat anti-CD35/CD21-APC antibody (purple), a rat anti-MAdCAM-1 
antibody followed by goat anti-rat AlexaFluor-568 secondary antibody (red) and a biotinylated 
rat anti-CD45R antibody followed by streptavidin-FITC secondary antibody (green). Merged 
images include the nuclear stain DAPI (blue). Scale bars are shown. 	
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Figure 5.16 | Neutralisation of TNFα results in a profound disruption to Lymph Node High 
Endothelial Venule morphology.  
Representative confocal microscope images showing disruption to PNAd+ HEV of lymph nodes 
in Treg depleted Foxp3DTR animals following treatment with anti-TNFα. Low power (top) and 
high power (bottom) images of lymph node sections from a Treg depleted Foxp3DTR animal (left) 
and from an anti-TNFα treated, Treg depleted Foxp3DTR animal (right) are shown. Sections were 
immunofluorescently co-stained using a biotinylated rat anti-PNAd primary antibody (clone 
MECA-79), which was detected using a streptavidin-555 secondary antibody (red), and rat anti-
CD4 and rat anti-CD8a primary antibodies, which were detected using an anti-rat donkey 
AlexFluor 488 secondary antibody (green). Merged images include the nuclear stain DAPI 
(blue). Scale bars are shown.  	
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PNAd+ CD31+ HEV were also present in tumours of Treg depleted anti-TNFα 
treated animals (Figure 5.17). However, similarly to TNFRII.Ig treated tumours, PNAd 
staining of HEV appeared weaker in some anti-TNFα treated tumours relative to Treg 
depleted control samples, and HEV endothelial cell morphology often appeared 
severely deflated (Figure 5.17 and 5.18 A). However, whilst anti-TNFα treatment 
resulted in an apparent reduction in intra-tumoural HEV number, HEV often appeared 
larger and with more open lumen relative to vessels of Treg depleted control tumours, 
reminiscent of HEV in LTβR.Ig treated tumours (Figure 5.18 A).  
These visual observations were corroborated by quantitative measures of intra-
tumoural HEV. There was a marked decrease in HEV density in Treg depleted tumours 
following anti-TNFα treatment, despite not reaching statistical significance 
(nsP=0.10373; Figure 5.18 B). Furthermore, in line with the visual observation that 
many of the HEV appeared larger with more open lumen, average HEV area was 
significantly greater following anti-TNFα treatment (***P=0.00023; Figure 5.18 C). There 
was a reduction in total HEV area in Treg depleted tumours following anti-TNFα 
treatment, again, despite not reaching statistical significance (nsP=0.60593; Figure 5.18 
D). This subtle change in total HEV area could reflect a combined affect of the overall 
reduction in number of vessels per unit area, but the significant increase in average 
vessel area. 
As for TNFRII.Ig treated tumours, there was a weak positive correlation 
between HEV density and number of tumour infiltrating CD4+ T cells in anti-TNFα 
treated tumours (r = 0.7472, *P=0.01124; Figure 5.19 A). The number of CD8+ T cells 
also appeared to correlate positively with HEV density, although statistical significance 
was not reached (r = 0.1458, nsP=0.67314; Figure 5.19 B). However, as for TNFRII.Ig 
treated tumours, numbers of tumour infiltrating T cells did not correlate with tumour 
growth rate in anti-TNFα-treated animals, in contrast to the control Treg depleted group 
(r = -0.2000, nsP=0.5574 for CD4+ T cells4; r = -0.04545, nsP=0.9033 for CD8+ T cells4; 
Figure 5.19 C-D). In agreement with these data, neither HEV density nor total HEV 
area showed any correlation with tumour growth rate following anti-TNFα treatment (r = 
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0.07745, nsP=0.8179 for HEV Density4; r = 0.1503, nsP=0.6538 for HEV Area4; Figure 
5.19 E-F). These data suggest that intra-tumoural HEV that develop during anti-TNFα 
treatment are severely compromised in terms of their ability to facilitate lymphocytic 
infiltration, and indirectly a reduction in tumour growth rate. 
Collectively, these data show that HEV neogenesis can occur in tumours of 
Treg depleted, anti-TNFα treated animals, but HEV density and total HEV area appear 
reduced, whilst average HEV area is increased. Furthermore, HEV functionality seems 
significantly diminished, as correlations between HEV density and infiltrating T cells are 
weak, and correlations between HEV density or total HEV area and tumour growth rate 
are completely lost after anti-TNFα treatment. These data corroborate the findings of 
Section 5.4, in suggesting that HEV neogenesis in tumours following Treg depletion 
appears to be at least partially reliant upon TNFR signalling. 
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Figure 5.17 | High Endothelial Venules are found in tumours following TNFα neutralisation. 
Confocal images of High Endothelial Venules (HEV) within tumours of Treg depleted (top) and 
anti-TNFα treated, Treg depleted (bottom) Foxp3DTR animals. Endothelial cells of HEV were 
detected by immunofluorescence staining using a biotinylated rat anti-PNAd primary antibody 
(clone MECA-79) and streptavidin Alexa Fluor® 555 secondary antibody (red). Tumour sections 
were dual-stained for PNAd and CD31 (rat anti-CD31-FITC; green). Merged images include the 
nuclear stain DAPI (blue). Scale bars are shown. 	
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Figure 5.18 | Measures of High Endothelial Venule density and total area are decreased when 
TNFα is neutralised. 
Quantitative measures of High Endothelial Venules (HEV) in tumours of anti-TNFα treated, Treg 
depleted Foxp3DTR animals. (A) Representative microscope images of HEV in paraffin 
embedded tumours. The anti-PNAd antibody (clone MECA-79) was detected using VIP 
chromogen (purple staining). Sections were counterstained using haematoxylin. Scale bars are 
shown. (B) HEV density was calculated per unit area of tumour (µm2). The insert shows an 
enlarged version of the boxed area. (C) Average area of HEV vessels calculated in µm2. (D) 
Total HEV area as a proportion of total tumour area, calculated as a percentage. Data are 
presented as individual datapoints plus median. Statistical significance was determined by 
Mann Whitney t tests. N = 11 anti-TNFα treated, Treg- tumours (9 in C); N = 21 Treg- tumours 
(20 in C). 	
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Figure 5.19 | Functionality of High Endothelial Venules in tumours in which TNFα is neutralised 
seems severely compromised.  
Correlations between number of intra-tumoural CD4+ and CD8+ T cells, High Endothelial Venule 
(HEV) density and total HEV area, and tumour growth rates for anti-TNFα treated, Treg 
depleted Foxp3DTR animals. (A-B) Numbers of intra-tumoural CD4+ and CD8+ T cells plotted 
against tumour HEV density; CD4+ T cells (A; purple); CD8+ T cells (B; blue). (C-D) Numbers of 
intra-tumoural CD4+ and CD8+ T cells plotted against tumour growth rates (k, days-1); CD4+ T 
cells (C; purple); CD8+ T cells (D; blue). (E-F) HEV density (E) and total HEV area (as 
proportion of total tumour area; F) plotted against tumour growth rate (k, days-1). Statistical 
significance was determined by the non-parametric Spearman’s correlation coefficient test, and 
the r statistic and P values are shown. N = 11. 	
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5.6 Results: The proportion of TNFα-producing T cells in the tumour correlates 
with HEV density 
 Having identified a role for CD4+ and CD8+ T cells (Chapter Four), and a 
putative role for TNFα (above) in HEV neogenesis, I investigated whether a link existed 
between T cells and TNFα. I first analysed serum from Treg replete and Treg depleted 
animals to establish whether circulating levels of soluble TNFα were altered following 
Treg loss. I found higher levels of soluble TNFα in serum of Treg depleted animals 
relative to Treg replete animals (nsP=0.05045; Figure 5.20). Despite not reaching 
statistical significance, the heavy skewing of the 95% confidence intervals (CI) of the 
mean away from zero indicate the existence of a biological difference between Treg 
replete and Treg depleted groups in terms of levels of TNFα in the serum (upper 95% 
CI: 31.2932; lower 95% CI: -0.0366). These data showing an increase in this pro-
inflammatory cytokine are not surprising, considering the systemic autoimmunity 
induced by Treg depletion in Foxp3DTR animals (Kim et al. 2007). Heightened levels of 
systemic TNFα allow for the speculation that this cytokine could be involved in HEV 
neogenesis in tumours following loss of Tregs.  
I next analysed proportions of intra-tumoral T cells or T cells in lymphoid organs 
expressing intracellular TNFα by flow cytometry, and correlated this measure with HEV 
density in tumours. I found a highly significant, striking positive correlation between the 
proportion of intra-tumoural CD4+ or CD8+ T cells producing TNFα and HEV density in 
tumours (r = +0.7500, *P=0.0255 for both CD4+ and CD8+ T cells4; Figure 5.21). In 
contrast, there was no correlation between proportion of T cells expressing TNFα in 
lymphoid organs and HEV density in tumour. Instead, a negative correlation existed 
between the proportion of CD8+ T cells producing TNFα in LNs and HEV density in 
tumour (r = -0.6833, nsP=0.0503 for NDLN4; r = -0.3000, nsP=0.4366 for DLN4; Figure 
5.21). These data directly index HEV density of tumours to TNFα production by T cells 
in the tumour, and strongly support the developing hypothesis that TNFα-producing T 
cells are key drivers of HEV neogenesis in tumours. 
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Figure 5.20 | Treg depleted animals have higher circulating levels of TNFα than Treg replete 
animals. 
Quantity of soluble TNFα (pg/ml) detected by Enzyme Linked ImmunoSorbent Assay (ELISA) in 
serum of Treg replete (Treg+; closed circles) and Treg depleted (Treg-; open circles) Foxp3DTR 
animals. Data are represented as individual datapoints plus mean. Sensitivity limit of the ELISA 
is shown by the dotted line. Statistical significance was determined by Welch’s unequal variance 
t test. N = 6.  	
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Figure 5.21 | Density of intra-tumoural High Endothelial Venules correlates with the proportion of 
T cells producing TNFα in the tumour.  
Correlations between High Endothelial Venule (HEV) density, calculated per unit area of tumour 
(µm2), and proportion (%) of CD4+ (purple circles) or CD8+ (blue circles) T cells expressing intra-
cellular TNFα, in Spleen, non-tumour draining lymph node (NDLN), tumour-draining lymph node 
(DLN), and Tumour. Statistical significance was determined by the non-parametric Spearman’s 
correlation coefficient test, and the r statistic and P values are shown. N = 9. 	
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5.7 Results: Comparison of T cell infiltration, HEV neogenesis and tumour 
growth across all cytokine blockade treatments 
 As for the data described in Chapter Four, I wished to compare the impact of 
different treatments on T cell infiltration, HEV neogenesis and growth rates of tumours 
collectively (Figures 5.22-5.24). Again, I separated the control Treg depleted group into 
“HEVlo” and “HEVhi” categories. Despite no statistically significant differences, tumours 
of LTβR.Ig treated animals and anti-TNFα treated animals most closely resembled the 
HEVhi control group and tumours of TNFRII.Ig treated animals most closely resembled 
the HEVlo control group, in terms of numbers of tumour infiltrating CD4+ T cells6 (Figure 
5.22 A). A similar pattern was observed for numbers of tumour infiltrating CD8+ T cells 
(Figure 5.22 B). Here, there was a statistically significant increase in the number of 
intra-tumoural CD8+ T cells in LTβR.Ig treated animals relative to both the HEVlo control 
group and TNFRII.Ig treated animals6. As my hypothesis states that intra-tumoural 
HEV dictate T cell infiltration into tumours, these data indicate that TNFRII.Ig treatment 
in particular significantly impacts HEV neogenesis in tumours, as frequencies of CD4+ 
and CD8+ T cells in the tumours are profoundly reduced in this treatment group relative 
to HEVhi Treg depleted tumours. 
 Both HEV density and total HEV area of tumours of LTβR.Ig treated animals 
were statistically significantly greater than tumours of the HEVlo control Treg depleted 
group, as was the case for HEVhi control Treg depleted tumours6 (Figure 5.23A-B). 
Tumours of TNFRII.Ig, and anti-TNFα treated animals contained a statistically 
significantly lower density of HEV relative to HEVhi control Treg depleted tumours6 
(Figure 5.23A). Interestingly, in line with previous observations, only TNFRII.Ig 
treatment, and not anti-TNFα treatment, resulted in a statistically significant decrease 
in total HEV area, relative to HEVhi control Treg depleted tumours6 (Figure 5.23B). 
These data underpin my conclusion that blockade of TNFR signalling, particularly via 
use of TNFRII.Ig, has a profound impact on the development of intra-tumoural HEV in 
this model. 
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 There were no statistically significant differences in tumour growth rate between 
treatment groups6 (Figure 5.24 A-B). However, there was a noticeable trend towards a 
decrease in tumour growth rate following LTβR.Ig treatment: this group more closely 
resembled the HEVhi control group than the HEVlo control group (Figure 5.24 B), and 
contained several samples with negative growth rates (i.e. tumours that were 
regressing). In contrast, the TNFRII.Ig treated group more closely resembled the HEVlo 
control group than the HEVhi control group (Figure 5.24 B), and contained several 
samples with high tumour growth rates (i.e. tumours that were progressing). These 
tumour growth data are in line with the hypothesis that blockade of TNFR signalling, 
particularly via use of the TNFRII.Ig protein, impedes HEV neogenesis in tumours, 
resulting in diminished intra-tumoural T cell infiltration and accelerated tumour growth. 
In contrast, blockade of LTβR signalling does not prevent HEV neogenesis in tumours, 
allowing these vessels to form and facilitate infiltration of high numbers of T cells, 
conferring a degree of tumour growth control. 
 As in Chapter Four, I used a linear model with fixed effects to determine 
whether tumour growth could be explained by HEV density and / or treatment regime. 
While treatment had a more profound effect on tumour growth (***P<0.001), HEV 
density, as an independent variable, significantly influenced tumour growth 
(*P=0.0105). Once again, these data emphasize that while treatment can influence 
tumour growth rate via a plethora of mechanisms, HEV density stands alone as an 
independent variable that significantly impacts upon the growth rate of tumorus. 
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Figure 5.22 | Signalling blockade or cytokine neutralisation treatments did or did not alter 
absolute numbers of CD4+ and / or CD8+ T cells inside tumours.  
Number of intra-tumoural CD4+ (A) and CD8+ (B) T cells for each of the following treatment 
groups: Treg depleted (Treg-) HEVlo, N = 6; Treg- HEVhi, N = 6; LTβR.Ig treated, Treg-, N = 13; 
TNFRII.Ig treated, Treg-, N = 17; and anti-TNFα treated, Treg-, N = 11. Data are presented as 
individual datapoints plus median. Statistical significance was determined by Kruskal-Wallis 
One-Way ANOVA and Dunn’s multiple comparisons tests (* = P≤0.05, ** = P≤0.01, *** = 
P≤0.001).  
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Figure 5.23 | Signalling blockade or cytokine neutralisation treatments did or did not alter High 
Endothelial Venule density and / or total area inside tumours.  
HEV density (A) and total HEV area (B) for each of the following treatment groups: Treg 
depleted (Treg-) HEVlo, N = 6; Treg- HEVhi, N = 6; LTβR.Ig treated, Treg-, N = 13; TNFRII.Ig 
treated, Treg-, N = 17; and anti-TNFα treated, Treg-, N = 11. Data are presented as individual 
datapoints plus median. Statistical significance was determined by Kruskal-Wallis One-Way 
ANOVA and Dunn’s multiple comparisons tests (* = P≤0.05, ** = P≤0.01, *** = P≤0.001).  
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Figure 5.24 | Signalling blockade or cytokine neutralisation treatments did or did not alter growth 
rate of tumours.  
Tumour growth rate (k, days-1) data for each of the following treatment groups: Treg depleted 
(Treg-) HEVlo, N = 6; Treg- HEVhi, N = 6; LTβR.Ig treated, Treg-, N = 13; TNFRII.Ig treated, Treg-
, N = 17; and anti-TNFα treated, Treg-, N = 11. Data are presented as individual datapoints plus 
median. Statistical significance was determined by Kruskal-Wallis One-Way ANOVA and Dunn’s 
multiple comparisons tests (* = P≤0.05, ** = P≤0.01, *** = P≤0.001).  
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5.8 Discussion 
 LTβR signalling is essential for normal development of HEV-containing LN 
during ontogeny (Mebius 2003), and blockade of LTβR signalling results in loss of 
PNAd-expressing HEV in TLOs associated with chronic inflammation (Gatumu et al. 
2009; Gräbner et al. 2009; Motallebzadeh et al. 2012; Rangel-Moreno et al. 2011). 
Furthermore, LTβR signalling has recently been implicated in the process of HEV 
neogenesis in tumours (Martinet et al. 2013; Martinet & Girard 2013). Here, I have 
shown that HEV neogenesis in MCA tumours following Treg depletion occurs entirely 
independently of LTβR signalling. The development of HEV in tumours of Treg 
depleted Foxp3DTR animals could represent a significant deviation from these other 
systems, as Treg depletion results in extensive systemic immune activation and 
disruption to lymphoid organ architecture. Indeed the results of Chapter Four suggest 
the existence of a distinct mechanism of HEV development, due to the absolute 
reliance on T lymphocytes.  
 Instead, my data point to a role for an alternative signalling circuitry, TNFα-
TNFR signalling, in driving HEV neogenesis in Treg depleted tumours (Figure 5.25). 
Blockade of TNFR signalling via two independent treatments (TNFRII.Ig fusion protein 
and anti-TNFα antibody) resulted in a decrease in the HEV density and total HEV area 
of Treg depleted tumours. Despite not reaching statistical significance, these measures 
were clearly altered following these treatments.  
Some studies have shown that abluminal expression of PNAd in LN HEV can 
be independent of LTβR signalling. In LTβ-/- animals or those treated with antagonist 
LTβR.Ig fusion protein, LN HEV maintain residual abluminal expression of PNAd 
(Drayton et al. 2003; Browning et al. 2005; Liao & Ruddle 2006). Furthermore, despite 
the loss of the characteristic morphology of HEV endothelial cells upon ablation of 
LTβR in vascular endothelial cells, PNAd expression remains (Onder et al. 2013). The 
recently published study by Peske and colleagues confirmed that PNAd expression on 
HEV vessels in tumours of melanoma and lung carcinoma mouse models is also 
LTβR-independent (Peske et al. 2015). Instead, the authors demonstrate the reliance 
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on CD8+ T lymphocytes and LTα3-TNFR signalling for development of PNAd+ 
vasculature in the tumour. 
Both HEV density and total HEV area datasets for the Treg depleted control 
group fit a bifurcated pattern of distribution, whereby one group of datapoints remain 
close to zero and another display significant departure from zero. In complete contrast, 
HEV density and total HEV area datasets for both TNFRII.Ig treated and anti-TNFα 
treated groups demonstrate significant departure from this bifurcated pattern of 
distribution, with all datapoints remaining close to zero or at least below a certain 
threshold. These data indicate that, while some PNAd+ HEV can indeed be found in 
tumours following either TNFRII.Ig or anti-TNFα treatment, signalling blockade 
prevented all tumours from reaching a high density or total area observed for some 
tumours in Treg depleted controls.  
The development of HEV in some tumours following TNFRII.Ig or anti-TNFα 
treatments (i.e. the partial rather than absolute phenotype) could represent either 
insufficient blockade of signalling using these agents, or the activity of an alternative 
signalling circuitry, which can compensate for the loss of TNFR signalling to a certain 
degree, but not entirely. The first explanation is unlikely: efficacy of treatment was 
confirmed in each case by analysis of MZ B cells and FDCs in the spleen, which 
displayed significant disruption in most animals, relative to Treg depleted controls. 
Therefore it seems likely that a distinct signalling circuitry can partially compensate for 
the loss of TNFR signalling in some cases. However, the data show that intact TNFR 
signalling is what is required to achieve HEV neogenesis to the extent observed in the 
Treg depleted control group of animals.  
TNFα is a pleiotropic cytokine with multiple roles in both inflammation and 
immunity. The pro-inflammatory effects of TNFα are well known; TNFR2 acts as a co-
stimulatory molecule for effector T cell activation, in a TCR-dependent manner. 
However, TNFα also contributes to anti-inflammatory and immunosuppressive 
processes of the immune system, via activation of Tregs through TNFR2, which is 
expressed at high levels by the vast majority of both mouse and human Tregs. The 
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effects of blocking signalling via the TNFRs on intra-tumoural T cell accumulation in the 
MCA tumours studied here could be reflective of a direct affect of signalling blockade 
on effector T cells, rather than an indirect affect of prohibiting HEV neogenesis (Chen & 
Oppenheim 2011). 
 TNFα is also a vasoactive agent (Chen et al. 2003). Targeting TNFα to tumour 
blood vessels can upregulate adhesion molecule expression on the surface of 
endothelial cells and subsequently enhance CD8+ cytotoxic T cell infiltration (Calcinotto 
et al. 2012). Blockade of TNFR signalling in my studies could therefore result in fewer 
T cells within the tumour due to induction of ‘endothelial cell anergy’ of the general 
tumour vasculature in the absence of TNFR signalling, thereby precluding effector T 
cell infiltration.  
 TNFα was originally identified for its anti-tumour activity via its ability to induce 
rapid haemorrhagic necrosis of cancers (Carswell et al. 1975). In light of the potent 
systemic pro-inflammatory activity in vivo, use of a new technique termed isolated limb 
perfusion (ILP) has enabled successful treatment of cancers growing in the extremities 
by local, isolated administration of TNFα (Aggarwal et al. 2012). TNFα can induce 
major destruction of tumour-associated vasculature, and has also been implicated in 
the T cell driven anti-tumour immune response (Balkwill 2009). Therefore, in the study 
described here, blockade of TNFα could have a multitude of effects, influencing T cell 
effector function or activation, tumour vasculature, and / or HEV neogenesis, all of 
which could culminate in changes in tumour growth.  
 The blocking activities of TNFRII.Ig (Etanercept) and anti-TNFα (MP6-XT22) 
differ slightly: Etanercept binds soluble TNFα and soluble LTα3 but forms only unstable 
associations with membrane-bound TNFα, from which it dissociates rapidly. In 
contrast, MP6-XT22 binds both soluble TNFα and membrane-bound TNFα, but not 
soluble LTα3 (Ware 2005; Taylor 2010; Tracey et al. 2008; Scallon et al. 2002; 
Grattendick et al. 2008). In each case, therefore, there remains at least one active 
ligand that can still stimulate signalling via the TNFRs; membrane-bound TNFα, in the 
case of Etanercept, and soluble LTα3, in the case of MP6-XT22. Therefore, this 
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incomplete blockade of signalling via the TNFRs could account for incomplete 
abolishment of HEV neogenesis in tumours. Indeed, a recent study of HEV neogenesis 
in the mouse B16 melanoma model strongly implicated LTα3-TNFR signalling in this 
process (Peske et al. 2015). Future studies will be required to definitively determine the 
role this signalling circuitry may play in HEV neogenesis in our MCA model following 
Treg depletion. Blockade of LTα3 by use of a monoclonal antibody, and administration 
of both TNFRII.Ig and anti-TNFα reagents simultaneously are possibilities to confirm 
the signalling pathway responsible for HEV development.  
 
Figure 5.25 | Updated hypothesis of HEV Neogenesis in Carcinogen-Induced Tumours 
after Treg Depletion. 
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Chapter Six 
6 Final Discussion 
6.1 Enrichment of CD69+ Foxp3+ Regulatory T cells in Tumours 
 Foxp3+ Tregs are enriched in mouse and human tumours (Curiel et al. 2004; 
Bates et al. 2006; Betts et al. 2007; Betts et al. 2006). Intra-tumoural Tregs facilitate 
establishment of an immunosuppressive microenvironment, impinging on anti-tumour 
immune responses (Nishikawa & Sakaguchi 2010; Gallimore & Godkin 2008). 
Modalities aimed at circumventing accumulation of Tregs in tumours could substantially 
improve efficacy of cancer immunotherapies in the future. 
 My data show that while a large proportion of intra-tumoural Tregs express the 
TH1-lineage transcription factor T-bet, T-bet-expressing Tregs were dispensable for 
control of tumour development. Sequestration of IL-2 in the TME did not represent a 
mechanism by which Tregs exert dominance at this site. More importantly, a large 
proportion of intra-tumoural Tregs expressed CD69. Furthermore, CD69 expression 
conferred a superior suppressive capacity on Tregs relative to those not expressing 
this marker. CD69 could therefore represent a potential biomarker of super-
suppressive Tregs in the TME, and also a therapeutic target. Indeed, treatment of 
CD69-expressing Tregs with an anti-CD69 monoclonal antibody downregulated CD69 
expression and blocked suppressive function (Sancho et al. 2006; Cortés et al. 2014).  
Selective targeting of CD69-expressing Tregs in the tumour would be 
challenging, as this marker is upregulated on recently activated T cells, ablation of 
which would hinder an anti-tumour immune response (González-Amaro et al. 2013). 
Therapeutic use of antagonistic mAbs to selectively decrease number or function of 
CD69-bearing Tregs within the tumour requires further understanding of the specific 
functional role of this receptor on different immune cells. Selectively targeting an 
antagonistic anti-CD69 antibody to intra-tumoural Tregs to simultaneously counteract 
their retention and accumulation, and modify their suppressive function, represents a 
potential clinical translation of the data presented in this thesis.  
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6.2 The function of Intra-Tumoural High Endothelial Venules 
 HEV in lymphoid organs facilitate infiltration of naïve and central memory 
lymphocytes (Girard et al. 2012). I hypothesised that ectopically formed HEV within 
MCA-induced tumours of Treg depleted Foxp3DTR animals served to allow infiltration of 
high frequencies of T cells. My data establish that HEV density in tumours of Treg 
depleted animals significantly and positively correlates with numbers of infiltrating CD8+ 
and CD4+ T cells.  
Despite this correlation, a causative link between HEV and intra-tumoural T 
cells has not yet been established in the model described here. In fact, considering the 
data presented here documenting a prominent role for T cells in the process of HEV 
neogenesis, it is entirely possible that the high numbers of T cells inside HEV-
containing tumours is a cause rather than an effect of HEV neogenesis. To resolve 
this, in vivo T cell trafficking studies will be performed, during which the Mel-14 anti-L-
selectin monoclonal antibody, which precludes interactions between L-selectin and 
PNAd ligands, will be used to block lymphocyte trafficking via HEV (Hou et al. 1995; 
Lepault et al. 1994; Ondondo et al. 2014b). By comparing numbers of TIL in relation to 
HEV density in animals treated with Mel-14 or control antibodies, we will determine 
whether interactions between L-selectinhi lymphocytes and PNAd on HEV endothelium 
are responsible for increased numbers of lymphocytes in HEV containing tumours. 
Importantly, considering my data describing a key role for T lymphocytes in the process 
of HEV neogenesis in tumours, the Mel-14 antibody must be administered after HEV 
have been allowed to form in tumours, as systemic blockade of L-selectin-PNAd 
interactions would inhibit lymphocytic recirculation and priming in LNs, which may be 
essential for conferring their HEV inducing capabilities. Due to our limited knowledge 
surrounding kinetics of HEV development in MCA tumours, this experiment may be 
technically challenging. Alternatively, short-term competitive homing studies using 
labelled L-selectin knockout and wild-type T cells could be performed, allowing 
assessment of intra-tumoural HEV functionality by analysing relative frequencies of 
differently labelled T cells that home to tumours by flow cytometry.  
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 It is plausible that, due to selective recruitment of L-selectinhi lymphocytes (i.e. 
central memory and naïve T lymphocytes), HEV may alter the specific composition of 
the tumour infiltrating T cell pool. Future experiments will seek to determine the degree 
of overlap of TCR repertoires of naïve (CD44lo L-selectinhi), central memory (CD44hi L-
selectinhi) and effector memory (CD44hi L-selectinlo) T cells isolated from HEV positive 
or HEV null tumours of Treg depleted animals. These data will help to establish 
whether intra-tumoural HEV facilitate infiltration of central memory and / or naïve T 
lymphocytes, and will indicate whether antigen-specific priming of naïve lymphocytes 
occurs at the tumour site. These data will help to identify immunological requirements 
for supporting an effective anti-tumour response following induction of HEV in tumours.  
 Currently the evidence for intra-tumoural HEV supporting increased T cell 
infiltration into MCA-induced tumours in our model is largely anecdotal, based on their 
highly specialised function in lymphoid organs. It is important to consider that intra-
tumoural HEV are not the only means by which effector T cells can access the TME: 
the activation status of the existing tumour vasculature is likely to play a significant role 
in this process. Indeed, tumours of anti-TNFα treated animals contained large numbers 
of T cells in the absence of ectopic HEV, suggesting other prominent mechanisms by 
which effector immune cells can access the tumour to mount an attack. However, the 
robust reduction in tumour growth rate conferred by HEV strongly supports the idea 
that these vessels mediate a distinctly potent anti-tumour activity.   
6.3 The mechanism of High Endothelial Venule formation in tumours 
 My data presented here elucidate a primary role for CD8+, and to a lesser 
extent, CD4+ T cells in HEV neogenesis in tumours following Treg depletion. The data 
also eliminate a role for signalling via the LTβ receptor, and instead strongly implicate 
signalling via the TNF receptor(s) by one of the cognate ligands, TNFα and / or LTα3, in 
HEV neogenesis. From these data, a new hypothesis has been formulated, stating that 
HEV neogenesis in tumours in the absence of Tregs is driven by T cell derived TNFα 
and / or LTα3 acting directly on tumour endothelium.  
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 To test this hypothesis, a series of studies will be performed in the near future. 
Firstly, a series of in vivo studies will be initiated, during which an antagonistic anti-LTα 
antibody will be administered alongside DT treatment of tumour bearing Foxp3DTR 
animals (Chiang et al. 2009). Analysis of tumours for HEV presence will ascertain the 
contribution of the LTα3 ligand to HEV neogenesis, in a similar manner to the cytokine 
blockade studies described in this thesis. In another set of experiments, the ability of 
purified, activated T cells from Treg depleted animals to induce HEV in tumours of Treg 
replete hosts will be tested. In preliminary studies, splenic CD3+ T cells were isolated 
from Treg depleted animals and injected into the base of the tumour-bearing leg of 
Treg replete hosts, a route known to drain to tumour via lymphatic vasculature 
(Ondondo et al. 2014b). HEV were absent from all 5 tumours analysed, indicating the 
inability of highly activated T cells to overcome the dominant immunosuppression 
enforced by Tregs within the tumour and induce HEV (unpublished observations). In 
future studies, T cells isolated by the same process will be administered by intravenous 
injection to tumour bearing Treg replete hosts, to investigate the possibility that 
activated T cells must directly access the tumour endothelium to induce a program of 
HEV differentiation in the presence of Tregs. If activated T cells are capable of inducing 
HEV in Treg replete tumours in this manner, these experiments will be repeated, and a 
cohort of animals will additionally be subjected to TNFα or LTα3 blockade by 
administration of blocking antibodies previously mentioned. Analysis of HEV presence 
in tumours will indicate whether blockade of either signalling molecule precludes the 
ability of T cells to induce HEV. In longer-term studies, and for definitive proof that T 
cell derived TNFα and / or LTα3 drives HEV neogenesis in tumours by direct contact 
with the endothelium, endothelial cell-TNFR conditional knockout animals, and T-TNF 
knockout and T-LTα knockout animals (in which the gene encoding TNFα or LTα is 
specifically ablated in T cells, respectively), will be crossed with Foxp3DTR animals 
(Grivennikov et al. 2005). In the resultant offspring, tumours will be induced by MCA 
injection, Tregs will be depleted by DT administration and tumours subsequently 
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analysed for HEV. These studies should collectively demonstrate that T cell derived 
TNFα or LTα3 is responsible for inducing a program of HEV neogenesis in tumours. 
6.4 The role of Foxp3+ Regulatory T cells in Prohibition of High Endothelial 
Venule Formation 
 An intriguing observation in the model of MCA-induced carcinogenesis is that 
intra-tumoural HEV form in animals devoid of Tregs: PNAd+ vessels are completely 
absent from tumours of Treg replete mice (Hindley et al. 2012). These data imply that 
Tregs inhibit neogenesis of HEV in tumours. Considering the profound paucity in 
numbers and / or functional impairment of Tregs in numerous autoimmune diseases 
(Lahl et al. 2007; Kim et al. 2007; Brunkow et al. 2001; Wildin et al. 2001; Bennett et al. 
2001), it could be logical to hypothesise that Tregs could play a regulatory role in 
development of ectopic lymphoid tissue (Carragher et al. 2008). 
Kocks and colleagues observed spontaneous development of highly organised 
iBALT containing PNAd+ HEV, which normally only develop in response to 
inflammatory insult in wild-type animals, in lung tissue of germ-free CCR7-/- mice 
(Kocks et al. 2007). CCR7 is essential for maintenance of Tregs and Treg-mediated 
peripheral immune regulation, evident from the dramatic decrease in Treg abundance 
and enhanced immunity in CCR7 deficient animals (Kocks et al. 2007; Schneider et al. 
2007). Adoptive transfer of wild-type but not CCR7-/- Tregs into CCR7-deficient hosts 
largely interrupted iBALT formation, and homing of Tregs to peripheral lymphoid 
organs was essential for their prevention of iBALT formation. Surprisingly, CCR7-/- 
animals had elevated numbers of Treg in peripheral tissues including the lung, 
suggesting LNs are the site of Treg-mediated regulation of iBALT manifestation (Kocks 
et al. 2007). A separate study reported the development of spontaneous iBALT in IL-2-
deficient animals, which are devoid of Tregs (Contractor et al. 1998). Such studies 
imply a crucial regulatory role for Tregs in prevention of ectopic lymphoid neogenesis 
(Carragher et al. 2008). 
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It will be important to define the mechanism by which Tregs impinge on intra-
tumoural HEV neogenesis in the MCA model if therapies aimed at encouraging HEV 
development are to be designed. Although Tregs can impinge on endothelial cell 
activation (He et al. 2010; Matrougui et al. 2011), Tregs could play an indirect role in 
the control of HEV neogenesis in tumours, via limitation of accumulation and / or 
effector activities of immune cell populations (Peske et al. 2015). Tregs limit DC 
activation and function (Shevach 2009; Schmidt et al. 2012; Vignali 2012), and 
considering recent data implicating DCs in orchestration of HEV formation in tumours 
(Martinet et al. 2013; Martinet & Girard 2013), some may speculate that Tregs could 
prohibit HEV neogenesis via suppression of DC activation or production of HEV-
inducing cytokines by DC (Gallimore et al. 2013). In light of my data establishing a 
crucial role for CD8+, and possibly CD4+, T lymphocytes in HEV neogenesis in MCA-
induced fibrosarcomas, however, I hypothesise that Tregs prevent HEV development 
in MCA tumours by actively suppressing the activation of and / or cytokine production 
by another immune cell subset: T lymphocytes. Indeed, there are multiple mechanisms 
by which Tregs suppress activation and proliferation of T lymphocytes (Shevach 2009; 
Schmidt et al. 2012; Vignali 2012), which could be co-opted to prevent HEV induction 
by T cells within the tumour. In vitro Treg suppression assays will be implemented in 
future studies to assess whether a direct or indirect mechanism of suppression exists 
between Tregs and conventional T lymphocytes in terms of T cell production of an 
HEV-inducing cytokine, putatively identified here as TNFα and / or LTα3. 
It is intriguing that a recently published study documented intra-tumoural HEV in 
several mouse models of cancer in the presence of normal proportions of Foxp3+ Tregs 
(Peske et al. 2015). The authors suggest that the fact that depletion of Foxp3+ Tregs 
was not required for HEV neogenesis in B16 tumour models engineered to express 
ovalbumin (OVA) likely reflects, at least in part, a difference in antigenic strength 
between OVA and neoantigens formed in carcinogen-induced tumours. Therefore, in 
the presence of a strong antigenic stimulus such as OVA, sufficiently robust effector 
activity can be generated in the presence of Tregs to enable HEV neogenesis to occur. 
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It is important to consider the fact that both B16-OVA and MCA induced tumour 
models may represent highly polarised systems in terms of high antigenic stimulus, 
relative to human cancers. The extremely high number of mutations induced by MCA 
lead to the formation of thousands of neoantigens, which can be considered a 
significant caveat of this model (Matsushita et al. 2012). However, although the high 
antigenic load of MCA tumours may lead to more robust HEV neogenesis following 
Treg depletion than might occur in human tumours, recent data from our lab 
documenting intra-tumoural HEV in the 4T1 mammary carcinoma model following Treg 
depletion imply the wide applicability of our data from the MCA tumour model. Whether 
antigenic stimulus plays a role in HEV neogenesis in tumours or not, Treg depletion 
appears to confer a robust amplification of the process of HEV neogenesis: both HEV 
in B16-OVA tumours (which required tyramide amplification protocols for visualisation) 
and tumour growth control were far inferior to that observed in our MCA model 
following Treg depletion (Peske et al. 2015). This is particularly relevant considering 
the plethora of clinical trials currently investigating Treg depletion as a prominent 
component of cancer immunotherapy regimes.  
To translate our findings to a clinically relevant setting, investigations into 
therapies specifically targeting Tregs will be conducted. Currently, there are no clinical 
agents available that specifically target Tregs. CTX is an FDA approved agent, and is 
already being used in clinical trials to specifically ablate the Treg compartment (Le & 
Jaffee 2012). Future studies will investigate the feasibility of CTX treatment in pre-
clinical mouse models to spontaneously induce HEV neogenesis in MCA-induced 
tumours of wild-type animals.  
Inhibitors of phosphoinositide-3-OH kinase (PI(3)K) have recently been shown 
to override Treg-mediated suppression of immune responses and result in profound 
anti-tumour immunity. Inactivation of the p110δ isoform of PI(3)K in Tregs was both 
necessary and sufficient to confer immunological tumour resistance (Ali et al. 2014). 
This method of breaking immune tolerance to unleash an effective anti-tumour immune 
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response shall be investigated for the ability to also induce intra-tumoural HEV in our 
model in future studies.  
Depletion of Tregs in the Foxp3DTR MCA model of carcinogenesis using 
diphtheria toxin results in effective anti-tumour immune responses at the expense of 
profound systemic autoimmunity and morbidity (Kim et al. 2007). It could be highly 
challenging to control autoimmune reactions in patients following systemic depletion of 
Tregs. This concern highlights a requirement to design therapies for targeted Treg 
depletion locally at the tumour site. In this regard, agents such as some anti-CTLA-4 
antibodies could be used to leverage the ability of the TME to selectively deplete Tregs 
in situ, thereby sparing host-protective peripheral Tregs (Simpson et al. 2013).  
It is clear, however, that ectopic lymphoid tissue and / or HEV form in a 
multitude of settings in the presence of normal frequencies of functional Foxp3+ Treg. 
NOD mice develop ectopic lymphoid tissue in lung and pancreas (Xu et al. 2003; 
Faveeuw et al. 1994), despite harbouring normal frequencies of Tregs (Mellanby et al. 
2007). Moreover, the vast majority of clinical reports of ectopic lymphoid tissue and / or 
isolated HEV in human malignancies develop in the context of the profound enrichment 
of Tregs observed in cancers (Goc et al. 2013; Neyt et al. 2012; Pitzalis et al. 2014; 
Ager & May 2015).  
A word of caution is issued by studies documenting intra-tumoural HEV 
formation in the presence of Treg, where HEV-containing TLO can paradoxically lead 
to immune tolerance and disease progression. Indeed, forced expression of CCL21 in 
B16 melanomas led to rapid recruitment of immunosuppressive Tregs and MDSCs, 
resulting in promotion of tumour progression (Shields et al. 2010). A study conducted in 
our lab documented the formation of extra-tumoural lymphoid aggregates containing 
HEV, which were associated with disease progression in CRC patients (Bento et al. 
2015). It is possible that accumulation of Tregs in tumour associated TLOs is at least 
partly responsible for disease progression, by exertion of local suppression of anti-
tumour immune responses. Indeed, Gobert and colleagues found that high frequencies 
of Tregs within tumour associated lymphoid tissue of breast cancer patients correlated 
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with poor survival (Gobert et al. 2009). Furthermore, a recently published study 
elegantly demonstrated the ability of tumour associated tertiary lymphoid structures 
(TA-TLS) to foster Treg-mediated suppression of endogenous anti-tumour T cell 
responses against lung adenocarcinomas (Joshi et al. 2015). Such studies illustrate 
that function of tumour associated TLOs is likely dictated by the immunological cellular 
composition of the TLO as well as the state of disease progression, and warrants 
further detailed investigations into specific immune responses harboured by TLOs prior 
to the development of strategies aimed at enhancing their development in tumours.  
6.5 The Requirement for a HEV-Permissive Tumour Microenvironment? 
 Interestingly, HEV develop in MCA-induced tumours of only a fraction 
(approximately 50%) of Treg depleted animals (Hindley et al. 2012) (and data shown 
here). These data establish that while depletion of Tregs is an essential prerequisite for 
HEV neogenesis in tumours of this model, it is certainly not sufficient for this process 
(Hindley et al. 2012; Gallimore et al. 2013). The mechanism that accounts for this 
inconsistent response to Treg depletion could be immunological in nature: T 
lymphocytes of some Treg depleted animals could become highly activated and 
synthesise HEV-inducing cytokine(s), while T cells of other animals devoid of Tregs 
could be unable to produce the necessary cytokine(s). However, profound systemic 
activation of T cells is observed in all animals following Treg depletion, suggesting a 
consistent immune response to Treg depletion among animals (Hindley et al. 2012). 
Alternatively, the immunogenicity of an individual tumour may dictate whether an 
immune response stimulated by depletion of Tregs efficiently clears tumour or not. 
Highly immunogenic tumours could activate tumour-specific T lymphocytes, which then 
drive HEV neogenesis in the tumour, while tumours that have escaped immune 
attention via immunoediting could fail to induce and / or support the necessary immune 
response for the HEV developmental program. Indeed, outgrowth of MCA-induced 
sarcomas can occur when the tumour lacks expression of strongly immunogenic 
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antigens, by a mechanism of T cell-dependent immunoselection (Matsushita et al. 
2012). 
Instead, HEV development could be dictated by tumour-intrinsic factors. A 
multitude of features of the TME could influence HEV neogenesis, collectively 
contributing to the creation of an environment either hostile or conducive to HEV 
formation. A key component of the TME that could be intricately linked to neogenesis 
of HEV is the tumour vasculature. Interestingly, data generated in our lab from 
microarray analyses of whole tumours revealed a noticeable decrease in expression of 
genes associated with a defined “angiogenesis” signature in HEV-containing tumours 
relative to HEV null tumours, including genes such as vegfa, encoding VEGF-A, and 
cadherin 5, encoding vascular endothelial (VE)-cadherin (unpublished data). In 
agreement with these microarray data, immunofluorescent staining revealed that HEV 
containing tumours contain fewer CD31+ vessels which appeared more ordered, 
relative to HEV null tumours that typically contained vast numbers of CD31+ vessels 
that appeared unruly and chaotic in nature (unpublished data). In line with these data, I 
hypothesise that tumours of high angiogenic activity contain vast numbers of vessels 
but that these are chaotic and therefore result in poor perfusion and oxygenation of 
tumours: low infiltration of effector T lymphocytes into such tumours would prohibit 
productive interactions leading to HEV neogenesis. On the other hand, tumours of low 
angiogenic activity contain fewer CD31+ vessels, which are better ordered and more 
mature and / or normal and / or activated and hence facilitate better perfusion and 
enable infiltration of T lymphocytes that can then initiate a HEV neogenic program. 
Furthermore, as tumours of Treg replete animals display a mixed angiogenic genetic 
signature, angiogenic activity prior to Treg depletion could determine and therefore 
predict whether HEV will form. Should the angiogenic signature of tumours prove to be 
a key predictor in HEV neogenesis following Treg depletion, anti-angiogenic modalities 
aimed at normalising tumour vasculature will be explored for efficacy to promote HEV 
neogenesis in all Treg depleted tumours. 
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In contrast to the endothelial cell extrinsic mechanisms discussed above, the 
ability of a tumour to support development of HEV following Treg depletion could 
instead be dictated by endothelial cell intrinsic mechanisms. HEV neogenesis could be 
determined by the ability of the endothelium of tumour vasculature to respond to HEV-
inducing cytokine(s) secreted in the TME: the “responsiveness” of the endothelium. 
Tumour endothelium is known to be incredibly refractory to activation induced by pro-
inflammatory cytokines (Chen et al. 2003). Variation in the responsiveness of the 
endothelium of different tumours, potentially determined by differential expression of 
various immunosuppressive molecules, could dictate the ability of the vasculature to 
differentiate into functional HEV-type vessels upon stimulation.  
Endothelial cells of HEV in LNs are of vascular origin, suggesting that HEV form 
from pre-existing, newly formed post capillary vasculature in the LN parenchyma under 
the influence of as yet unidentified factors. Whether tumour associated HEV derive by 
differentiation of pre-existing tumour vasculature that forms during tumour 
angiogenesis, or are initiated by circulating endothelial progenitors during an 
alternative process of tumour vasculogenesis is unknown (Ager & May 2015). 
Endothelium-dependent vessel growth can be insufficient to sustain rapid growth of 
tumours, in which case tumours employ a mechanism of vasculogenic mimicry (VM), 
during which vascular networks form from non-endothelial, tumour cell origins (Maniotis 
et al. 1999; Zhang et al. 2007). Multiple other origins of tumour vasculature have been 
reported, including an epithelial derived origin via processes of epithelial-mesenchymal 
transition (EMT), and even a CD11b+ myeloid origin (Yang et al. 2004; Qiao et al. 
2015). Vessels in MCA-induced tumours co-expressed CD31 and PNAd, supporting 
the hypothesis that HEV develop by differentiation of the endothelium belonging to 
existing tumour vasculature. Furthermore, I noted that only portions of CD31+ vessels 
expressed PNAd, rather than continuous colocalisation of the two markers along the 
entirety of individual vessels, suggesting that different areas of vessels could be at 
various stages of differentiation, perhaps in response to local signals released by 
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proximal HEV-initiator cells. A detailed characterisation of tumour derived vascular 
cells will be carried out in future, to identify the precise origins of tumour HEV cells. 
 The ability of tumour-associated HEV to aid disease progression by selective 
recruitment of immunosuppressive Tregs and MDSCs (Shields et al. 2010), indicates 
that neogenesis of HEV is unlikely to be sufficient to underpin an effective anti-tumour 
immune response capable of eradicating tumour. Whether an effective immune 
response is established following recruitment of T cells to tumour via HEV will 
significantly depend on the inherent immunogenicity of that individual tumour/ 
malignant cells within the tumour, and exposure to highly immunogenic tumour 
antigens for incoming T lymphocytes. Furthermore, local signals within the tumour 
must support priming of tumour antigen-specific T cells. It is attractive to speculate that 
by lowering the threshold for both HEV neogenesis in tumours and activation of 
immune cells via depletion of Tregs, it could be possible to elicit a robust anti-tumour 
immune response against even low immunogenicity tumours (Gallimore et al. 2013). If 
confirmation of my data could be obtained from independent studies in different 
models, an inviting prospect for future cancer immunotherapy would be that of 
disabling Tregs, either via blockade of their intra-tumoural accumulation or modification 
of Treg suppressive function in tumours, perhaps via targeting of retention-promoting, 
suppressive function-enhancing molecules such as CD69, together with therapies that 
specifically encourage intra-tumoural HEV neogenesis. Furthermore, if my hypothesis 
regarding the impact of a highly angiogenic TME on HEV neogenesis proves correct, 
anti-angiogenic agents will additionally be required in a multipronged combinatorial 
therapy to simultaneously inhibit angiogenic activity.  
6.6 Final Conclusion 
In conclusion, I have shown here that intra-tumoural Tregs express high levels 
of CD69, a molecule potentially involved in retaining Tregs at the site of antigen and 
promoting enhanced suppressive function, thereby contributing to their dominance 
within the tumour mass. In the absence of Tregs, HEV neogenesis within tumours is 
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associated with profound infiltration of CD4+ and CD8+ T lymphocytes, which underpin 
an effective anti-tumour immune response to exert tumour growth control. The process 
of HEV neogenesis critically relies upon CD8+ T cells, with a potential accessory role 
for CD4+ T lymphocytes. While signalling via the LTβR is dispensable for HEV 
neogenesis in Treg depleted tumours, TNFR mediated signalling is required, with 
TNFα and / or LTα3 cytokines representing prime candidates for activation of TNFR(s) 
in this process (Figure 6.1). Further understanding of the molecular mechansims 
underpinning HEV neogenesis in MCA-induced tumours could facilitate clinical 
translation of the findings described here in the near future.  
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Figure 6.1 Schematic representing the final conclusion of the work of this thesis. 
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Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5.1 | Efficacy of LTβR.Ig, as assessed by Marginal Zone (MZ) B cells in 
spleen of Treg replete or Treg depleted Foxp3DTR animals. (A-B) Proportion of CD19+ CD45R+ B 
cells that are CD21hi CD23lo MZ B cells (A) and absolute number of CD21hi CD23lo MZ B cells 
per 100 total live cells (B) in spleen of Treg replete and Treg replete LTβR.Ig treated Foxp3DTR 
animals (closed circles) or Treg depleted and Treg depleted LTβR.Ig treated Foxp3DTR animals 
(open circles), as shown in Figure 5.2. Data are presented as mean ± Standard Deviation (SD). 
Statistical significance was determined by One-way ANOVA with Tukey’s multiple comparison 
tests to compare pairs of means (* = P≤0.05, ** = P≤0.01, *** = P≤0.001). N = 3 per group. (C) 
Representative flow cytometry plots showing proportion of CD19+ CD45R+ B cells that are 
CD21hi CD23lo MZ B cells, in the spleen of Non-treated C57BL/6 animals (top), and diphtheria 
toxin treated C57BL/6 animals (bottom). Cells are gated on CD19+, CD45R+. Numbers represent 
MZ B cells (gated), as a proportion of live CD19+ CD45R+ B cells. Expression of CD23 is shown 
on the y axis; expression of CD21 is shown on the x axis. (D) Proportion of CD19+ CD45R+ B 
cells that are CD21hi CD23lo MZ B cells (left hand graph) and absolute number of CD21hi CD23lo 
MZ B cells per 100 total live cells (right hand graph) in spleen of Non-treated C57BL/6 animals 
(closed squares), and diphtheria toxin treated C57BL/6 animals (open squares). Data are 
presented as individual datapoints with mean ± Standard Deviation (SD). Statistical significance 
was determined by unpaired t tests. N = 4 per group. 	
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Supplementary Figure 5.2 | Two representative confocal high power microscope images 
showing CD35/CD21+ Marginal Zone (MZ) B cells, MAdCAM-1+ staining of marginal sinus lining 
cells and B cells in spleen of Treg depleted Foxp3DTR animals. Sections were co-stained using 
the following antibodies: rat anti-CD35/CD21-APC (purple), rat anti-MAdCAM-1 detected using 
goat anti-rat IgG Alexa Fluor® 568 (red) and biotinylated rat anti-CD45R detected using 
Streptavidin-FITC (green). Merged images include the nuclear stain DAPI (blue). Scale bars are 
shown. 	
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Supplementary Figure 5.3 | A representative confocal high power microscope image showing 
CD35/CD21+ Marginal Zone (MZ) B cells, MAdCAM-1+ staining of marginal sinus lining cells and 
B cells in spleen of a Treg depleted Foxp3DTR animal treated with LTβR.Ig. Sections were co-
stained using the following antibodies: anti-CD35/CD21-APC (purple), anti-MAdCAM-1 detected 
using anti-rat IgG Alexa Fluor® 568 (red) and biotinylated-anti-CD45R detected using 
Streptavidin-FITC (green). Merged images include the nuclear stain DAPI (blue). Scale bars are 
shown. 	
	 
235 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5.4 | A representative confocal high power microscope image showing 
CD35/CD21+ Marginal Zone (MZ) B cells, MAdCAM-1+ staining of marginal sinus lining cells and 
B cells in spleen of a Treg depleted Foxp3DTR animal treated with TNFRII.Ig. Sections were co-
stained using the following antibodies: anti-CD35/CD21-APC (purple), anti-MAdCAM-1 detected 
using anti-rat IgG Alexa Fluor® 568 (red) and biotinylated-anti-CD45R detected using 
Streptavidin-FITC (green). Merged images include the nuclear stain DAPI (blue). Scale bars are 
shown. 	
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Supplementary Figure 5.5 | A representative confocal high power microscope image showing 
CD35/CD21+ Marginal Zone (MZ) B cells, MAdCAM-1+ staining of marginal sinus lining cells and 
B cells in spleen of a Treg depleted Foxp3DTR animal treated with Anti-TNFα (MP6-XT22). 
Sections were co-stained using the following antibodies: anti-CD35/CD21-APC (purple), anti-
MAdCAM-1 detected using anti-rat IgG Alexa Fluor® 568 (red) and biotinylated-anti-CD45R 
detected using Streptavidin-FITC (green). Merged images include the nuclear stain DAPI (blue). 
Scale bars are shown. 	
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Isotype and Fluorescence Minus One (FMO) controls 
 
Figure A | High power confocal microscope images of immunofluorescently stained tumour and 
Lymph Node (LN) sections, showing the appropriate isotype controls for stains included in 
Results Sections. A) Sections were co-stained using a biotinylated rat anti-PNAd primary 
antibody (clone MECA-79) and streptavidin-555 secondary antibody (red) and Rat IgG2a-FITC 
isotype control antibody (green). B) Sections were co-stained using a biotinylated Rat IgM 
isotype control antibody and streptavidin-555 secondary antibody (red) and rat anti-CD31-FITC 
antibody (green). C) Sections were co-stained using a biotinylated rat anti-PNAd primary 
antibody (clone MECA-79) and streptavidin-555 secondary antibody (red) and Rat IgG2a 
isotype control antibody and donkey anti-rat AlexaFluor-488 secondary antibody (green).  D) 
Sections were co-stained using a biotinylated Rat IgM isotype control antibody and streptavidin-
555 secondary antibody (red) and rat anti-MAdCAM-1 antibody followed by donkey anti-rat 
AlexaFluor-488 secondary antibody (green). In each case, tumour sections are shown on top 
and LN sections are shown on bottom. Scale bars are shown. 
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Figure B | High power confocal microscope images of sections of immunofluorescently stained 
tumour and Lymph Node (LN) sections, showing the appropriate isotype controls for stains 
included in Results Sections. Sections were co-stained using a biotinylated Rat IgM isotype 
control antibody and streptavidin-555 secondary antibody (red) and either a rat anti-CD4 
antibody (A), a rat anti-CD8 antibody (B), or a rat anti-CD45R antibody (C), each detected using 
donkey anti-rat Alexa Fluor® 488 secondary antibody (green). In each case, LN sections are 
shown on the left and tumour sections are shown on the right. Scale bars are shown. 
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Figure C | Low power confocal microscope images of sections of immunofluorescently stained 
Lymph Node (LN) sections (A-C), and microscope images of paraffin embedded tumour 
sections (D-E), showing the appropriate isotype controls for stains included in Results Sections. 
A) LN sections were co-stained using a biotinylated rat anti-PNAd antibody (clone MECA-79) 
and streptavidin Alexa Fluor® 555 (red) and a Rat IgG2a isotype control antibody and donkey 
anti-rat AlexaFluor-488 secondary antibody (green). B-C) LN sections were co-stained using a 
biotinylated Rat IgM isotype control antibody and streptavidin-555 secondary antibody (red) and 
either a rat anti-CD8 antibody (B), or a rat anti-CD4 antibody (C), each detected using donkey 
anti-rat Alexa Fluor® 488 secondary antibody (green). D-E) Paraffin embedded tumour sections 
were stained using a Rat IgM isotype control antibody, detected using either VIP chromogen 
(purple; D) or DAB chromogen (brown; E). Scale bars are shown. 
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Figure D | Low power confocal microscope images of sections of immunofluorescently stained 
Spleen sections, showing the appropriate isotype controls for Marginal Zone (MZ) B cell stains 
included in Results Sections. A) Sections were co-stained using a Rat IgG2b-APC isotype 
control antibody (purple), a Rat IgG2a isotype control antibody detected using a goat anti-rat 
Alexa Fluor® 568 secondary antibody (red), and a Rat IgG2a-FITC isotype control antibody 
(green). B) Sections were co-stained using a Rat IgG2b-APC isotype control antibody (purple), 
a rat anti-MAdCAM-1 antibody detected using a goat anti-rat Alexa Fluor® 568 secondary 
antibody (red), and a rat anti-CD45R-FITC antibody (green). C) Sections were co-stained using 
a rat anti-CD21/CD35-APC antibody (purple), a Rat IgG2a isotype control antibody detected 
using a goat anti-rat Alexa Fluor® 568 secondary antibody (red), and a rat anti-CD45R-FITC 
antibody (green). D) Sections were co-stained using a rat anti-CD21/CD35-APC antibody 
(purple), a rat anti-MAdCAM-1 antibody detected using a goat anti-rat Alexa Fluor® 568 
secondary antibody (red), and a Rat IgG2a-FITC isotype control antibody (green).  Scale bars 
are shown. 
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Figure E | Flow cytometry plots showing Fluorescence Minus One (FMO) controls for CXCR3-
APC antibody (top) or Ki67-BV421 antibody (bottom) in stained Spleen single cell suspension 
samples. Cells are gated on live CD4+ Foxp3- conventional T cells (Tconv; left column), or live 
CD4+ Foxp3+ regulatory T cells (Treg; right column). Numbers represent proportion of cells in 
each quadrant. 
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